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 Abstract 
 
Background Metastases are the major cause of death from melanoma, a skin cancer 
which has the fastest rising incidence of any malignancy in the Western world. Molecular 
pathways that drive melanoblast migration in development are believed to underpin the 
movement and ultimately the metastasis of melanoma.  
Aims In this thesis we use genetically modified mice models to characterise two novel 
anticancer targets, P-Rex1 and focal adhesion kinase (FAK). Embryonic melanoblast 
migration is compared with cancer outcomes for each genetic modification. 
Results Mice lacking P-Rex1, a Rac-specific Rho GTPase guanine nucleotide exchange 
factor (GEF), have a melanoblast migration defect during development evidenced by a 
white belly. These P-Rex1-/- mice are resistant to metastasis when crossed to a murine 
model of melanoma, an effect specifically channeled through loss of P-Rex1 GEF activity. 
FAK disruption compromises melanoblast cell numbers and migration in development, 
but has no long-term effect on melanocyte homeostasis. FAK-deleted mice have a 
divergent role in melanomagenesis, delaying primary melanoma onset whilst promoting 
metastasis following disease onset.  
Conclusions We conclude that P-Rex1 and FAK play important roles in melanoblast 
embryology and melanoma development and progression. Both P-Rex1 and FAK 
represent interesting therapeutic targets for the treatment of cancer. 
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1.1 Melanoma 
Melanoma is the most lethal form of skin cancer, accounting for the majority of skin 
cancer deaths. There are approximately 132,000 new cases each year, an incidence that 
has been steadily rising in the Western world for the last few decades (World Health 
Organisation, www.who.int/uv/faq/skincancer/ en/index1.html): this increase relates to 
improved detection, as well as an increase in the frequency of holidays abroad (de Vries 
et al, 2005). 80% of melanoma cases will be cured by surgical resection, while the 
remaining 20% will develop metastatic disease which confers a poor prognosis: median 
survival is 6 months, with a 5 year survival rate of less than 5% (Gray-Schopfer et al, 
2007). Primary melanomas with a Breslow depth of ≥4mm are sufficient to predispose to 
significant risk of metastatic disease, with a 43-47% 5-year patient survival 
(www.cancerresearchuk. org/type/melanoma/treatment/melanoma-statistics-and-
outlook). Moreover, no treatment had been developed for metastatic patients that could 
offer an improvement in their overall survival until very recently. 
The pathogenesis of melanoma is characterised by the two main physiological properties 
of other cells from the melanocyte lineage: adult melanocytes (MCs) are resistant to 
apoptosis, while their embryological precursors, melanoblasts (MBs), have a propensity to 
migrate. MCs are the pigment-producing cells in the skin that can give rise to melanoma. 
Their major role is lifelong protection of the skin from ultraviolet radiation (UVR) through 
the production of melanin and the consequent tanning response. Loss of melanin 
production in albinism is caused by mutations in genes involved in melanin-synthesis 
(tyrosinase, TRP1 and TRP2), and renders sufferers hyper-sensitive to the damaging 
effects of UV, producing higher than average reported rates of melanoma (Boissy et al, 
1997; http://cancerhelp.cancerresearchuk.org/type/skin-cancer/about/skin-cancer-risks-
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and-causes). Normal MCs in the human skin are tethered to the basement membrane 
(BM) of the epidermis and the hair follicle (HF), where their homeostasis is controlled by 
keratinocytes (KCs) (Gray-Schopfer et al, 2007). The capacity of MCs to resist apoptosis 
and survive the highly mutagenic skin environment is reflected in melanoma, a cancer 
characterised by its resistance to traditional cytotoxics that can confer clinical efficacy in 
the majority of human epithelial cancers (Terzian et al, 2010). Melanoma cells display 
resistance to drug-induced apoptosis in vitro, and also show low levels of spontaneous 
apoptosis in vivo (Soengas et al, 2003).    
The migratory propensity of MCs is indicated by their anatomical localisation in adults, 
where they classically reside in the skin but also exist in the eyes, heart, inner ear, brain, 
and gut mucosa (Brito et al, 2008). It is hypothesised that malignant transformation of 
these distant visceral populations of MCs is responsible for the rare cases of melanoma 
which originate outwith the skin, such as primary CNS melanoma (Brito et al, 2008). MCs 
arise from a uniquely motile embryonic precursor population, MBs. The genetic 
predisposition of MBs to migrate can re-arise at an early stage in primary melanoma, 
where metastases can have quickly devastating effects and involve multiple viscera. It is 
not unusual in the clinic to discover metastatic disease without having identified a 
primary source of cancer (Gupta et al, 2005). Given its biological capacity for aggression, it 
seems likely that the relatively high 80% survival rate from melanoma is mainly possible 
because of early detection of primary tumours on an easily visualised organ, the skin. 
1.1.1 A model of progression for melanoma 
50-75% of human melanoma will occur de novo, with the other 25-50% arising from pre-
existing naevi (Garcia-Cruz, 2009). It is likely that the stochastic occurrence of critical 
mutations will determine which one of these pathways of melanomagenesis may occur. 
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Patients who develop de novo melanomas may have a poorer prognosis (Kumasaka et al, 
2010), although identification of which patients succumb to each pathway can be 
inherently difficult to assess. At present, mouse models still concentrate on mimicking the 
genetics, anatomy and histology of primary melanoma and its metastases, with little 
focus as yet on identifying whether a primary lesion has arisen from a pre-existing naevus 
or not. Using depilation of coat hair and prospective assessment of melanocytic lesions, a 
recent report assessing mouse naevi has followed the early progress made in this field 
using zebrafish models (Dhomen et al, 2009, Patton et al, 2005, Dovey et al, 2009). 
The classical stepwise model of melanoma development describes initial proliferation and 
spread of MCs within the epidermis or dermis to form a benign naevus (Figure 1.1). Most 
naevi will generally not progress from this point, although in melanomagenesis, intra-
epidermal naevi can enter the radial growth phase (RGP) where they proliferate further in 
the epidermis and exhibit cellular dysplasia. Following the RGP, collections of cells can 
progress to the more dangerous vertical growth phase (VGP), where they invade the 
dermis and acquire metastatic potential through involvement with the micro-vasculature 
and the lymphatic system. It is assumed that de novo melanomas will follow a similar 
pattern, but with quicker progression to the VGP by isolated MCs (Miller et al, 2006). The 
genetics associated with these various phases of melanoma development is discussed 
below. 
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Figure 1.1 Stepwise model of melanoma development  
Schematic anatomical diagram of classical melanoma progression model. Progression through 
various growth phases and their common associated genetics indicated below. Further details in 
section 1.1.1. Unpublished but adapted from figure originally provided by Gallacher laboratory, 
Conway Institute, Dublin. 
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1.1.2 Aetiology of melanoma and UVR 
Risk factors for melanoma include family history, a history of previous melanoma, fair and 
freckling skin, large numbers of melanocytic naevi, the presence of blond/red hair, and 
exposure to UVR (Strizzi et al, 2011). In Scotland, a particular increase in the incidence of 
new melanoma cases over the past few decades is thought in part to be secondary to the 
large numbers of people with type I skin type (freckling skin, red/fair hair, blue/green 
eyes) (Whiteman et al, 2008, http://www.cancerresearchuk.org/cancer-info/cancerstats 
/types/skin/riskfactors /skin-cancer-risk-factors). 
UVR is the most ubiquitous environmental carcinogen, and there is evidence in particular 
that UVB has a specific role in melanomagenesis (Zaidi et al, 2008). A strong 
epidemiological connection between exposure to sunlight and induction of melanoma has 
been established, especially through intense intermittent exposure to UVR during 
childhood (Elwood et al, 1997, Holman et al, 1983). Familial studies have suggested that 
UVR may be acting in a tumour-promoting capacity, with other genetic factors prompting 
tumour initiation (Serrano et al, 1996). Despite this, the mechanistic relationship between 
UVR and the development of genetic alterations that predispose to melanoma is still 
relatively poorly resolved. 
One explanation for the relationship between UVR and melanoma is the ‘divergent 
pathway’ hypothesis (Whiteman et al, 2003). This suggests that one pathway of disease 
onset typically occurs at older age with lesions predominantly arising on areas of skin 
chronically exposed to UVR (eg head and neck) (‘Chronic sun-exposed’, CSE), while the 
second pathway affects younger patients with melanomas occurring in less sun-exposed 
anatomical areas (‘non chronic sun-exposed’, non-CSE). The second pathway to 
melanomagenesis is more associated with genetic risk, as evidenced by the fair skin and 
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high number of naevi affecting patients in this group. Patients with the largest histological 
subtype of melanoma, superficial spreading melanoma (SSM), will often form part of the 
non-CSE pathway, while patients with lentigo malignant melanoma (LMM) comprise a 
majority of the CSE pathway (Walker et al, 2011). 
Although there are data to suggest a connection between UVR-related DNA damage and 
other types of skin cancer, little evidence exists which shows signature patterns of UVR 
damage in genes known to be mutated in melanoma. This is the case for NRAS, BRAF, and 
CDKN2A loci commonly mutated in the disease (Hocker et al, 2007, Davies et al, 2002), 
although it is notable that these mutations are most often related to melanoma arising 
from either acute intermittent sun exposure or little UVR exposure at all (non-CSE 
pathway). For example, oncogenic BRAF mutations in melanoma arise early in life at low 
cumulative UV exposures (Bauer et al, 2011).   
Another mechanism by which UV has been proposed to promote melanomagenesis is 
through the induction of reactive oxygen species (ROS) (Wang et al, 2010). In particular, 
this is a mechanism by which UVA has been shown to induce melanoma in a manner 
sensitised by melanin (Kvam et al, 2004). Wang and colleagues found that UVA induces 
ROS in melanocytes, which have a lower nucleotide excision repair capacity for UV 
photoproducts than normal human stromal fibroblasts (NHSFs). UV photoproducts also 
induced more mutations in melanocytes than in NHSFs. This led to the proposition that 
UVA-induced, melanin-augmented ROS in melanocytes, allied with the reduced repair 
capacity of these cells, are two key factors that contribute to melanomagenesis (Wang et 
al, 2010). 
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As this thesis focuses on mouse models in the non-CSE pathway, UV-induced mouse 
models of melanoma have not been detailed here, although a number have been 
described (Kelsall et al, 1998, Broome Powell et al, 1999, Kato et al, 2000, Recio et al, 
2002, Yamazaki et al, 2005, Hacker et al, 2006). The most efficient method of melanoma 
induction remains a single neonatal exposure of UVR, perhaps because neonatal skin has 
an enhanced proliferative and inflammatory capacity as well as a higher proportion of MC 
progenitors (Recio et al, 2002). It is arguable that this treatment might model UV-
exposure in the non-CSE pathway more accurately than the CSE pathway, although often 
features of CSE melanoma such as solar elastosis have been described. 
1.1.3 Histological subtypes of melanoma 
The World Health Organisation (WHO) described four histological subtypes of melanoma: 
superficial spreading melanoma, nodular melanoma (NM), lentigo malignant melanoma, 
and acral lentiginous melanoma (ALM). The most common subtype in the Western world 
is SSM, accounting for approximately 70% of melanomas. SSM arises in the basal 
epidermis and can follow the classical model of melanoma progression described in 
Section 1.1.1. NM is predominantly observed in the dermis, and often involves the 
epidermis too. There exists conflicting hypotheses as to whether NM may be a quicker 
extension of the epidermal progression model seen in SSM, or whether it may represent a 
separate disease entity of dermal origin (Walker et al, 2011). The similar mutational 
constitution of both SSM and NM subtypes (frequent mutations of BRAF or NRAS) suggest 
that the former hypothesis is more likely, while both SSM and NM are also associated 
with non-CSE skin (Bastian et al, 2000, Curtin et al, 2006).  
CSE skin is most frequently associated with LMM, which invariably exhibits dermal solar 
elastosis with a component of MC proliferation in the epidermis (Walker et al, 2011). 
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These melanomas are KIT mutated in 20% of cases, and can be p53 mutated also (Curtin 
et al, 2006, Hocker et al, 2007). ALM affects 10% of melanoma patients, and describes 
melanoma occurring in the nail apparatus or glabrous skin. It is associated with mutation 
or amplification of KIT in 40% of cases (Curtin et al, 2006), and the anatomy and similar 
incidence of ALM between all ethnic backgrounds helped reveal that it occurs 
independent of UVR damage. Mutations of BRAF are infrequent in patients with LMM or 
ALM (Lee et al, 2011).  
Outwith the WHO classification, it should be remembered that ocular melanoma is the 
most common and lethal form of eye cancer, and can be defined and recognised by its 
unique genetic make-up. It mostly originates in the uveal tract rather than the 
conjunctiva, and has been associated with UVR (Singh et al, 1998). A striking incidence of 
liver metastases (50%) affects patients with uveal melanoma. Pioneering work by Bastian 
and colleagues identified and characterised unique activating mutations of the GNAQ and 
GNA11 oncogenes in many cases (van Raamsdonk et al, 2009, van Raamsdonk et al, 
2010). KIT mutations have also been identified in 33% of primary lesions (Wallander et al, 
2011). 
1.1.4 Molecular pathways of melanoma and their animal models 
This section details the most aberrantly regulated pathways and genes in melanoma, and 
their contributions to the hallmarks of cancer (Hanahan et al, 2010). With the exception 
of SSM, the mutational signatures described here still account for less than 50% of each 
melanoma subtype. This is despite the development of large scale genomics studies such 
as comparative genomic hybridisation (CGH), which can comprehensively identify the 
genetic make-up of human melanoma. In part, this will be because many genetic changes 
identified using these techniques have yet to be functionally validated. Early efforts to 
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dovetail histological and genetic components of melanoma have shown considerable 
overlap between the two classifications, with histological features such as larger cells and 
increased pigmentation leading to an 82% predictability of melanomas with mutated 
BRAF (Broekaert et al, 2010). Human and mouse melanoma histology will doubtless be 
further analysed in this way once characterisation of functional melanoma genetics has 
progressed further.   
Similar to other cancer types, development of melanoma is characterised by the 
combination of mutations that activate oncogenes (most commonly BRAF and NRAS) with 
mutations that lead to loss of tumour-suppressor gene (TSG) function (frequently PTEN or 
INK4a/ARF) (Table 1.1). As detailed below, animal models genetically modified with this 
combination consistently develop melanoma. 
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 Melanocyte Naevus Melanoma  
BRAF status  normal V600E V600E 
NRAS status normal Q61K Q61K 
MAPK status low increased high 
PI3K status low low high 
CDKN2a status  low induced lost 
Phenotype quiescent senescent malignant 
Table 1.1 Synopsis of common mutations and signaling pathways that are aberrantly 
affected in melanoma.  
The MAPK pathway is upregulated in 90% of human melanoma, most often by somatic mutation of 
BRAF (50-70%) or NRAS (15-30%) (www.sanger.ac.uk/genetics/CGP/cosmic/) (Cohen et al, 
2002). Mutations of GNAQ and GNA11 are alternative upstream signalling mediators of this 
upregulation (Van Raamsdonk et al, 2009, Van Raamsdonk et al, 2010). Further details of this 
pathway and other mutations are covered in Sections 1.1.4.1-1.1.4.4 below. 
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1.1.4.1 Ras/Raf/MEK/ERK  
Ras/Raf/MEK/ERK signalling. The Ras-Raf-MEK-ERK mitogen-activated protein kinase 
(MAPK) signalling pathway is a central oncogenic component of many human cancers. It 
mediates melanoma cell proliferation and regulates cell fate decisions downstream of G-
protein-coupled receptors (GPCRs) and receptor tyrosine kinases (Gray-Schopfer et al, 
2007). By signalling through these receptors, growth factors such as fibroblast growth 
factor (FGF), stem-cell factor (SCF), and hepatocyte growth factor (HGF) activate the small 
G protein Ras which is attached to the inner leaflet of the plasma membrane (Bohm et al, 
1995). The serine/threonine kinase Raf is recruited from the cytoplasm to the plasma 
membrane and activated by a scaffold complex involving active Ras, with cytosolic MEK 
and ERK then sequentially phosphorylated and activated in turn (Kolch et al, 2000). 
Finally, ERK will translocate to the nucleus and activate a variety of transcription factors 
to stimulate downstream effectors (Strizzi et al, 2011). The complex heterogeneity of the 
MAPK pathway is revealed by the multiplicity and differential functions of it myriad 
components: three Ras (Hras, Nras, Kras), three Raf (Araf, Braf, Craf), two MEK (MEK 1/2), 
and two ERK (ERK1/2) proteins (Heidorn et al, 2010). 
Ras/Raf/MEK/ERK in melanoma. ERK is upregulated in 90% of human melanoma, often by 
somatic mutation of BRAF (50-70%) or NRAS (15-30%) (Figure 1.1, Table 1.1) 
(www.sanger.ac.uk/genetics/CGP/cosmic/) (Cohen et al, 2002). Over 90% of melanoma 
BRAF mutations are a glutamic acid substitution for valine at position 600 (BRAFV600E), 
while the most common RAS mutation is an NRAS substitution of leucine for glutamine at 
position 61 (NRASQ61L) (Davies et al, 2002, Demunter et al, 2001). Both are oncogenic 
gain-of-function mutations that render Braf or Nras constitutively active. On rarer 
occasions, the pathway can also be upregulated by mutational activation of growth factor 
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receptors such as c-Kit (Willmore-Payne, 2005). Downstream signalling of BrafV600E  has 
been shown to regulate a variety of proteins common to both melanoma and cancer 
signalling, such as vascular endothelial growth factor (VEGF), microphthalmia-associated 
transcription factor (MITF), BRN-2 and p16INK4a (Gray-Schopfer et al, 2007). BrafV600E is also 
present in up to 80% of human naevi and can induce senescence in MCs, suggesting that 
it is not sufficient by itself to promote melanoma (Figure 1.1, Table 1.1) (Pollock et al, 
2003, Michaloglou et al, 2005). The same applies to NrasQ61L, which can also be found in a 
majority of human congenital naevi (Figure 1.1, Table 1.1) (56%) (Papp et al, 1999). 
Importantly, melanoma activating mutations of BRAF and NRAS are generally mutually 
exclusive, suggesting they stimulate the same linear pathway involving MAPK 
deregulation (Davies et al, 2002, Rajagopalan et al, 2002, Goel et al, 2006). 
Ras/Raf/MEK/ERK animal models. Mouse models expressing MC-specific BRAFV600E or 
NrasQ61K generally confirm the capacity of these mutations to stimulate development of 
melanocytic lesions without full development to melanoma (Ackermann et al, 2005, Goel 
et al, 2009, Dhomen et al, 2009, Dankort et al, 2009).  Dhomen and colleagues reported 
an inducible mouse model of MC-specific expression of BrafV600E at endogenous levels, 
with a primary melanoma incidence of ~70% at a median latency of 12 months (Dhomen 
et al, 2009); together with the information provided by other BrafV600E mouse models 
which more rarely progress to primary melanoma (Goel et al, 2009, Dankort et al, 2009), 
one surmises that it must require additional oncogenic insults for melanomas to develop. 
Consistent with this, zebrafish expressing BrafV600E develop ‘fish naevi’ in the absence of 
other oncogenic disruptions, and only a minority of mice expressing NrasQ61K will develop 
primary melanomas at 1 year (Ackermann et al, 2005, Patton et al, 2005). An indirect 
comparison of Ackermann and Dhomen mouse models would suggest that BrafV600E is 
more efficient than NrasQ61K at inducing primary melanoma (Ackermann et al, 2005, 
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Dhomen et al, 2009). However this is not paralleled by zebrafish models, with low grade 
melanomas consistently seen in NrasQ61K fish at 1 year compared to no melanomas 
occurring in BrafV600E models (Patton et al, 2005, Dovey et al, 2009). 
1.1.4.2 Phosphoinositide-3-OH kinase (PI(3)K)  
PI(3)K signalling. Another signalling pathway oncogenic Ras can stimulate is the PI(3)K 
pathway. Here, hyper-phosphorylation by members of the PI(3)K family convert 
phosphoinositide membrane lipids into second messengers that activate numerous 
downstream targets including the serine-threonine kinase Akt, which in turn can activate 
downstream effectors such as mammalian target of rapamycin (mTOR). PI(3)K signalling 
can be terminated by the lipid phosphatase phosphate and tensin homologue (PTEN). The 
pathway mediates hallmarks of cancer such as cell proliferation, survival, and growth, and 
is often upregulated in melanoma (Sansal et al, 2004). However, the differential signalling 
patterns of PI(3)K pathway isoforms have yet to be fully elucidated: several different 
isoforms of Akt and PI(3)K exist, as well as two separate complexes through which mTOR 
can exert its effects (Marone et al, 2008).  
PI(3)K in melanoma. PTEN is a tumour-suppressor gene, mutated in germline disorders 
such as Cowden disease where it is associated with tumour susceptibility. This contrasts 
with cardio-facial-cutaneous syndrome, a BRAF/MEK germline genetic disorder which has 
no specific association with cancer disposition (Bentires-Alj et al, 2006).  PTEN is also 
mutated in many spontaneous human cancers (Sansal et al, 2004). Absence or reduction 
of PTEN (by genetic or epigenetic means) occurs in the majority of primary melanomas 
(50-90%), although its mutation is relatively infrequent (<15%) (Figure 1.1, Table 1.1) 
(Inoue-Narita, 2008). Upregulated Akt occurs in 43-60% of spontaneous melanomas (Stahl 
et al, 2004, Dhawan et al, 2002), and PI(3)K activating mutations are present in only 3% of 
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cases (Omholt et al, 2006). The combination of Pten loss and oncogenic Braf is present in 
approximately 20% of human melanomas (Dankort et al, 2009). Pten loss and Nras 
activation were assumed to be mutually exclusive in human melanoma, due to their 
individual ability to activate the PI(3)K pathway, although it was later asserted that a 
small number of melanomas will harbour both alterations with functional consequences 
(Tsao et al, 2000, Nogueira et al, 2010). 
PI(3)K animal models. Genetic evidence for in vivo co-operation of PTEN and BRAF in 
melanomagenesis was first reported by Dankort and colleagues (Dankort et al, 2009). In 
this mouse model, melanocyte-specific ablation of PTEN allowed progression to 
spontaneous melanomas driven by BrafV600E in 100% of mice; no melanomas were 
observed in those mice with BRAFV600E alone. In another mouse model, melanocyte-
specific deletion of PTEN alone has been shown to predispose mice to carcinogen-induced 
invasive melanomas and metastases (Inoue-Narita, 2008). The loss of one copy of PTEN in 
a Tyr::HRASV12G; CDKN2a-/- mouse model led to more aggressive melanomagenesis and 
metastases, suggesting that more than one TSG loss can co-operate in melanoma 
(Nogueira et al, 2010). No mice carrying Akt activation have been reported in melanoma. 
1.1.4.3 Senescence  
Senescence signalling. The INK4a/ARF (CDKN2a) gene encodes two splice variants which 
can act as TSGs, p16INK4a and p14ARF (p19ARF in mice), by acting through the pRB and p53 
pathways, respectively. Their function is to regulate cellular senescence, a cancer-
protection mechanism by which cells with active oncogenes can exit the cell cycle and 
enter a quiescent state. Cell cycle proteins cyclin-dependent kinase 4 and 6 (CDK4/CDK6) 
are unable to phosphorylate and inactivate the retinoblastoma (Rb) family of tumour 
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suppressors as a result of binding by p16INK4a. p53 is stabilized by p14ARF potentiation of its 
main regulatory protein, Mdm2 (Sharpless et al, 1999).  
Senescence in melanoma. The INK4a/ARF (CDKN2a) gene has been identified as a 
susceptibility locus in both familial and sporadic melanoma, inactivated at high frequency 
(Chin et al, 1998). Most germline or somatic CDKN2a mutations in human melanoma 
disrupt both p16INK4a and p14ARF (Figure 1.1, Table 1.1) (Sharpless et al, 1999). p16INK4a is 
inactivated in somatic melanomas by deletions, point mutations, and transcriptional 
silencing by promoter methylation (Gray-Schopfer et al, 2007). p14ARF is genetically or 
epigenetically deactivated in 43% of somatic human melanomas (Freedberg et al, 2008). 
p53 mutations are present in 0- 10% of all melanomas: it is thought that this low 
frequency is related to the frequent loss of p14ARF, leaving p53 mutations functionally 
redundant within the same pathway (Terzian et al, 2010). However, heterozygous 
deletion of p53 has been reported in up to 50% of metastatic melanoma, suggesting a 
role in later melanoma progression (Hussein et al, 2004). Germline mutations of CDK4 
also abolish normal pRb-mediated cell cycle control and lead to melanoma susceptibility 
(Zuo et al, 1996). 
Senescence in animal models. Animal models with ablation of the CDKN2a/p53 loci or 
CDK4 activating mutations rarely develop melanoma without other genetic alterations, 
although tumour development can be stimulated by UVR exposure (Chin et al, 1997, 
Bardeesy et al, 2001, Sharpless et al, 2001, Recio et al, 2002, Ackermann et al, 2005, 
Patton et al, 2005, Hacker et al, 2006, Tormo et al, 2006, Yang et al, 2007, Goel et al, 
2009, Terzian et al, 2010). One of ten p16INK4a-null mice with p19ARF heterozygosity was 
reported to develop metastatic melanoma, an effect that was increased with 7,12-
dimethylbenz[α]anthracene (DMBA) treatment and not seen with p16INK4a-null mice alone 
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(Krimpenfort et al, 2001). Similar to PTEN, the key function of CDKN2a in mouse and 
human melanoma is therefore to act as a senescence ‘brake’, preventing progression of 
naevi driven by oncogenic mutation of NRAS and BRAF. This is best demonstrated by a 
mouse model that combines oncogenic Nras expression with a CDKN2a knockout 
(‘Tyr::NrasQ61K/°; INK4a-/-‘ mice) to recapitulate common human genetics and pathology: 
Tyr::NrasQ61K/° mice alone predominantly develop naevi unless they are combined with 
CDKN2a loss (‘INK4a-/-‘), where they suffer a 94% incidence of primary melanoma at 6 
months (Ackermann et al, 2005). Loss of p16INK4a has also been demonstrated to promote 
tumourigenesis in senescent MCs with mutation of BRAF (Michaloglou et al, 2005).  
Finally, it should be noted that the CDKN2a locus is not the only ’brake’ that can prevent 
development of BRAF or NRAS mutated melanoma, and therefore not essential for 
senescence. This is best demonstrated by CDKN2a null patients who can still develop 
naevi (Pavel et al, 2003). It was also reflected and characterised further in the Tyr::CreER 
BrafV600E/+ mouse model described earlier in section 1.1.4.1, where loss of p16INK4a did not 
preclude formation of nevi and did not contribute to metastatic propensity once 
melanomas had developed (Dhomen et al, 2009). Consistent with this, a ‘mosaic’ pattern 
of p16INK4a staining has been described in immunohistochemistry (IHC) of human naevi 
(Gray-Schopfer et al, 2006). 
1.1.4.4 GNAQ/GNA11 and GPCR signalling 
GNAQ and GNA11 encode members of the q class of G-protein α-subunits. Their function 
is to mediate signals between GPCRs and downstream effectors. Important driver 
mutations of GNAQ and GNA11 in melanoma were recently discovered following the 
genetic characterisation of mice with intradermal melanocytoses histologically similar to 
human ‘blue naevi’ (rare discrete bluish moles) (Van Raamsdonk et al, 2009).  Subsequent 
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sequencing analysis of GNAQ and GNA11 in a variety of human benign and malignant 
melanocytic neoplasms uncovered striking results: somatic mutations of GNAQ 
(exclusively GNAQQ209L) were present in 45% of uveal melanoma and 22% of uveal 
melanoma metastases, while mutations of GNA11 (predominantly at Q209) were found in 
32% of uveal melanomas and 57% of their metastases (Van Raamsdonk et al, 2009, Van 
Raamsdonk et al, 2010). The limited frequency of BRAF and NRAS mutations in uveal 
melanoma (despite a consistent upregulation of MAPK signalling) was partly explained by 
these findings (Zuidervaart et al, 2005). Indeed, this was the first characterisation of 
mutations of these genes in human neoplasia, and the presence of GNAQ mutations in 
human cancer seems to be unique to uveal melanoma (Lamba et al, 2009). Functional 
examination of their Q209 mutations using cell lines and xenografts confirmed an 
upregulation of MAPK signalling that, like oncogenic BRAF and NRAS, was insufficient to 
drive melanoma without additional genetic modification. 
GPCRs are a large family of cell surface receptors that can regulate multiple aspects of 
cellular behaviour, including MAPK signalling and motility. When ligand bound, they are 
activated by an associated G-protein by exchanging its GDP for a GTP. The α subunit of 
the G-protein can then dissociate from the β and γ subunits to further interact with a 
multitude of downstream intracellular signalling proteins, or target functional proteins 
directly depending on the α subunit type. Deregulation of GPCRs is important in 
melanoma:  metabotrophic glutamate receptor 5 (Grm5) has been functionally implicated 
as a driver of melanoma, while melanoma mutations of GRM3 have also recently been 
identified (Lee et al, 2008, Prickett et al, 2011).  
Perhaps the earliest and most straightforward examination of GPCR signaling in 
melanoma was performed by Pollock and colleagues, who identified and characterised 
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the driver role of Grm1 by mapping an insertional mouse mutant predisposed to 
developing melanoma (Pollock et al, 2003). Grm1 was expressed in 7 of 19 human 
melanoma samples, compared to no expression observed in benign naevi. This was the 
first time a role for GRM1 had been seen in human neoplasia, and the similarities 
between this and the GNAQ/GNA11 study described above are striking. With the insight 
gleaned from functional studies such as those described in this section, it is easy to 
speculate that deregulated GPCR signaling might feature strongly in the large subset of 
melanomas which are not driven by oncogenic NRAS or BRAF. 
1.1.5 What melanoblasts tell us about melanoma 
A highly motile embryonic cell population called the neural crest gives rise to a number of 
differentiated cell types, including MBs, as they migrate through the embryo. Figure 1.2 
details this prevailing and historical model of melanoblast migration in the developing 
mouse embryo, a focus for much of the work in this thesis. However, it should be noted 
that recent results have suggested there may be an alternative origin and migratory 
pathway of melanocyte progenitor cells in the trunk: melanocytes can arise from a 
stem/progenitor niche containing Schwann cell precursors (SCPs), located in nerves 
situated throughout the embryo (Adameyko et al, 2009).   
In the neural crest model of migration, MBs in mouse embryos between E8.5 and birth 
migrate to populate the dermal skin and HFs using signalling from c-Kit, their major 
tyrosine kinase receptor. Ventral migration at E10.5-E15.5 follows an initial dorsolateral 
movement at E8.5-10.5 (Figure 1.2). Upward movement into the epidermis can occur 
from E13.5, although epidermal MCs are only found in the HFs of adult mice (Jordan & 
Jackson, 2000). Outside of the skin, a good example of the unique migratory capacity of 
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MBs is the commonly observed presence of histologically normal MC aggregates in 
human lymph nodes (LNs) (Gupta et al, 2005).  
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Figure 1.2 Neural crest model of melanoblast migration in embryogenesis 
Representative E15.5 X-gal stained embryo derived from DCT-lacZ mice (further detail in section 
1.1.5). Each blue ‘dot’ in the embryo represents a melanoblast. Schematic diagram indicates how 
dorsolateral movement of melanoblasts from the neural crest (red arrow) is followed by ventral 
migration (white arrows).  
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A number of studies have highlighted similarities between the molecular machinery 
involved in MB migration and melanoma invasion/metastasis, suggesting a circumstance 
where these physiological processes are ‘hijacked’ and deregulated in melanoma cells 
that lack major regulatory checkpoints. The capacity of KIT to drive MB migration as well 
as some subtypes of melanoma is an obvious example (Walker et al, 2011). Gupta and 
colleagues demonstrated using xenografts that, compared to epithelial cells, the inherent 
molecular predisposition of MBs for migration is crucial to metastatic melanomagenesis – 
rather than the mutations incurred to develop melanoma (Gupta et al, 2005). Slug, a 
regulator of migration and neural crest specification, was shown to be functionally 
required for melanoma metastasis in this study. Another example of melanoma ‘hijacking’ 
of MB molecular physiology is Nodal, an embryonic morphogen not normally expressed in 
adult tissues, which contributes to Notch4-mediated metastases and tumour cell 
plasticity after its expression re-emerges in melanomagenesis (Strizzi et al, 2011). 
Mutations of several other genes that are implicated in melanoma can impair hair 
pigmentation through their role in MB development (Inoue-Narita et al, 2008). 
Melanocyte-specific constitutive expression of BRAFV600E during embryogenesis is lethal 
(Mercer et al, 2005, Dhomen et al, 2010). Embryos with melanocyte-specific expression of 
BRAFV600E succumb to hydrocephalus, micropthalmia, and ventricular septal defects, a 
result that again suggests the importance of MB migration to parts of the body other than 
skin. Developmental defects in this model were caused by overgrowth of recombined 
cells which upregulated MAPK signaling. It is clear therefore that MBs are more sensitive 
to BRAFV600E than adult MCs with tamoxifen-induced expression of the same construct 
(Dhomen et al, 2009). 
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Collectively, these studies that focus on the convergence of embryonic and melanoma 
signalling have already provided key insights regarding cancer formation and progression. 
It is likely that a ‘developmental model’ of cancer may eventually prove to be too 
simplistic, but there is no doubt that it is an extremely effective tool for identifying and 
characterising new cancer-related genes. The inherent migratory capacity of MBs 
suggests that their physiology could be further exploited to uncover genes involved in 
melanoma invasion and metastases. 
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1.2 Metastasis 
Metastases account for over 90% of cancer-related death (Sethi et al, 2011). The 
pathological process of metastases involves a series of biological steps which require the 
co-ordinated spatiotemporal activation of a multitude of signaling pathways (Figure 1.3) 
(Langley et al, 2011). First, tumour cells with metastatic potential detach from the 
extracellular matrix (ECM) at their primary site and invade the basement membrane using 
localised proteolysis to become a malignant cancer. Invasion towards the vasculature 
follows, with eventual penetration of vessel walls (‘intravasation’), the process whereby 
metastatic cells enter the bloodstream. Cancer cells then must withstand the shear 
pressures of the bloodstream as circulating tumour cells (CTCs), and can ultimately 
deposit in distal vascular beds by both active and passive mechanisms. Finally, 
‘extravasation’ into the parenchyma occurs, with heterotypic signalling networks in the 
surrounding stroma creating an environment that promotes metastatic growth.  
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Figure 1.3 Stepwise model of melanoma metastasis (detailed in section 1.2) 
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The inefficiency and challenges of the metastatic process are highlighted by an estimate 
that only 0.01% of CTCs will eventually form secondary tumour growths (Fidler, 1970). 
Experimental evidence suggest that secondary growth of cancer is the most rate-limiting 
step of metastasis: some tumour cells will be unable to promote angiogenesis and 
microenvironmental support, while others will stop proliferating and lie dormant in distal 
organs (Chambers et al, 1995, Barkan et al, 2010). We have already mentioned that the 
metastatic phenotype can be contributed to by both oncogenic mutations and the 
inherent molecular predisposition of different cell lineages for metastases, two concepts 
which are not mutually exclusive and will likely both influence a final cancer outcome. 
This section of the introduction details the cell-autonomous and environmental 
mechanisms which can promote this 0.01% metastatic success, as well as describing some 
of the preclinical and early phase clinical trial challenges involved in assessing metastases 
in the future. 
1.2.1 Metastatic theory 
Two sets of paradigms for metastases encompass different stages of its pathological 
process: the linear progression and parallel progression models debate the point at which 
a primary tumour can develop metastatic potential, while the seed & soil and 
anatomical/mechanical hypotheses dispute the mechanism of metastatic organ spread. 
1.2.1.1 Linear versus parallel progression models 
The central tenet of the linear progression model is that metastatic potential can be 
determined at the primary site of cancer, where tumour cells accrue successive stages of 
mutation and selection in response to environmental pressures (Sethi et al, 2011). In this 
model, an aggressive cancer cell phenotype may be selected after survival within 
conditions foreign to their normal physiological organisation (hypoxia or mediators of 
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inflammation, for instance). Support for this theory comes from the historical 
demonstration that only subsets of cells in heterogeneous primary tumours can 
metastasise, as well as the clinical correlation of metastatic risk with primary tumour size 
(Fidler et al, 1972, Koscielny et al, 1984). More recently, high-powered genomic studies 
have suggested a common late clonal origin of metastases from primary tumours, with 
other non-clonal mutations required to facilitate the metastatic phenotype (Liu et al, 
2009, Campbell et al, 2010, Ding et al, 2010, Yachida et al, 2010). 
Parallel progression describes a process whereby primary tumour cells disseminate very 
early in malignant progression, possibly accruing further mutations to acquire the 
metastatic phenotype at secondary sites (Sethi et al, 2011). This possibility has been 
described preclinically with a genetically modified breast cancer mouse model (Husemann 
et al, 2008). One imagines that the parallel progression model may be more relevant to 
melanoma cells, given their inherent migratory capacity and their cumulative 
physiological vulnerability to mutations from lifelong UVR exposure: this thought is 
supported clinically by the knowledge that primary lesions only a few mm deep can 
predispose patients to metastases (Balch et al, 2009).  
Taken together, although the recent systems biology studies described above favour the 
linear progression paradigm, the clinical reality is that these models of metastatic 
potential are not mutually exclusive and both will apply to tumour progression depending 
on the cancer-context. It is worth noting that either hypothesis would be consistent with 
the melanoma ‘phenotype switching’ model, which has identified two specific subgroups 
of melanoma cells in vitro by their expression of specific genes: a proliferative subgroup 
and an invasive subgroup. Switching between these two phenotypes in response to 
microenvironmental cues provides a biological rationale for the metastatic cascade, as 
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well as lesion heterogeneity and heterogeneity of response to treatments (Widmer et al, 
2012). 
1.2.1.2 Seed & soil versus anatomical/mechanical models 
In 1889, Paget described the Seed and Soil hypothesis after studying a series of autopsy 
specimens from breast cancer patients (Paget, 1887). This model proposes that 
metastatic cells (‘the seed’) have a propensity to inhabit and grow in select host organ 
environments (‘the soil’). A number of later experiments validated this with more detail. 
For instance, Kinsey showed that melanoma cells with a predilection for lung secondaries 
metastasised to host and ectopically explanted lungs preferentially over other organs 
(Kinsey, 1960). Moreover, tumour cells have been shown to selectively adhere to the 
vasculature of their respective target organ (Auerbach et al, 1987). It is impossible to 
imagine that the 50% rate of liver metastases in uveal melanoma does not conform to 
this model. The ‘pre-metastatic niche’ hypothesis extends the theory by suggesting that 
bidirectional signalling between primary and metastatic tumours fashions a hospitable 
vascular microenvironment for the survival and expansion of secondary tumours (Kaplan 
et al, 2005). 
Nonetheless, the seed & soil hypothesis is again not mutually exclusive from the opposing 
anatomical/mechanical model of metastases, and it is likely that both explanations are 
correct to varying extents in different cancer contexts. The anatomical/mechanical model 
proposes that vascular and lymphatic anatomical distribution are the primary 
determinants of metastasis localization (Langley et al, 2011). Such a hypothesis could 
straightforwardly explain the propensity for liver metastases in gastro-intestinal tumours, 
for example. The high incidence of lung metastases in many cancers could also be 
considered a consequence of metastatic tumour cells becoming randomly embedded in 
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the tiny capillaries of the lung microvasculature. However, the experimental evidence 
begun by Paget suggests that this is only the beginning of the story: the challenge of 
understanding the cellular and molecular basis for the complex events in metastases 
continues and remains a difficult process. A good example of this complexity is the ‘self-
seeding’ hypothesis: the process where CTCs re-colonise their primary site of cancer could 
clinically explain local recurrences after seemingly ‘clean’ tumour resections (Kim et al, 
2009). 
1.2.2 Translational considerations in metastasis 
This section focuses on translational issues specific to cancer metastases in general, while 
section 1.4 describes and discusses translational successes in melanoma with some key 
examples in other cancers. Much progress up till now has come with the use of novel 
cytotoxic or cytostatic inhibitors, but not ‘anti-metastatic’ agents. In part this is because 
the concept and design of ‘anti-metastatic’ early phase clinical trials can cause many 
methodological difficulties. One central problem with characterising anti-metastatics is 
that patients referred for phase I trials nearly always already have metastatic disease: 
doctors will have first performed their ethical duty to try all ‘evidence-based’ treatment 
options before referring for an untested option based only on preclinical theory. This 
leaves us with an obvious question, how do you confirm the efficacy of a potentially new 
anti-metastatic drug in patients that already have metastases? The alternative would be 
to ethically justify administration of an unproven and potentially toxic anti-metastatic 
agent to patients who are seemingly cured of their cancer following primary surgery: such 
a trial would be costly, time-consuming, and involve large patient numbers. To add to this 
problem, the possible increased treatment resistance conferred by mutational 
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accumulation in metastases often makes pharamaceutical companies wary of developing 
compounds as pure ‘anti-metastatic’ targets.  
Many other preclinical considerations feature in strategic decisions on how to treat 
metastatic disease for a given cancer. For instance, should we target the tumour 
microenvironment concomitant with treating the tumour itself? It is undisputed that the 
microenvironment plays a greatly extended role in metastases compared to primary 
tumourigenesis, perhaps best demonstrated by the ‘pre-metastatic niche’ concept 
described above (Langley et al, 2011). The success of denosumab (a human monoclonal 
antibody against RANK ligand) in the treatment of breast cancer-related bone metastases 
suggests that this may be particularly important for prevention of organ-specific spread 
(Stopeck et al, 2010). However, attempts to target tumour microvasculature using novel 
therapeutics targeted to the VEGF receptor have so far been relatively unsuccessful, with 
one key problem being a lack of availability of predictive biomarkers (Sethi et al, 2011).  
Another consideration will be how to establish predictors of response to anti-metastatic 
treatment, particularly given the evidence that, in line with the linear progression model, 
metastatic tumours may select against and outgrow their initial driver mutations (Kim et 
al, 2006, Sanz-Moreno et al, 2008). Given the myriad microenvironmental and stromal 
contributions to metastasis, the key to identifying metastatic predictors is likely to involve 
a systems biology approach, including next generation sequencing of primary tumours 
and their metastases, as well as characterisation of transcriptomic, epigenomic, and 
proteomic alterations (Sethi & Kang, 2011). While these methodologies are quickly 
evolving, the creation of a network for publically available tumour banks (pre and post 
treatment) will also assume increasing importance. Finally, robust animal models will be 
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required to efficiently validate candidate metastatic genes as well as novel therapies 
targeted against their proteins. 
Taken together, it seems inevitable that early phase clinical trials will require considerable 
upheaval to accommodate anti-metastatics. It was encouraging to see that recent clinical 
trial assessment of mammalian target of rapamycin (mTOR) inhibitors had evaluated their 
role in alternative clinical settings other than the ‘last line’, including one neo-adjuvant 
study prior to curative surgery (Baselga et al, 2009; Baselga et al, 2012). This was only 
possible due to the combination of the novel mTOR inhibitor with established hormonal 
treatments, but hopefully its success will encourage a transition towards even bolder 
clinical trials. 
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1.3 Melanoma Metastasis 
Approximately 20% of melanoma sufferers over the age of 65 years will present with 
metastases and therefore be incurable at diagnosis. In contrast, 7% of 15-64 year olds 
present with metastases (www.cancerresearchuk.org/cancer-info/cancerstats 
/types/skin/incidence/). The five year survival of these patients is <5%, with a median 
survival of 6 months. Metastases to skin and lungs have a better prognosis than those to 
brain, bone and liver, where patients are often faced with rapidly progressive and 
aggressive disease that confers a life expectancy of 1-2 months (Balch et al, 2001). This 
section attempts to order and discuss the key in vivo molecular components of melanoma 
metastasis that have been reported.  
None of the key melanoma driver mutations or TSG losses (BRAF, NRAS, PTEN, CDKN2a) 
have been particularly related to the development of metastases or diminished outcomes 
in humans. With a 50% rate of liver metastatic disease in uveal melanoma, one might 
have expected GNAQ or GNA11 to associate with worse outcomes. However, a 
retrospective analysis of these patients suggested GNAQ and GNA11 mutation improves 
overall survival in uveal melanoma compared to those patients with uncharacterised 
genetics (Van Raamsdonk et al, 2010). These findings are predictable given that it is not 
individual mutations, but mutation burden, that is important for the metastatic 
phenotype (Walker et al, 2011). Metastatic cells often undergo high rates of spontaneous 
mutation compared to benign cells, often conferring resistance to therapeutics with their 
mutational ‘drift’ (Talmadge et al, 1984). The identification of NEDD9 as a melanoma 
‘metastasis gene’ in mouse tumours that have lost their dependence on Ras signalling 
suggests that the fundamental driver mutations in primary melanoma can become less 
important with cancer progression (Kim et al, 2006, Sanz-Moreno et al, 2008). 
Chapter 1: Introduction  45 
 
1.3.1 Mouse models of melanoma metastasis 
The first melanoma mouse work was performed in the early 20th century, with the 
observation of an inbred mouse strain that was noted to have developed spontaneous 
melanocytic tumours (which ultimately led to derivation of the near-ubiquitous B16 cell 
line). Following this, a number of models employed mutagens such as UVR, DMBA, and 
12-O-tetradecanoylphorbol-13-acetate (TPA). Genetically modified mouse models of 
melanoma were first reported in the 1990s (Damsky Jr et al, 2010).  
Two prescient and contrasting thoughts will likely define the future utility of genetically 
modified mouse models of melanoma metastases.  
1. It is impossible to observe and experimentally manipulate the entire multistep 
process of metastatic melanomagenesis in humans, and there is little knowledge 
of how faithfully in vitro primary and metastatic models can characterise this 
process (Kumasaka et al, 2010). Moreover, despite improved access to metastatic 
tissue with human melanoma, we still have limited insight of metastatic 
mechanisms compared to those of tumour initiation. Therefore, genetically 
modified mice still represent the primary utility for studying the metastatic 
process in its entirety, and one would predict that this will remain the case in the 
longer-term.  
2. There is now a greater emphasis on a systems biology approach for studying 
metastases, which will ultimately lead to large numbers of novel candidate 
‘metastasis’ genes requiring functional validation with traditional laboratory 
approaches. At present, genetically modified mouse models represent a 
potentially time-consuming and expensive bottleneck in this process. 
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The challenge will be to square the above two considerations into rapid, adaptable and 
faithfully representative models of metastatic melanoma in mice.  
1.3.1.1 An optimal genetically modified model 
An optimal genetically modified mouse model of metastatic melanoma helps reveal 
disease biology and can be used for assessment of new therapies. Ideally it will closely 
recapitulate characteristic human melanoma genetics and pathology, including 
metastases to relevant organs within a manageable and reflective timeframe. It may also 
be used to discover and validate driver mutations of disease onset, explore TSGs 
constraining disease progression, and define mechanisms of melanoma invasion and 
metastases. Spatial and temporal control of genetic modifications is important to 
accurately recapitulate spontaneous melanoma (Dankort et al, 2009). Aetiology of disease 
(eg. UVR) may also be represented. With all this in mind, great strides have been made in 
the last 20 years towards this ideal model, although even the best examples will still have 
several limitations.  
1.3.1.2 Working towards an optimal genetically modified model 
Table 1.2 delineates the current advantages and limitations of melanoma mouse model 
systems used to delineate metastasis. Below this, three key conceptual advances towards 
improved metastatic melanoma mouse models are detailed. 
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Mouse Model 
System 
Advantages Disadvantages 
Allografts  Intact immune system and 
correct species environment 
 Potential for real-time 
imaging with reporter genes 
 Multiple genetic 
manipulations can be 
investigated 
 Drug testing and 
development  
 Primary tumour resection often 
required before metastatic 
development 
 Can only use mouse 
melanoma-derived cancer cells  
 Organ tropism not fully 
accurate 
Germline 
genetically 
modified models 
 Intact immune system and 
correct species environment 
 More accurate biological 
model of primary initiation, 
local invasion, and 
metastatic spread 
 More accurate drug testing 
and development possible 
 More accurate histology 
 
 Difficult assessment of cell-
autonomous versus non-cell-
autonomous effects 
 Labour and resource intensive 
 Difficult to track metastases, 
primary tumour resection often 
required 
 Limited metastases and 
metastatic sites, often LN and 
lung 
 Restrictive timeframe of 
primary and metastatic 
development 
Conditional 
genetically 
modified models 
 Temporal and tissue-specific 
control faithfully 
recapitulates features of 
spontaneous disease. 
 No problem distinguishing 
cell-autonomous and non-
cell-autonomous effects 
 Otherwise similar to above 
 Same as last 4 bullet points 
above. 
 
Table 1.2 Mouse models systems used to delineate metastases  
Adapted from Sethi et al, 2011. 
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 Primary tumour removal. Other than finding the time and money required to cope 
with the output from high throughput sequencing analyses, a key challenge with all 
models mentioned in Table 1.2 is the development of efficient and standardised 
protocols for primary tumour removal. This is not a new idea and was reported with 
some success in a previous metastatic model (Kelsall et al, 1998). It is necessary 
because primary tumour burden will often prompt euthanisation of a mouse before 
full development of metastases has been possible: resection could avoid this 
limitation and more accurately reflect the clinical course of melanoma recurrence in 
humans (Francia et al, 2011). However, the technique itself can be difficult and 
impractical: mice often have multiple asynchronous primary tumours which are at 
different stages of growth and local invasion when eventually analysed histologically. 
More time, money and mice could optimise this technique in the short-term, investing 
in a future that can more accurately predict the efficacy of new anti-metastatic 
targets. 
 Tumour histology. This is another issue important to genetically modified models of 
melanoma initiation, and will likely be important to local invasion and metastasis also. 
A key difference between humans and mice is the localisation of MCs and melanoma: 
although they characteristically reside and develop in the dermis of most mouse 
models, humans typically harbour MCs and develop melanomas in the epidermis or 
epidermal-dermal junction (Herlyn et al, 2000).  It is not surprising therefore that the 
majority of melanoma mouse models exhibit primary melanoma more characteristic 
of the human NM subtype, rather than the more frequent SSM (Walker et al, 2011). A 
variety of spindle, epithelioid and mixed primary tumour histologies have been 
reported, as well as differing levels of pigmentation. Taken together or separately, the 
effect of these primary tumour variables on the subsequent development of 
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metastases remains uncharacterised. It is also unclear whether artificially 
manipulating mouse genetics to fully recapitulate human histology is a desirable 
endpoint: the success of the mutant Braf inhibitor, vemurafenib, suggests we should 
concentrate on mouse models that correctly reflect human melanoma genetics first 
(Flaherty et al, 2010). 
 Defining metastatic parameters. One final aspect of improving mouse metastatic 
assessment should be readily applicable. Measures of metastases and metastatic 
propensity are often not reported and could easily be standardised to mimic those 
performed in clinical trials. This could include details such as naevi, mitotic rate, 
ulceration, lesion size at spread, and sites of metastases. A couple of older mouse 
models offered admirable macroscopic and microscopic details of their metastases, 
but one fears that this quality of content may have been lost with reporting some of 
the novel mouse models which have improved genetic recapitulation (Table 1.3) 
(Kelsall et al, 1998, Zhu et al, 1998).  
1.3.1.3 Current optimal models of metastatic melanoma 
Table 1.3 presents a synopsis and some detail of all models which have developed 
metastases. Modelling metastatic melanoma in mice has made great advances in the last 
20 years: this section will focus on two models that most satisfactorily recapitulate the 
genetics, timing, and metastases of the human disease, as well as offer amenability to 
therapeutic treatment.  Between these two models, the four most common genetic 
modifications in human melanoma are represented: NRASQ61K, BRAFV600E, loss of CDKN2A, 
and loss of PTEN. Here we do not detail other reported models, such as those with 
mutant HRAS or over-expression of HGF, which are more dated and less reflective of 
common human melanoma genetics.  
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Report Year Genetic 
Modification 
Carcinogen/ 
Induction 
Histology Metastasis detail 
Nogueira et 
al 
2010 Tyr::HrasG12V; 
CDNK2a-/-; 
PTEN+/- 
no spindle 2/21: lung and LN 
Terzian et al 2010 TPras; 
Mdm4+/- 
DMBA no 7% mets in control TPrasO/+ 
mice: liver, lung, LN 
Kumasaka 
et al 
2010 MT::Ret; 
Ednrb+/- 
no no 44% lung in MT::Ret, increased 
in MT::Ret; Ednrb+/- 
Goel et al 2009 Tyr::BrafV600E; 
CDKN2a+/- 
no spindle/ 
epithelioid 
Lung/LN/brain – no detail 
Dankort et 
al 
2009 Tyr::CreER 
BrafV600E/+; 
PTENlox/lox 
tamoxifen spindle/ 
epithelioid 
100% LN; lung – no detail. 
Inoue-
Narita et al 
2008 DCT::Cre 
PTENfl/fl 
DMBA/TPA spindle 20% lung mets 
Tormo et al 2006 MT::HGF/SF; 
CDK4R24C/R24C 
DMBA/TPA spindle LN in MT::HGF/SF; 
CDK4R24C/R24C and MT::HGF/SF; 
CDK4R24C/+ - no details; lung in 
MT::HGF/SF; CDK4R24C/R24C only 
– no details 
Hacker et al 2006 TPras; 
CDK4R24C/R24C 
UVR no All LN: 92% TPras; CDK4R24C/R24C 
with UVR, 60% TPras; 
CDK4R24C/R24C no UVR, 16% 
TPras with UVR 
Yamazaki et 
al 
2005 K14::SCF; 
XPA-/- 
UVR no 11/20 to LN 
Ackermann 
et al 
2005 Tyr::NrasQ61K/°;  
CDKN2a-/- 
no epithelioid 64% LN; 36% liver or lung 
Von Felbert 
et al 
2004 MT::Ret; IL-6-
/- 
no spindle/ 
epithelioid 
Multiple organs for MT::Ret, 
MT::Ret; IL-6+/-, and MT::Ret; 
IL-6-/- - no details  
Pollock et al 2003 DCT::Grm1 no no LNs – no details 
Recio et al 2002 MT::HGF/SF; 
CDKN2a-/- 
UVR no LN/liver – no details 
Krimpenfort 
et al 
2001 INK4a-/-; 
ARF+/- 
DMBA no 1/10 without DMBA, 2/14 with 
DMBA: LN, lung, spleen, liver 
Kato et al 2000 MT::Ret UVR no 1/2 mice analysed - lung met 
Broome 
Powell et al 
1999 TPras UVR/DMBA/ 
TPA 
no >40% LN/lung with DMBA 
treatment 
Otsuka et al 1998 MT::HGF/SF no spindle/ 
epithelioid 
21% to various organs 
Kato et al 1998 MT::Ret no no 13/25 to various organs 
Kelsall et al 1998 Tyr::SV40E UVR spindle/ 
epithelioid 
36%: lung, LN, kidney 
Zhu et al 1998 TG3 no spindle/ 
epithelioid 
Up to 41% in organs, 100% in 
LNs 
Table 1.3 Details of metastases observed in genetically modified mouse models of 
melanoma. 
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In 2005, Ackermann and colleagues described a Tyr::NrasQ61K/°  mouse which developed a 
36% incidence of lung/liver metastasis when CDKN2a (‘INK4a-/- ‘) was constitutively 
knocked out (Tyr::NrasQ61K/°; INK4a-/- mice) (Ackermann et al, 2005). 64% of these mice 
also had enlarged LNs, although it was impossible to ascertain if these lesions were of 
primary or metastatic origin. Common features of metastatic potential were reported, 
such as macroscopic ulceration and microscopic vascularisation. Timing of primary and 
metastatic melanoma typically occurred within a realistic timeframe of 6-9 months, 
offering an appealing window for therapeutic intervention and characterisation. 
Pigmented dermal primary melanomas occurred with 94% prevalence, and no primary 
tumour removal was attempted. 
More recently, three mouse models expressing melanocyte-specific BrafV600E were 
reported, with one study describing 100% metastatic spread when mutated BRAF was 
combined with melanocyte-specific PTEN deletion (Tyr::CreER BrafV600E/+; PTENlox/lox mice) 
(Dankort et al, 2009, Dhomen et al, 2009, Goel et al, 2009). These Tyr::CreER BrafV600E/+; 
PTENlox/lox mice always developed LN metastases (the issue of whether these were 
primary or metastatic lesions was not addressed), with an unspecified number of lung 
metastases also observed. Pigmented primary dermal lesions with epidermal spread were 
rapidly progressive, requiring euthanisation at 25-50 days after tamoxifen induction. 
Despite this short latency, treatment intervention with combined rapamycin and MEK 
inhibition was effective and induced tumour regression. No primary tumour removal was 
attempted.  In a recent extension of this study, β-catenin was identified as a central 
mediator of metastasis observed in the same mouse model (Damsky et al, 2011). 
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The above two metastatic melanoma mouse models constitute a basis for the results of 
large parts of this thesis: section 7.3 in the discussion will analyse their relative merits and 
disadvantages in more detail. 
1.3.1.4 Xenografts and other models 
The deficiencies of xenograft models of metastatic melanoma have been well 
characterised. Some common examples are cited below (Francia et al, 2011, de Bono et 
al, 2010): 
 Sub-cutaneous (SC)-injected tumours grow rapidly: this is not representative of 
human primaries, and often leads to false positive results when therapeutic 
interventions that target dividing cells are administered. 
 Cell lines used are often genetically ill-defined, and after years of growth adapted 
to a laboratory, may not be indicative of the tumours from which they were 
derived. 
 Immuno-compromised mice do not accurately recapitulate the tumour 
microenvironment. 
 Species-specific incompatibility between mouse stroma and human tumours will 
not accurately recapitulate the tumour microenvironment. 
 Tumours are often injected outwith their orthotopic site: it is unclear whether 
they would grow or respond to treatment similarly in their site of origin. 
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 Novel treatment studies often do not involve previous lines of therapy that would 
provoke resistance in a mouse, and therefore do not accurately represent patients 
receiving novel drugs in early phase trials. 
 The primary tumours traditionally analysed in xenograft treatment studies do not 
reflect the high metastatic and mutational burden of patients receiving novel 
drugs in early phase trials. 
 Endpoints are often ill-defined and unstandardised. 
Nonetheless potential uses of xenografts include pharmacokinetic (PK) analyses, as well 
as validation and further characterization of in vivo results obtained with another more 
representative model. Moreover, orthotopic transfer and direct transfer of human 
tumours may offer valuable results with relatively little time and expense. 
Zebrafish models of melanoma have provided excellent insights into melanomagenesis, as 
well as offering an adaptable resource for genetic manipulation and treatment 
administration (Patton et al, 2005, Patton et al, 2010). Other animals are not easily 
genetically modifiable and their husbandry is extremely expensive (Walker et al, 2011). 
Many carcinogen-induced mouse models of melanoma have been described over the past 
few decades (Table 1.3): as discussed earlier (section 1.1.2), more insight could be 
gleaned from these once we have fully established the mechanistic relationship between 
carcinogens such as UVR and the development of genetic alterations that predispose to 
melanoma. 
Chapter 1: Introduction  54 
 
1.4 Clinical translation and melanoma 
Older cancer drugs such as tamoxifen sometimes achieved success in cancer clinical trials 
using a ‘one size fits all’ approach. For example, although no predictive evaluation of 
oestrogen receptor status was performed in its breakthrough breast cancer trial, the 
benefits of tamoxifen in the majority of women who were oestrogen receptor-positive led 
to a statistically significant result which was not diminished by a lack of response in the 
significant minority of women who were oestrogen receptor-negative (Ingle et al, 1981). 
It is noteable that this strategy would have catastrophically failed if it had been applied to 
the vast majority of translational successes in the last 15-20 years, but pressured 
pharmaceutical companies will often still pursue such an approach, wasting vast amounts 
of time, money, and resource for limited patient benefits (de Bono et al, 2010).  
1.4.1 Lessons from translational research 
For translational research to progress in the future, it is imperative that we recognise the 
reasons for prior successes and failures. Four key steps can help to achieve this: 
1. Strong biological hypothesis. Poor validation of anticancer drug targets has been a 
longstanding problem that leads to clinical trial failures, and is often exacerbated by 
the use of unrepresentative xenograft mouse models (detailed in section 1.3.1.4). 
Biological concepts such as ‘oncogene addiction’ and ‘synthetic lethality’ characterise 
modern rational approaches, identifying predictive biomarkers and providing a 
therapeutic window for potential treatments. Rare success stories here include 
crizotinib, a small molecule inhibitor which reverses the oncogene dependence of a 
subset of non-small cell lung cancers (NSCLC) by targeting an anaplastic lymphoma 
kinase (ALK) fusion rearrangement, and olaparib, a small molecule which induces 
synthetic lethality in BRCA-deficient cancer patients by inhibiting poly(ADP)-ribose 
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polymer formation (PARP) (Fong et al, 2009, Kwak et al, 2010). The identification of 
RAS mutations as a negative predictor of success for epidermal growth factor receptor 
(EGFR) inhibition in colon cancer is a good example of a straightforward biological 
hypothesis that could easily have been considered prior to its clinical characterisation 
years later (Karapetis et al, 2008). 
2. Improved clinical trial design. Consideration of clinical efficacy of novel drugs should 
be expedited in the early clinical trial phases. Phase I trials are traditionally designed 
to dose-find as well as evaluate toxicity, PKs and pharmacodynamics (PDs). Phase II/III 
trials, often performed years later with large patient numbers, will usually be the first 
assessment of treatment efficacy. However, treatment success with vemurafenib 
(small molecule inhibitor of BrafV600E) has demonstrated the clear advantage of 
preclinical identification of enrichment biomarkers (BRAFV600E) to instruct patient 
selection in phase I trials (Flaherty et al, 2010). Conversely, a number of equivocal 
trials with no genotyping input led to a 10 year gap between drug development and 
confirmation of efficacy for EGFR inhibitors (Mok et al, 2009). Characterisation of 
treatment benefits at phase I can lead to the expedition of later phase II/III to confirm 
this efficacy, and also reduce the high frequency of wasted time and money invested 
in failed later phase trials. If an enrichment biomarker is not available at phase I, 
clinical trial designs should include putative biomarkers that could predict treatment 
benefit, early discontinuation, or toxicity at intermediate endpoints. A network of pre- 
and post-treatment tumour banks will become imperative to assist this process. 
3. Re-iterative research. Failed clinical trials can too often lead to pharmaceutical 
companies withdrawing development of potentially effective drugs. It is critical to 
biologically re-interrogate the mechanisms of action of a failed drug, as well as re-
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examine clinical trial design to ensure delivery of an optimal chance of success. A 
common reason for clinical trial rejection that requires further biological dissection is 
drug resistance. EGFR-mediated resistance to vemurafenib in BrafV600E-driven colon 
cancer is a recent example (Prahallad et al, 2012). 
4. Communication. Within a framework that incorporates the sometimes opposing 
cultures of university academia and the pharmaceutical industry, drug development 
requires expert input from molecular and cell biologists, oncologists, molecular 
pathologists, chemists, and structural biologists. Strong communication, particularly 
between academia and pharmaceutical companies, will be imperative for the 
improvements suggested above to become possible.  
1.4.2 Metastatic melanoma translation 
Until very recently, no therapy administered to UK patients with metastatic melanoma 
could extend overall survival. Dacarbazine, a cytotoxic that has been used for years, offers 
limited success though an improvement in symptoms of carefully selected patients 
(Tarhini et al, 2006). Unlike many other cancers with developed treatment protocols, 
melanoma therefore offers an attractive niche for the development of targeted 
treatments that are tailored to their underlying genetic modifications. 
1.4.2.1 Vemurafenib  
In 2011, vemurafenib, a small molecule inhibitor of BrafV600E, was reported as the first 
agent targeted to melanoma genetics that could offer an extension in overall survival of 
metastatic patients, with a hazard ratio of 0.37 compared to control patients treated with 
dacarbazine (Chapman et al, 2011). Response rates were 48% for vemurafenib and 5% for 
dacarbazine. As patient selection was strictly limited to the 50-60% of melanoma patients 
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carrying the BRAFV600E mutation, toxicity was generally tolerable. Several resistance 
mechanisms to vemurafenib have already been described, offering important insights for 
oncologists to re-iteratively dissect treatment of progressing patients with further 
rationally designed 2nd line trials (Poulikakos et al, 2010, Heidorn et al, 2010, 
Hatzivassiliou et al, 2010, Johannessen et al, 2010, Nazarian et al, 2010, Gopal et al, 2010, 
Shao et al, 2010). 
1.4.2.2 Imatinib 
Similar to the protracted timeline of EGFR inhibition in cancer, imatinib in metastatic 
melanoma is unfortunately another paradigm of poorly considered translational research. 
KIT is mutated or amplified in 20% of LMM and 40% of ALM, two melanoma subtypes 
which represent a significant minority of patients (Curtin et al, 2006). Despite this, only 1 
of 64 metastatic melanoma patients showed a partial treatment response in three phase 
II trials of imatinib in ungenotyped metastatic melanoma patients (Ugurel et al, 2005, 
Wyman et al, 2006, Kim et al, 2008).  After a delay of 6 years, a fourth phase II trial 
assessed metastatic melanoma patients for KIT mutation or amplification, and showed a 
23% response rate and 30% rate of disease stability; the mutations and amplification 
state of patients resistant to imatinib were also clarified in this trial, offering further 
opportunities for re-iterative translational research (Guo et al, 2011). 
1.4.2.3 Ipilimumab 
The main other metastatic melanoma success recently described is ipilimumab, a 
monoclonal antibody that targets cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), 
a negative regulator of T cells, and thereby augments T-cell activation and proliferation. 
Both with and without dacarbazine, this drug has also been shown to extend patient 
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survival, although with a smaller response rate and higher toxicity owing to its ‘one size 
fits all’ approach (Hodi et al, 2010, Robert et al, 2011).  
1.4.2.4 Other agents 
Other emerging agents include a variety of preclinically successful MEK and PI(3)K 
inhibitors which are tailored to melanoma genetics and, if they follow the example of 
vemurafenib development, offer exciting potential for further progress. Perhaps the most 
disappointing targeted therapeutic applied in melanoma trials is sorafenib, employed on 
the basis of its anti-VEGFR and anti-Raf activity: poor efficacy was seen in both 
monotherapy and combination trials (Eisen et al, 2006, Hauschild, 2009, Ott et al, 2010). 
Clinical efficacy through inhibition of oncogenic Ras was not achieved by farnesyl 
transferase inhibitors, and remains elusive for treatment of melanoma and other cancers 
(Flaherty et al, 2006). 
 
 
 
Chapter 1: Introduction  59 
 
1.5 Two Novel Melanoma Anticancer Targets 
This thesis examines the anticancer potential of two putative melanoma targets, PIP3-
dependent Rac-exchanger 1 (P-Rex1) and focal adhesion kinase (FAK) (Figure 1.4). As both 
proteins have particularly important roles in physiological migration, we focus on their 
roles in melanoma invasion and metastases, often additionally assessing embryonic 
mouse models as a paradigm for their cancer phenotypes. The two metastatic melanoma 
mouse models described in section 1.3.1.3 provide platforms for the evaluation of P-Rex1 
and FAK that can recapitulate common human genetics: Tyr::NrasQ61K/°; INK4a-/- and 
Tyr::CreER BrafV600E/+; PTENlox/+ mice. Throughout chapters 3-7, there is a commentary on 
potentially relevant translational aspects of this preclinical research. 
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Figure 1.4 Drug discovery cascade 
Schematic flowchart showing the multiple steps required to generate a novel anti-cancer inhibitor 
following inital target discovery. The potential roles of academia, pharma-academic partnerships, 
and pharmaceutical companies are indicated. This thesis focuses on a step of the cascade that can 
only be performed in academia, target validation. P-Rex1 and FAK are the targets studied. 
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1.5.1 PIP3-dependent Rac-exchanger 1 (P-Rex1)  
PREX1 encodes the P-Rex1 Dbl family of Rho guanine nucleotide exchange factors which 
can activate Rho family small GTPases, a major branch of the Ras superfamily of small 
GTPases (e.g. RhoA, Rac1/2/3 and Cdc42) (Wennerberg et al, 2005).  Specifically, P-Rex1 is 
a guanine-nucleotide exchange factor (GEF) for Rac, whose primary cell function is 
induction of actin-mediated membrane ruffling and lamellipodia formation at the leading 
edge of cell migration (Welch et al, 2002, Hill et al, 2005, Barber et al, 2007). Stimulation 
of Rac-GEFs is thought the most important mechanism of Rac activation, allowing Rac to 
function as a bimolecular switch that is able to adopt different conformational states as a 
consequence of GDP or GTP-binding (Rossmann et al, 2005) (Figure 1.5a). The exchange 
of GDP for GTP permits Rac binding to a myriad of different downstream effectors which 
can initiate a diversity of cellular processes, including actin cytoskeletal control, cell cycle 
progression, and ROS formation (Mack et al, 2011). Most characterised of the Rac 
effectors are actin-associated proteins such as WASP, WAVE, and Pak (Ben-Yaacov et al, 
2001, Cotteret et al, 2002); NADPH oxidase has also been identified downstream as a link 
to its role in ROS formation (Bokoch et al, 1995). 
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Figure 1.5 Structure and function of P-Rex1 
(a) Rac-GEFs such as P-Rex1 catalyse Rac cycling from a GDP-bound inactive form to a GTP-
bound active form, thus altering its conformation so that it can interact with downstream effectors.  
GAPs promote the intrinsic GTPase activity of Rac, returning it to its inactive GDP-bound state. 
GDIs sequester the inactive Rac-GDP so that it cannot be activated by GEFs. GEFs = guanine-
nucleotide exchange factors, GAPs = GTPase activating proteins, GDIs = guanine-nucleotide 
dissociation inhibitors (b) Schematic diagram showing P-Rex1 domain structure (see Section 1.5.1 
for further detail). DH = Dbl homology, PH = pleckstrin homology, IP4P = inositol polyphosphate 4-
phosphatase. 
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There are three members of the P-Rex family: P-Rex1, P-Rex2a, and P-Rex2b. Normally, P-
Rex1 is expressed in haematopoietic cells and the brain, while P-Rex2a and P-Rex2b are 
more ubiquitously expressed in other tissues, including the skeletal muscle and heart 
(Welch et al, 2002, Donald et al, 2004, Rosenfeldt et al, 2004). They have similar domain 
structure and can all exhibit GEF activity: tandem Dbl homology (DH)/pleckstrin homology 
(PH) domains, typical of Rho family GEFs, are followed by 2 DEP and 2 PDZ domains. An 
inositol polyphosphate 4-phosphatase (IP4P)-like domain follows in P-Rex1 and P-Rex2a 
(Figure 1.5b). P-Rex1 is a cytosolic 185kDa protein with 41 exons (Welch et al, 2002). 
1.5.1.1 P-Rex1 discovery and physiological regulation 
Approximately 70 Rho-family GEFs with tandem DH/PH domains have been identified to 
date, each exhibiting their own tissue, substrate, and upstream specificity. It is thought 
that they apply these different inputs to confer signalling specificity, with consequent 
coupling of Rac or other RhoGTPases to varying downstream effectors (Rossmann et al, 
2005). Despite the large number of GEFs described, P-Rex1 was uniquely characterised as 
a result of its activity, using functional and biochemical purification from the cytosol of 
motile neutrophils (Welch et al, 2002). Before this, GEFs had previously been identified 
either by their homology to other known GEFs, or as oncogene products (Weiner et al, 
2002). 
The unique character of P-Rex1 is also evidenced by its direct stimulation from PI(3)K-
stimulated phosphatidylinositol (3,4,5)-trisphosphate (PIP3) production and the beta-
gamma subunits of the heterotrimeric G proteins (Gßγ) (Welch et al, 2002, Hill et al, 2005, 
Barber et al, 2007). The PI(3)K pathway had only been shown to indirectly regulate other 
Rho-GEFs prior to P-Rex1 discovery, and P-Rex1 was also the first Rho-GEF shown to be 
directly stimulated by Gßγ. These two activators of P-Rex1 were shown to stimulate its 
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activity synergistically, raising its potential as a ‘coincidence detector’, designed to 
respond to the combined or isolated appearance of at least two different inputs that 
would likely bind separate P-Rex1 domains. 
Myriad reports of P-Rex1 physiology over the past 10 years have detailed further 
functions in neuronal migration and angiogenesis, but still predominantly focus on its 
neutrophil role (Hill et al, 2005, Yoshizawa et al, 2005, Welch et al, 2005, Dong et al, 2005, 
Zhao et al, 2007, Barber et al, 2007, Waters et al, 2008, Carretero-Ortega et al, 2010, 
Lawson et al, 2011). A P-Rex1-deficient mouse (impaired catalytic GEF domain) exhibited 
no gross phenotype and a normal lifespan; further evaluation revealed that they were 
constitutively smaller than wild-type mice, with a mild neutrophilia and aberration of 
their normal neutrophil activity (Welch et al, 2005, Dong et al, 2005). Another report 
assessed the domain function of P-Rex1 using targeted deletion mutants: an in vitro assay 
measuring GTP-loading of Rac showed that the DH domain mutant was catalytically 
inactive, confirming it as the catalytic site of GEF activity typical to Rho-GEFs; mutation to 
the PH domain precluded PIP3 stimulation and control (Hill et al, 2005). Mutation of the 
DEP, PDZ, or IP4P-like domains, which confer structural specificity of P-Rex1 compared to 
other Rho-GEFs, had no major consequences but likely have important functional 
interactions with the tandem DH/PH domains (Hill et al, 2005, Urano et al, 2008). Of note, 
the IP4P-like domain has no phosphatise activity and its role remains largely 
uncharacterised (Welch et al, 2002). The relative roles and contributions of P-Rex1 with 
another Rac-GEF, Vav, has also been assessed, while an in vitro study suggested P-Rex1 
activity could also be controlled by protein kinase A phosphorylation (Mayeenuddin et al, 
2006, Lawson et al, 2011). 
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1.5.1.2 P-Rex1 in cancer 
In addition to its activation by both PI(3)K and GPCR signaling, a number of factors 
implicated a role for P-Rex1 in cancer during the early stages of its physiological 
characterisation: 
1. Aberrant activation of Rac in cancer. Rac control of the actin cytoskeleton can be 
disrupted in cancer for invasion and metastasis (Mack et al, 2011). For example, 
inhibition of Rac diminishes the motility and proliferation of breast cancer cells in 
response to EGFR or ErbB3 ligands (Yang et al, 2006, Yang et al, 2008).  
2. Aberrant activation of Rac-GEFs in cancer. Unlike Ras proteins, mutations of Rho-
GTPases are uncommon in cancer despite the evidence for malignant deregulation of 
Rac. A cancer-specific role for Rac-GEFs including TIAM1, Vav1/2 and DOCK3 can 
alternatively contribute to this, with tumour type not necessarily related to the tissue-
specific function of a given RacGEF (Minard et al, 2004, Fernandez-Zapico et al, 2005, 
Patel et al, 2007, Sanz-Moreno et al, 2008). For instance, Vav1 is normally expressed 
in haemopoietic cells, but unexpectedly upregulated in pancreatic cancer to promote 
proliferation in synergy with the EGF receptor (Katzav et al, 1989, Fernandez-Zapico et 
al, 2005). Alternatively, TIAM1 is ubiquitously expressed in human tissue and now has 
a role described in a number of different cancer types (Hoffmann et al, 2008). It is 
likely that several other Rac-GEFs will contribute to tumourigenesis in ways that are 
yet to be characterised (Minard et al, 2004, Fernandez-Zapico et al, 2005, Patel et al, 
2007, Sanz-Moreno et al, 2008).  
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3. PREX1 amplification. PREX1 is situated at chromosome region 20q13.13, a site 
commonly amplified in human cancer where a number of ‘cancer-initiating’ genes 
were recently identified (Hodgson et al, 2003, Rahman et al, 2011, Tabach et al, 2011). 
4. mTOR interaction. mTOR, another protein commonly deregulated in human cancer, 
has been reported to interact with P-Rex1 to mediate Rac-driven cell migration 
(Hernandez-Negrete et al, 2007, Zoncu et al, 2011). This interaction was subsequently 
reported in ovarian cancer, whereby endogenous P-Rex1 was shown to promote 
mTOR complex 2-mediated Akt1 activation and cell migration (Kim et al, 2011). 
The importance of P-Rex1 in cancer was confirmed in 2009, with reported roles in 
prostate and breast cancer in particular: 
 Prostate cancer. Qin and colleagues showed that exogenous and endogenous P-Rex1 
expression promotes migration and invasion of prostate cancer cell lines, in a manner 
consistent with Rac activity (Qin et al, 2009). P-Rex1 is not present in normal prostate 
tissue but was upregulated in metastatic cell lines. Ectopic P-Rex1 increased 
lamellipodia formation and facilitated LN metastases in a xenograft model, while 
increased P-Rex1 IHC expression in human tissue was associated with more aggressive 
disease. This initial study was later supplemented with a mechanism for P-Rex1 
upregulation in prostate cancer, which is not frequently affected by amplification of 
the 20q13 locus (Wong et al, 2011). Chemical and genetic experiments validated 
epigenetic regulation of P-Rex1: the P-Rex1 promoter and its Sp1 binding sites were 
identified, and an interaction between Sp1 and histone deacetylases (HDACs) were 
demonstrated to regulate P-Rex1 promoter transcription. Finally, HDAC disassociation 
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from Sp1 was suggested as a putative mechanism for P-Rex1 derepression in invasive 
cancer.  
 Breast Cancer. A clear role for P-Rex1 in breast cancer has also been demonstrated 
(Montero et al, 2010, Sosa et al, 2010). First, Sosa and colleagues were surprised to 
discover the unique upregulation of P-Rex1 relative to other Rac-GEFs in a host of 
luminal breast cancer cell lines. Similar to the prostate, its expression is normally 
minimal in breast tissue. IHC and cDNA analysis of human cancer tissue revealed the 
cell-autonomous association of high P-Rex1 with ER positivity, HER2 positivity and LN 
metastases. P-Rex1 siRNA interference diminished Rac-GTP levels, depleted cell 
ruffles, and reduced migration of HER2-expressing cells, and a marked impairment of 
xenograft tumourigenesis was also observed with P-Rex1 depletion. Second, further 
insight of P-Rex1 tumourigenic regulation was offered by Montero and colleagues 
(Montero et al, 2010). Multisite phosphorylation of P-Rex1 was identified by 
neuregulin stimulation of cell lines, and a serine phosphorylation/ dephosphorylation 
cycle that had similar kinetics to Rac activation was identified. A role for endogenous 
P-Rex1 in breast cancer proliferation, as well as invasion, was highlighted. Finally, a P-
Rex2a study reported its inhibition of PTEN lipid phosphatase activity and stimulation 
of the PI(3)K pathway in cancer: a significant association of PTEN and P-Rex2a by qRT-
PCR in a breast tumour dataset was demonstrated (Fine et al, 2009). To date, this is 
the only report of the involvement of P-Rex2 in tumourigenesis. 
1.5.1.3 Aims: P-Rex1 in melanoma 
A role of P-Rex1 in melanoma or any cells of the MC lineage had not been reported prior 
to this PhD. We hypothesised that there were several reasons for an important 
contribution to melanoma from P-Rex1 (Figure 1.6): 
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1. Deregulation of the PI(3)K pathway is a central feature of melanomagenesis, and P-
Rex1 is directly stimulated by PIP3 (see Section 1.1.4.2). 
2. Amplification of the chromosome site of PREX1, 20q13, has been described in 
melanoma (Koynova et al, 2007). 
3. A microarray study of melanoma cell lines identified P-Rex1 as a key gene 
downstream of MAPK signalling and repressed by MEK inhibition: the importance of 
this pathway in melanoma is also detailed earlier in the introduction (see Section 
1.1.4.1) (Shields et al, 2007). 
4. Although there has been a low frequency of Rac mutation characterised in cancer so 
far, Rac-GEFs have been implicated in melanomagenesis through their regulation of 
Rac, helping to delineate the contribution of Rac to invasion (http://cancer. 
sanger.ac.uk/cosmic/gene/overview?ln=RAC1, Uhlenbrock et al, 2004, Sanz-Moreno 
et al, 2008). Sanz-Moreno and colleagues showed that, in melanoma cells, Rac 
controlled MLC2 phosphorylation to dynamically switch between mesenchymal and 
amoeboid modes of cell movement; in addition, the RacGEF DOCK3 was shown to 
combine with NEDD9 to activate Rac, thereby reducing MLC2 phosphorylation and 
promoting mesenchymal movement (Sanz-Moreno et al, 2008). Conversely, ectopic 
TIAM1 signalling through Rac has been shown to promote a morphological change to 
amoeboid-type in metastatic melanoma cells (Uhlenbrock et al, 2004). Taken 
together, these studies suggest the upstream control of Rac by its GEFs can 
temperospatially control its role in invasion; one suspects that a myriad of other as 
yet uncharacterised RacGEFs will signal through Rac using other mechanisms to affect 
this process. 
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Figure 1.6 Potential P-Rex1 signalling in melanoma 
P-Rex1 has been associated with several important pathways described in melanomagenesis: 
Ras-Raf-MEK-ERK, PI(3)K-mTOR, GPCR, and Rac signalling. Its main reported downstream 
function is to promote Rac-mediated migration through formation of lamellipodia and membrane 
ruffles (white arrows), shown here in a photomicrograph of the CHL1 melanoma-derived human 
cell line using 2D timelapse.  
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Given the the highly motile nature of melanoma cells and the known physiological and 
cancer-specific functions of P-Rex1, this thesis concentrates on its contribution to 
metastases and the invasive phenotype. P-Rex1 has not previously been characterised in 
genetically modified animal models of cancer that can genetically and pathologically 
recapitulate the human disease: this thesis described its role in the two mouse models 
summarised earlier in the introduction, Tyr::NrasQ61K/°; INK4a-/-  and Tyr::CreER BrafV600E/+; 
PTENlox/lox mice (Section 1.3.1.3) (chapters 3 and 5). Studies of P-Rex1 in embryonic mouse 
models were also used to provide mechanistic insight and consolidate our results 
(chapters 4 and 5). Chapter 3 also elaborates on the translational significance of our 
results, detailing what might be an optimal method for targeting P-Rex1. 
1.5.2 Focal adhesion kinase (FAK) 
FAK is a 125kDa highly conserved non-receptor tyrosine kinase and scaffold protein, first 
described in 1992 (Schaller et al, 1992, Hanks et al, 1992). It is expressed in a wide variety 
of tissues where it localises to focal adhesions. Its amino-terminal four-point-one, ezrin, 
radixin, moesin (FERM) domain is followed by a central catalytic domain, and then a 
carboxy-terminal Focal Adhesion Targeting (FAT) domain (Figure 1.7).  
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Figure 1.7 Structure and function of FAK 
Schematic diagram showing FAK domain structure (see Section 1.5.2 for further detail). Its two 
most characterised phosphorylation sites, Y397 and Y925, are also represented. FERM = four-
point-one, ezrin, radixin, moesin; FAT = Focal Adhesion Targeting. 
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The only other FAK family member is another non-receptor tyrosine kinase, proline-rich 
tyrosine kinase 2 (Pyk2), predominantly expressed in haematopoietic cells and cells of the 
nervous system (Lev et al, 1995). Pyk2 shares 65% sequence homology with FAK (Schultze 
et al, 2010). Its tyrosine phosphorylation sites are similar to those of FAK, although it 
generally localises to peri-nuclear sites within the cell, rather than focal adhesions (Ilic et 
al, 1997). Pyk2 has been shown to compensate for depleted FAK signalling in endothelial 
cells, demonstrating that dual inhibition of FAK and Pyk2 may be required for efficient 
targeting of angiogenesis (Sieg et al, 1998). An isoform of FAK with no amino-terminal, 
FAK related non-kinase (FRNK), has been identified and shown to function as dominant 
negative regulator of FAK function (Schaller et al, 1993, Richardson et al, 1996). 
1.5.2.1 Regulation of FAK 
FAK is regulated through a series of complex intra- and inter-molecular interactions 
involving all three of its domains. It has 6 sites of tyrosine phosphorylation (Y397, Y407, 
Y576, Y577, Y861, Y925), the most characterised of which is its major site of 
autophosphorylation, Y397 (Figure 1.7) (Calalb et al, 1995). Following integrin-ECM 
interaction, phosphorylation of FAK-Y397 leads to the recruitment of several proteins 
including Src. Src-dependent phosphorylation will in turn mediate phosphorylation of the 
other 5 FAK tyrosine residues, enhancing FAK activity and stimulating its role as a focal 
point of multiple pathways (Schlaepfer et al, 1999). Further data has suggested that FAK-
Y397 is regulated by differential phosphorylation of the other FAK tyrosine residues (Leu 
et al, 2002). Associations with both the P(I)3K  and MAPK pathways have been described 
with FAK-Y397 and FAK-Y925, respectively (Schlaepfer et al, 1999, Chen et al, 1996). FAK 
serine phosphorylation is also likely to play an important role within the cell, with 4 major 
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sites described (S732, S840, S843, and S910); in particular, FAK-732 has a described role in 
neuronal migration and microtubule organization (Ma et al, 2001, Xie et al, 2003). 
The FERM domain of FAK resides in its amino-terminal, where it controls a myriad of 
complex signalling pathways. It mediates intra-molecular interactions between the FAK 
kinase domain and the FAK amino-terminal domain, negatively regulating both FAK 
phosphorylation and activity; an effect that can be reversed by its abrogation (Cooper et 
al, 2003). Structural evidence has suggested that this loss of activity results from the 
folding and binding of the FERM domain to the kinase domain, leading to a closed and 
inactive conformation of FAK (Dunty et al, 2004, Lietha et al, 2007). FERM is also known 
to functionally associate inter-molecularly with growth factors implicit in cell migration, 
such as the epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor (PDGFR) (Sieg et al, 2000). In the carboxy-terminal of FAK, the focal adhesion 
targeting (FAT) domain is required for its localisation to focal adhesions, a process shown 
to be dependent on its binding to the protein Paxillin  (Tachibana et al, 1995).  
1.5.2.2 Physiology of FAK 
FAK acts as a key regulator of adhesion and migration in healthy cells (Zachary et al, 1992, 
Kornberg et al, 1992). Its importance in development has also been extensively 
characterised, with roles described in key processes such as angiogenesis and 
proliferation that may reflect its reported tumourigenic activity (Fonar et al, 2011, Zhao et 
al, 2010). Moreover, genetic manipulation of FAK has also highlighted an important pro-
survival role, protecting cells from a number of potentially apoptotic insults (Sonoda et al, 
1999, Sonoda et al, 2000, Xu et al, 2000, Sakurai et al, 2002, Huang et al, 2007). 
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The key role of FAK in cell migration is perhaps best illustrated by the developmental 
lethality of mice with constitutive FAK deletion, a direct consequence of defective cell 
movement leading to problems with embryonic gastrulation (Ilic et al, 1995). Depletion of 
FAK in mouse embryo fibroblasts (MEFs) has been shown to markedly impair growth-
factor induced cell migration, whereas its over-expression has been shown to enhance 
this effect (Schlaepfer et al, 1999, Cary et al, 1996). One way by which FAK can promote 
this migration is through phosphorylation of neural wiskott aldrich syndrome protein (N-
WASP), a mediator of the actin-related protein 2/3 (Arp2/3) complex which can regulate 
filopodia formation and cell spreading (Wu et al, 2004).  
1.5.2.3 FAK in cancer 
FAK is deregulated in human cancer, where it is thought to contribute to proliferation, 
invasion, survival and angiogenesis (Owens et al, 1995, Weiner et al, 1993, Ilic et al, 2003, 
Schaller et al, 2001). These hallmarks of cancer are promoted by FAK upregulation of a 
number of intracellular signalling cascades common to malignancy, such as the MAPK, 
PI(3)K, and JNK pathways (Schaller et al, 2001, Zhao et al, 2009). Transgenic animal 
models have described a role for FAK in breast and skin cancer progression and 
metastasis (McLean et al, 2004, Lahlou et al, 2007, Provenzano et al, 2008).  
In contrast to these pro-tumourigenic properties of FAK, a conflicting picture has emerged 
in myriad studies analysing its expression in human cancer tissue. In various human 
cancers, high FAK expression has been associated with worse prognostic outcomes (Fujii 
et al, 2004, Lark et al, 2005, Giaginis et al, 2009, Gabriel et al, 2009, Tavernier-Tardy et al, 
2009), no change in prognosis (Schmitz et al, 2005, Theocharis et al, 2003, Furuyama et al, 
2006), and improved outcomes in some cases (Gabriel et al, 2006, Giaginis et al, 2009). 
Reduced expression of FAK in liver metastases compared to a matched colonic 
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adenocarcinoma primary has also been reported (Ayaki et al, 2001). However, none of 
these studies offer information on whether FAK may contribute to these prognoses rather 
than just being an association. Cell biological work is just beginning to suggest 
mechanisms and tumourigenic contexts in which FAK can act as a tumour suppressor 
(Zheng et al, 2009, Sandilands et al, 2011). 
1.5.2.4 Aims: FAK in melanoma 
Chapter 6 details the role of FAK in melanoma using the same genetically modified in vivo 
models described in the other results chapters. FAK is an altogether different anticancer 
target to P-Rex1, with a long reported role in malignancy that has led to recent evaluation 
of FAK kinase inhibitors in early phase trials. It seemed likely that, through its myriad 
biological functions, FAK would contribute to melanoma also.  
Although its role in melanoma and cells of the melanocyte lineage is relatively unstudied, 
Meierjohann et al have described a phenotype for FAK using the Xiphophorus melanoma 
system as well as mouse-derived cell lines (Meierjohann et al, 2006).  Stimulation of the 
EGFR variant, Xmrk, produced an interaction with FAK and an increase in focal contact 
and actin cytoskeleton turnover. Consistent with this, over-expression of dominant-
negative FAK reduced Xmrk-induced migratory activity by 40% in mouse melanoma cells 
to the otherwise scarcely motile melanocytes turnover. 
This thesis aims to clarify the role of FAK in melanomagenesis using genetically modified 
mouse models. The establishment of FAK as a therapeutic anticancer target also serves as 
a useful backdrop for some of the more translational caveats in the P-Rex1 study.
  
 
Chapter 2 
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2.1 Embryo analysis: ß-galactosidase (Dct-lacZ) staining 
Time of gestation was calculated using noon on the day of detection of a vaginal plug as 
E0.5, but also noting and comparing the external appearance of the embryo.  Embryos 
were dissected at E13.5 or E15.5 then fixed in 0.25% glutaraldehyde at 4°C for 45 min on 
a rolling platform. Embryos washed in PBS at 4°C for 15m on a rolling platform, detergent 
washed (2 mM MgCl2, 0.01% Na-deoxycholate, 0.02% NP-40 in PBS) at room temperature 
x3 (30 min, 15 min x 2). ß -galactosidase substrate (1M MgCl2, 0.02% NP-40, 0.01% Na-
deoxycholate, 0.04% X-Gal (Promega), 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6) then added to 
the embryos which were incubated in darkness overnight. Embryos post-fixed in 4% 
paraformaldehyde for 2h at 4°C. 
2.1.1 Migration assays  
Cells counted and distances measured using Image J (Figure 2.1). Minitab used to 
compare parameters between genotypes.  
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Figure 2.1 Dct-lacZ melanoblast migration assays  
Schematic picture detailing quantification of melanoblast migration in the forepaw at E15.5. Levels 
1 to 6 from top to bottom represent areas of 500µm x 500µm. Melanoblasts counted at each level 
and numbers compared between genotypes (b) As per (a), except at E13.5. Levels 1 to 3 across 
torso of each embryo represent areas of 500µm x 1500µm. Melanoblasts counted at each level 
and their numbers compared between genotypes (c) Schematic picture detailing alternative 
method for quantification of melanoblast migration in the forepaw at E15.5. The distance between 
5
th
 most distal melanoblast and the end of the forepaw was measured and compared between 
genotypes. 
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2.1.2 Melanoblast cell number assays  
Cells counted using Image J (Figure 2.2). Minitab used to compare numbers between 
genotypes.  
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Figure 2.2 Dct-lacZ melanoblast cell number assays  
(a) Schematic picture detailing quantification of melanoblast cell numbers at E15.5. Area 
represented: 1mm x 3mm (b) Schematic pictures detailing method for quantification of 
melanoblasts at E13.5. Areas represented 500µm x 1500µm. Melanoblasts were counted and their 
numbers compared between genotypes. For both (a) and (b), the area used for quantification of 
cell numbers represented the most proximal point of melanoblast migration from the neural crest 
which could be accurately assayed. Counting melanoblasts in more distal regions would have 
introduced a migrational component to the assay which we aimed to avoid. 
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2.2 Embryo analysis: Ex vivo melanoblast live imaging  
Performed as described by Mort and colleagues (Figure 2.3) (Mort et al, 2010). A freshly 
dissected E15.5 embryonic skin sample was sandwiched between a nucleopore 
membrane (Whatman) and a gas permeable Lumox membrane in a Greiner Lumox 
culture dish (Greiner Bio-One GmbH) so that the epidermal side of skin was in contact 
with the Lumox membrane. To immobilize the sample, Growth Factor Reduced Matrigel 
(BD Bioscience) was used to cover the whole assembly and incubated at 37°C for 10 min. 
Culture medium (Phenol red free DMEM supplied with 10% FBS) was added. 
Drugs/inhibitors were added to Matrigel and medium 1 hr before imaging. Time-lapse 
images were captured using an Olympus FV1000 or Nikon A1 confocal microscope in a 
37°C chamber with 5% CO2 at 20× magnification for 6h with slices taken every 7.5 min. 
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Figure 2.3 Tyr::Cre Z/EG melanoblast technique 
Schematic diagram demonstrating technique for migration and cell number assessment of E15.5 
embryos derived from Tyr::Cre Z/EG mice (further detail in section 2.2). Mouse with any gene 
manipulation of interest can be bred to the Tyr::Cre Z/EG reporter mice, then their melanoblast 
characteristics assessed. White arrow shows typical flap of skin microdissected and then placed in 
ex vivo culture, as demonstrated in the top right diagram. Each green ‘dot’ in the two bottom right 
panels represents a melanoblast under confocal imaging. Timelapse allows live assessment of 
cells in flank skin of embryo. 
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2.2.1 GFP migration assays  
20 cells per timelapse sample (if possible) were manually tracked using ImageJ. ImageJ 
chemotaxis tool was then used to quantify co-ordinates. Timelapse images were focused 
on flank skin of embryo rather than limbs (as described in section 2.1.1 with DCT-lacZ 
assays). Minitab was finally used to compare speed and Euclidean distance between 
genotypes. Euclidean distance is the distance between two points that one would 
measure with a ruler, no matter what tortuous route the cell may have taken to reach 
that point. 
2.2.2 GFP cell number assays  
Number of cells present in images at 3 separate timepoints of a sample were quantified 
using Image J. Standard image measured at x20 magnification was 635x 635µm. Minitab 
was used to compare cell numbers between genotypes.  
2.3 Mouse treatments, ageing and survival cohorts 
For the P-Rex1 project, 80 Tyr::NrasQ61K/°; INK4a-/- and 10 C57BL6 mice were monitored 
for up to 18 months for development of melanoma and signs of metastasis. For the FAK 
project, 50 Tyr::NrasQ61K/°; INK4a-/- mice were monitored for up to 18 months for 
development of melanoma and signs of metastasis. For Tyr::Cre Racfl/fl; P-Rex1-/- mice, 7 
pups were followed until approximately 3 weeks of age, after which they were all 
euthanised for developing signs of a neurological defect.  
All mice were checked 3x weekly for development of malignant melanoma or any other 
pathology. For all genetically modified and injected mice, endpoint criteria were 
melanomas ≥ 15mm, ulcerating melanomas, cachexia, significant weight loss, or 
weakness and inactivity. Upon meeting these criteria, mice were euthanised. Mice were 
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examined for the presence of frank metastasis upon dissection, but also visualisation of 
haematoxylin and eosin (H&E) stained sections for further identification of microscopic 
metastases. Organs/tumours were removed and fixed in 10% buffered formalin overnight 
at room temperature. In particular, melanomas and skin were placed on Whatman paper 
then subjected to vertical incision prior to formalin immersion. Fixed tissues were paraffin 
embedded and 5mm sections placed on sialynated/poly-L-lysine slides for IHC analysis. LN 
metastases were not included in this analysis due to difficulty in distinguishing them from 
normal melanocyte populations that can be found in lymphoid tissue.  
Tumour frequency of primary melanoma was calculated as median value from weekly 
counting of number of melanomas per live mouse. Tumour burden of primary melanoma 
was calculated as median value from weekly assessment of length/breadth of largest 
melanoma affecting each affected live mouse (eg. Figure 5.7).  Tumour frequency and 
burden of metastases was calculated as mean value by tallying melanocytic lesions and 
measuring the length/breadth of lesions from 3 histological slices of each affected organ 
(eg. Figure 3.3). For tumour burden: with each give mouse and timepoint, length and 
breadth were measured and multiplied for a final result measured in mm2.  
2.3.1 Tail vein (TV) treatments  
For TV-injections into C57BL6 mice, cultured cells were maintained in antibiotic-free 
media for 1 week prior to injection. Cells were detached with trypsin, then blocked 
through suspension in complete culture media supplemented with 10 % foetal bovine 
serum. Cells were subjected to two rounds of washing, involving centrifugation at 100g 
for 5m followed by resuspension in 1 x Hanks’ Balanced Salt Solution (HBSS).  Cells were 
finally resuspended in HBSS to a concentration of 1 x 107 cells/ml and TV-injected at 1 x 
106 cells/animal in a volume of 100μl.  
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2.3.2 Tamoxifen  
For tamoxifen induction of Tyr::CreER BrafV600E/+ mice, dorsal hair was shaved and 1mg in 
200µl of 100% ethanol applied to shaved area once daily for 5 days. 
2.4 Statistical analyses 
Statistical analyses in mice were carried out using Minitab® version 15 for Windows. Cell 
migration, invasion, and cell number differences were determined using the Mann-
Whitney test. Distinction of metastasis and primary melanoma incidence was achieved 
using chi-square testing. Survival differences were determined with log-rank testing. All p 
values were considered significant at p = <0.05. All appropriate value sets were tested for 
normality using a Kolmogorov-Smirnoff normality test. 
2.5 Small Animal Regulations  
All studies were conducted in accordance with UK home office guidelines. All mice were 
maintained under non-barrier conditions and given a standard diet (Harlan) and water ad 
libitum.  All mouse experiments were performed on a C57BL6 background apart from 
DCT-lacZ experiments which were performed on mice which were 50% mixed and 50% 
C57BL6. 
2.6 Techniques used in mouse modelling 
The general principles of creating genetically modified mouse models are similar to those 
utilised in other forms of genetic engineering. Using recombinant DNA techniques, an 
isolated gene of interest is added to a genetic construct where it is combined with other 
genetic elements in order for it to work efficiently. These will often include a promoter to 
initiate transcription of the gene and control its localisation, and a selectable marker to 
determine which cells have been transformed by the new gene. Most commonly, the next 
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step is for construct DNA to be co-cultured and incorporated into embryonic stem cells, 
which exploits the potential to create defined mutations through homologous 
recombination. Successfully transformed cells are selected for and injected into mouse 
blastocysts. Blastocysts are then transferred into the uterus of female mice and tail 
biopsies of offspring taken to isolate DNA for analyses by Southern blot or PCR, resulting 
in the identification of transgenic founders. These founders are then bred to produce 
genetically modified offspring. 
2.6.1 Transgenic expression or inactivation of genes 
Unlike other mice used in the thesis (sections 2.6.2-2.6.4), these mice express genes in a 
non-physiological manner owing to ectopic promoter and enhancer elements. The 
random nature of transgene integration can often lead to formation of large concatamers 
which invariably promote over-expression. Examples of this strategy in the thesis are 
Tyr::NrasQ61K/°, P-Rex1-/-, and INK4a-/- mice.  
2.6.2 Endogenous inactivation of tumour suppressors or oncogenes 
Endogenous genetically modified mice (those described in sections 2.6.2-2.6.4) use their 
native promoters for genetic manipulation through the use of ‘knockout’ technology. In 
modern conditional gene mutation strategies, the gene of interest is flanked by 
recombinase recognition sites (eg. ‘loxP’ or ‘flox’ sites) and will be deleted in the presence 
of recombinase (‘Cre’ recombinase in this thesis) by inter-crossing with mice that express 
recombinase in a melanocye-specific fashion (Tyr::Cre or Tyr::CreER). An example of this 
technique in this thesis is PTEN manipulation in chapter 5. Examples of this strategy in the 
thesis are Tyr::Cre PTENlox/lox and Tyr::Cre FAK fl/fl mice. 
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2.6.3 Endogenous expression of oncogenes 
Principle is the same as described in section 2.7.1, except this time a transcriptional 
terminator (eg. a ‘STOP’ codon) is flanked by recombinase recognition sites to separate an 
oncogene from its tissue-specific promoter. Expression of recombinase deletes the STOP 
codon, allowing oncogene expression to occur. An example of this strategy in the thesis 
are the Tyr::CreER BrafV600E/+ mice described in chapter 5. 
2.6.4 Endogenous inducible oncogene expression 
The Tyr::CreER BrafV600E/+ model described in chapter 5 also exploits tamoxifen-
regulatable oncogene activity using melanocyte-specific expression of a fusion protein 
incorporating BrafV600E and a ligand-binding domain from the oestrogen receptor. The 
fusion protein is sequestered by heat shock proteins in the absence of an inducer. The 
presence of tamoxifen results in release of BrafV600E from the oestrogen receptor fusion. 
2.6.5 Reporter mouse strains 
The phenotypes induced by the genetic manipulations described in this thesis are 
characterised by inter-crossing mice carrying genes of interest with reporter mouse 
strains that carry a marker gene separated from their melanocyte-specific promoter by a 
transcriptional terminator.   The marker is transcribed when recombination deletes the 
transcriptional terminator. Melanocyte-specific reporter mice strains employed in this 
thesis are Tyr::Cre Z/EG and DCT::β-galactosidase (otherwise referred to as DCT-lacZ). 
Cells derived from Tyr::Cre YFP mice (MRC Human Genetics Unit, Edinburgh) were also 
used for Figure 4.2a. 
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2.7 Mouse Alleles 
Mice alleles described in experiments were: P-Rex1 (Welch et al, 2005), CDKN2a (‘INK4a’) 
(Ackermann et al, 2005), NrasQ61K (Ackermann et al, Cancer Res 2005), Tyr::Cre (Delmas et 
al, 2003), Tyr::Cre ERT2 (Yajima et al, 2006), Dct-lacZ (Mackenzie et al, 1997), Z/EG (Novak 
et al, 2000), LSL-BrafV600E (Mercer et al, 2005), PTEN (Backman et al, 2001), FAK (McLean 
et al, 2004), and Rac1fl/fl (Walmsley et al, 2003). Table 2.1 offers detail of mice offspring 
bred for study in this thesis: 
Mouse (chronological order) Allele description 
Tyr::Nras
Q61K/°
; INK4a
-/-
; P-
Rex1
+/+ 
 
One copy Nras
Q61K
 transgene, unconditional knockout 2 copies of INK4a, 
wild-type P-Rex1 
Tyr::Nras
Q61K/°
; INK4a
-/-
; P-
Rex1
-/-
 
One copy Nras
Q61K
 transgene, unconditional knockout 2 copies of INK4a, 
unconditional knockout 2 copies of P-Rex1 
Tyr::Nras
Q61K/°
; P-Rex1
+/+
 One copy Nras
Q61K
 transgene, wild-type P-Rex1 
Tyr::Nras
Q61K/°
; P-Rex1
-/-
 One copy Nras
Q61K
 transgene, unconditional knockout 2 copies of P-Rex1 
P-Rex1
-/-
 unconditional knockout 2 copies of P-Rex1 
DCT-lacZ; Tyr::Nras
Q61K/°
; P-
Rex1
+/+
 
Melanocyte-specific expression of β-galactosidase reporter, one copy 
Nras
Q61K
 transgene, wild-type P-Rex1 
DCT-lacZ; Tyr::Nras
Q61K/°
; P-
Rex1
-/-
 
Melanocyte-specific expression of β-galactosidase reporter, one copy 
Nras
Q61K
 transgene, unconditional knockout 2 copies of P-Rex1 
DCT-lacZ; P-Rex1
+/+
 Melanocyte-specific expression of β-galactosidase reporter, wild-type P-
Rex1 
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DCT-lacZ; P-Rex1
-/-
 Melanocyte-specific expression of β-galactosidase reporter, unconditional 
knockout 2 copies of P-Rex1 
Tyr::Cre Z/EG; P-Rex1
+/+
 Melanocyte-specific expression of Z/EG (GFP) reporter, wild-type P-Rex1 
Tyr::Cre Z/EG; P-Rex1
-/-
 Melanocyte-specific expression of Z/EG (GFP) reporter, unconditional 
knockout 2 copies of P-Rex1 
Tyr::Cre Rac1
f/f
 Melanocyte-specific knockout of 2 copies of Rac1 
Tyr::Cre Rac1
f/f
; P-Rex1
-/-
 Melanocyte-specific knockout of 2 copies of Rac1, unconditional knockout 
2 copies of P-Rex1 
DCT-lacZ; Tyr::Cre Rac1
f/f
 Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific knockout of 2 copies of Rac1 
DCT-lacZ; Tyr::Cre Rac1
f/f
; P-
Rex1
-/-
 
Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific knockout of 2 copies of Rac1, unconditional knockout 2 copies of 
P-Rex1 
Tyr::Cre Z/EG; Tyr::Cre Rac1
f/f
 Melanocyte-specific expression of Z/EG (GFP) reporter, melanocyte-
specific knockout of 2 copies of Rac1 
Tyr::Cre Z/EG; Tyr::Cre Rac1
f/f
; 
P-Rex1
-/-
 
Melanocyte-specific expression of Z/EG (GFP) reporter, melanocyte-
specific knockout of 2 copies of Rac1, unconditional knockout 2 copies of 
P-Rex1 
Tyr::CreER Braf
V600E/+
 Melanocyte-specific expression of one copy of Braf
V600E
 
Tyr::Cre Z/EG; Tyr::CreER 
Braf
V600E/+
 
Melanocyte-specific expression of Z/EG (GFP) reporter, melanocyte-
specific expression of one copy of Braf
V600E
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DCT-lacZ; Tyr::Cre PTEN
 lox/+
; 
P-Rex1
-/-
 
Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific deletion of one copy PTEN, unconditional knockout 2 copies of P-
Rex1 
DCT-lacZ; Tyr::Cre PTEN
 lox/lox
; 
P-Rex1
-/-
 
Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific deletion of both copies PTEN, unconditional knockout 2 copies of 
P-Rex1 
Tyr::CreER Braf
V600E/+
; Tyr::Cre 
PTEN
 lox/lox
; P-Rex1
-/-
 
Melanocyte-specific expression of one copy of Braf
V600E
, melanocyte-
specific deletion of both copies PTEN, unconditional knockout 2 copies of 
P-Rex1 
Tyr::CreER Braf
V600E/+
; Tyr::Cre 
PTEN
 lox/+
; P-Rex1
-/-
 
Melanocyte-specific expression of one copy of Braf
V600E
, melanocyte-
specific deletion of one copy PTEN, unconditional knockout 2 copies of P-
Rex1 
Tyr::Cre FAK
 fl/fl
 Melanocyte-specific deletion of both copies FAK 
Tyr::Cre FAK
 fl/+
 Melanocyte-specific deletion of one copy FAK 
DCT-lacZ; Tyr::Cre FAK
 fl/fl
 Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific deletion of both copies FAK 
DCT-lacZ; Tyr::Cre FAK
 fl/+
 Melanocyte-specific expression of β-galactosidase reporter, melanocyte-
specific deletion of one copy FAK 
DCT-lacZ; Tyr::Nras
Q61K/°
; 
Tyr::Cre FAK
 fl/fl
 
Melanocyte-specific expression of β-galactosidase reporter, one copy 
Nras
Q61K
 transgene, melanocyte-specific deletion of both copies FAK 
DCT-lacZ; Tyr::Nras
Q61K/°
; 
Tyr::Cre FAK
 fl/+
 
Melanocyte-specific expression of β-galactosidase reporter, one copy 
Nras
Q61K
 transgene, melanocyte-specific deletion of one copy FAK 
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Tyr::Nras
Q61K/°
; Tyr::Cre FAK
 fl/fl
 One copy Nras
Q61K
 transgene, melanocyte-specific deletion of both copies 
FAK 
Tyr::Nras
Q61K/°
; Tyr::Cre FAK
 fl/+
 One copy Nras
Q61K
 transgene, melanocyte-specific deletion of one copy 
FAK 
Tyr::Nras
Q61K/°
; INK4a
-/-
; 
Tyr::Cre FAK
 fl/fl
 
One copy Nras
Q61K
 transgene, unconditional knockout 2 copies of INK4a, 
melanocyte-specific deletion of both copies FAK 
Tyr::Nras
Q61K/°
; INK4a
-/-
; 
Tyr::Cre FAK
 fl/+
 
One copy Nras
Q61K
 transgene, unconditional knockout 2 copies of INK4a, 
melanocyte-specific deletion of one copy FAK 
Table 2.1 Description of alleles used in each mouse studied within this thesis 
 
2.8 Mouse Genotyping 
Mice were genotyped by polymerase chain reaction (PCR). The majority of the samples 
were processed by Transnetyx Inc, although protocols were established or tested inhouse 
initially by various members of the R18 lab group including myself.  Ear biopsies were 
taken at weaning. DNA was extracted from biopsies using puregene DNA extraction kit 
(Qiagen).  Tails were lysed in 500μl cell lysis solution (Puregene) and 10μl proteinase K 
(20mg/ml, Sigma), and shaken overnight at 37ºC.   Tails were left to cool at room temp 
and 200μl of protein precipitation solution (Puregene) then added to each tube, vortexed 
and centrifuged at top speed for 5 min. Supernatant fluid was pipetted into a clean tube 
containing 500μl of isopropanol, vortexed and centrifuged as before for 5 min.   
Supernatant was decanted and DNA pellet left to dry overnight.  DNA was finally 
resuspended in 500μl DNA hydration solution (Puregene). PCR reactions performed in 
50l volumes using 2.5l DNA preparation. PCR products were resolved by 
electrophoresis on 2% agarose gels.  
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CRE PCR Protocol  
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
Cre A  = TGA CCG TAC ACC AAA ATT TG 
Cre B = ATT GCC CCT GTT TCA CTA TC 
Reaction Conditions: 95°C, 3min (95°C, 30s; 55°C, 30s; 72°C 1min)30, 72°C, 5min. 15°C, hold. 
Bands: Cre = ~1000bp 
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2.8.1 LACZ PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
LACZ A = CTG GCG TTA CCC AAC TTA AT 
LACZ B = ATA ACT GCC GTC ACT CCA AC 
Reaction Conditions: 95°C, 3min (95°C, 30s; 55°C, 30s; 72°C 1min)30, 72°C, 5min. 15°C, hold. 
Bands: LacZ = ~500bp 
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2.8.2 NRASQ61K PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
NRas A = GAT CCC ACC ATA GAG GAT T 
NRas B = CTG GCG TAT TTC TCT TAC C 
Reaction Conditions: 94°C, 4min (94°C, 30s; 56°C, 30s; 72°C, 1min) 35 72°C, 10min. 15°C, hold. 
Bands: Nras= ~400bp 
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2.8.3 CDKN2A PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
P16 WT A = ATG ATG ATG GGC AAC GTT C 
P16 WT B = CAA ATA TCG CAC GAT GTC 
P16 Null A = CTA TCA GGA CAT AGC GTT GG   
P16 Null B = AGT GAG AGT TTG GGG  ACA GAG 
Reaction Conditions: 94°C, 3min (94°C, 1min; 60°C, 1min; 72°C 1min) 30; 72°C, 10min. 
15°C, hold. 
Bands: WT = 236bp; null = 723bp 
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2.8.4 PREX1 PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
P-Rex1 WT A = GAC CTG AGG TTT TTT TCT GGC CTC CGT GGC 
P-Rex1 WT B = GAA AGA GGC AGA AGC TGG GCA CGC CTG GCC 
P-Rex1 Null A = AGG GGG AAG GCT GAG GTG CTG GTG ATG CTG   
P-Rex1 Null B = TCC TCG TGC TTT ACG GTA TCG CCG CTC CCG 
Reaction Conditions: 95°C, 3min (95°C, 30s; 60°C, 30s; 72°C 1min) 30; 72°C, 5min. 4°C, 
hold. 
Bands: WT = 1kb; null = 436bp 
 
 
Chapter 2: Materials & Methods  97 
 
2.8.5 BRAFV600E PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
BrafV600E A = GCT TGG CTG GAC GTA AAC TC 
BrafV600E B= GCC CAG GCT CTT TAT GAG AA 
BrafV600E C = AGT CAA TCA TCC ACA GAG ACC T   
Reaction Conditions: 94°C, 5min (94°C, 30s; 60°C, 30s; 72°C, 30s) 35; 72°C, 10min. 4°C, 
hold. 
Bands: targeted allele = 140bp (primers A+B); WT = 466bp (primers B+C); Cre-deleted 
allele = 518bp (primers B+C). 
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2.8.6 FAK PCR Protocol 
PCR Mix μl 
10x Buffer 5 
MgCl2 (50mM) 2.5 
dNTPs (10mM) 1 
Primer (100μM) 0.2 (of each) 
Platinum Taq* 0.2 
H2O to final volume of 47.5 μl 
*Platinum Taq (Invitrogen) 
Primers: 
FAK A = ATT GTG CTA TAC TCA CAT TTG GA 
FAK B = TTA ATA AGA CCA GAG GAC TCA GC 
FAK C = GGA AGA AGC TTG TAT ACT GTA TG 
Reaction Conditions: 95°C, 5min (95°C, 45s; 64°C, 45s; 72°C, 1min)35, 72°C, 7min. 4°C, hold. 
Bands: WT = ~650bp; Flox = ~580bp 
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2.8.7 PTEN PCR Protocol 
PCR Mix μl 
10x Buffer 5 
MgCl2 (50mM) 2.5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.1 (of each) 
Platinum Taq* 0.2 
H2O to final volume of 47.5 μl 
*Platinum Taq (Invitrogen) 
Primers: 
PTEN A = CTC CTC TAC TCC ATT CTT CCC 
PTEN B = ACT CCC ACC AAT GAA CAA AC 
Reaction Conditions: 95°C, 2.5min (94°C, 1min; 58°C, 1min; 72°C, 1min)35, 72°C, 10min. 15°C, hold. 
Bands: WT = 228bp; Flox = 335bp 
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2.8.8 Z/EG PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
Z/EG A = TGG TCG AGC TGG ACG GCG AC  
 
Z/EG B = CTC GAA CTT CAC CTC GGC GC   
 
Reaction Conditions: 95°C, 2.5min (94°C, 1min; 60°C, 30s; 72°C, 30s)30, 72°C, 10min. 4°C, hold. 
Bands: Z/EG = 300bp 
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2.8.9 RAC1 PCR Protocol 
PCR Mix μl 
5x Colorless GoTaq Flexi Buffer* 10 
MgCl2 (25mM) 5 
dNTPs (10mM) 0.4 
Primer (100μM) 0.2 (of each) 
Go Taq* 0.2 
H2O to final volume of 47.5 μl 
*GoTaq Flexi DNA Polymerase from Promega.  
Primers: 
RAC1 A = ATT TTG TGC CAA GGA CAG TGA CAA GCT 
RAC1 B = GAA GGA GAA GAA GCT GAC TCC CAT C 
RAC1 C = CAG CCA CAG GCA ATG ACA GAT GTT C  
Reaction Conditions: 94°C, 5min (94°C, 30s; 55°C, 30s; 72°C, 30s)30, 72°C, 7min. 4°C, hold. 
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2.9 Immunohistochemistry 
IHC performed by myself except for Figures 3.1 and 3.5 (Dr William Faller). Standard 
paraffin sections were de-waxed in xylene (3 x 3 min) and then rehydrated through 
decreasing concentrations of ethanol to distilled water. Antigen retrieval was performed 
in 10mM citric acid (pH 6.0) by the water bath method. 5ml of Citrate antigen retrieval 
buffer (Thermo) diluted 1 in 10 with distilled water to a final volume of 50ml in a Coplin 
jar. This was placed in a cold water bath and then heated to 99.9oC, prior to immersion of 
the slides. Slides then placed in the pre-heated solution for 20 min before being allowed 
to cool in the solution for 30 min at room temperature. Endogenous peroxidase activity 
was then blocked by incubating slides in 3% hydrogen peroxide for 10 min. Washing steps 
consisted of 3x 5 min immersions in Tris-Buffered Saline and Tween (TBST). Primary 
antibodies were incubated in the presence of 5% normal goat serum (Dako). Staining was 
visualised using DAB (3,3'-diaminobenzidine) chromogen in FAK project (Thermo 
Scientific), otherwise using Vector Red Alkaline Phosphatase Substrate Kit (Vector Labs) in 
P-Rex1 and Braf projects. Finally, slides were counterstained with haematoxylin, prior to 
dehydration in increasing concentrations of ethanol before mounting.  
2.9.1 Ki67  
Primary rabbit anti-Ki-67 antibody (1:200; Thermo RM-9106) applied for 1 h at room 
temp.  
2.9.2 P-Rex1  
Primary rabbit anti-P-Rex1 antibody (1:150, Sigma A001927) applied for 1 h at room 
temp. 
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2.9.3 MelanA  
Primary mouse anti-melanA antibody (1:100, Abcam AB731) applied overnight at 4oC. 
2.9.4 S100 
Primary rabbit anti-S100 antibody (1:250, Dako Z0311) applied overnight at 4oC. 
2.9.5 FAK  
Primary rabbit anti-FAK antibody (1:200, Cell Signaling #3285) applied overnight at 4oC. 
2.10 Melanocyte Isolation 
Performed by Dr Sam Lawn and Dr Andrew Muinonen-Martin. For melanocyte isolation 
from mice, pup skin was dissected at P2 then placed in ice cold PBS. Quickly it was cut 
into pieces and incubated in 1.5ml of collagenase type 1 and 2 at 37oC, 5% CO2 for 
approximately 25-50 min. Contents were transferred into 10ml wash buffer (1 x HBSS, 
1mM CaCl2, 0.005% DNase) and centrifuged at 200g for 5 min at room temperature. 
Samples were resuspended in 2ml dissociation buffer, placed in small Petri dish and 
incubated at 37oC, 5% CO2 for 10 min. Thereafter, samples were put through an 18 gauge 
then 20 gauge needle and transferred into 10ml wash buffer for 10 min. The supernatant 
was centrifuged at 200g for 5 min at room temp, the pellet resuspended in 2ml PBS, then 
re-centrifuged at 200g for 5 min. The resuspended pellet was maintained in Hams F12 
medium supplemented with 10% foetal calf serum, L-glutamine at 200μM, 
penicillin/streptomycin at 100 U/ml, and 200nM TPA.   
2.11  Cell Culture 
Performed by Dr Andrew Campbell. Normal human melanocytes (NHM) were maintained 
in Mln254 medium (M-254-500, Cascade Biologics) supplemented with Human 
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Melanocyte Growth Serum (S-002-5, Cascade Biologics) and penicillin/streptomycin at 
100 U/ml. Mel224, Mel505, SK-Mel 2, 5, 23, 119, 147 and 187, CHL-1, A375 and WM266.4 
were maintained in Dulbecco’s Modified Eagle Medium supplemented with 10% foetal 
calf serum, L-glutamine at 200μM and penicillin/streptomycin at 100 U/ml.  SBCL2, 
Lu1205, WM852, MeWo, Dauv-1, Gerlach, 888mel, 501mel, MNT-1, WM 35, 278, 793, 
902b, 1552c and 1789 were maintained in RPMI 1640 supplemented with 10% foetal calf 
serum and penicillin/streptomycin at 100U/ml.  
2.12  Immunoblotting 
Performed by Dr Andrew Campbell except for Figure 6.6 (performed by myself). Cells 
were washed in PBS, then lysed in cell extraction buffer (50mM Tris-HCl (pH 7.6), 150mM 
sodium chloride, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 10μg/ml aprotinin, 
125mM phenylmethylsulfonyl fluoride, 100μM sodium orthovanadate and 0.5mM sodium 
fluoride). Tissue samples were homogenised in Tissue Protein Extraction Reagent 
(Thermo) for 2 min at 2,200g.  Protein concentration was determined by comparison of 
absorbance against known BSA concentrations. Lysates were then cleared by 
centrifugation and resolved by 10% Bis-Tris gel electrophoresis (Invitrogen).  Proteins 
were transferred to PVDF membrane, blocked and probed with either 1:500 anti-P-Rex1 
(Sigma), 1:10000 anti-β-actin (Sigma), 1:1000 anti-TIAM1 (Bethyl), 1:2000 anti-ERK2 (BD 
Biosciences), or 1:1000 anti-FAK (Cell Signalling) antibodies.  Bound antibody was 
detected by incubation with anti-mouse or anti-rabbit horseradish peroxidase-conjugated 
secondary antibody and visualized by Enhanced Chemiluminescence (Amersham). 
2.13  siRNA Treatments and RacGEF Constructs 
Performed by Dr Andrew Campbell. Stable cell lines expressing Myc-epitope tagged 
human P-Rex1 were generated by retroviral infection using the modified Retro-X 
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retroviral expression system (Clontech).  An Hpa I restriction site, followed by Kozak 
consensus translation initiation site was introduced to the 5’ end of the coding sequence 
of myc-P-Rex1 (Hill et al, 2005), myc-P-Rex1 GEF-dead (Hill et al, 2005), or myc-Tiam1 by 
PCR (5’ GTTAACCACCATGGAGCAGA AGCTGATC 3’), with a Cla I restriction site introduced 
to the 3’ end in the same reaction (P-Rex1/P-Rex1 GEF-dead - 5’ 
CCATCGATTCAGAGGTCCCCATCCACCGG 3’), with pCMV-P-Rex1, pCMV-P-Rex1 GEF-dead 
or pcDNA3.1-myc-Tiam1 used as template. In each case, the Hpa I-Cla I DNA fragments 
produced were subcloned into Hpa I and Cla I sites of the pLHCX retroviral expression 
vector.  High-titre, replication-incompetent retroviral particles encoding the RNA of 
interest were produced in the Phoenix Ampho packaging line (Orbigen), for human target 
cells, and the Phoenix Eco packaging line (Orbigen) for murine target cells.  Subsequent 
infection of target lines resulted in transfer of the coding region of interest, along with a 
selectable marker. Pooled cell lines stably expressing the construct of interest were 
isolated by selection with hygromycin-B (500 µg/ml) over multiple passages.  Control lines 
were infected with retroviral particles expressing an empty pLHCX control vector 
transcript, and subjected to an identical selection procedure. Expression of the 
ectopically-introduced proteins of interest was determined by western blot and 
immunodetection with both epitope-tag specific and protein specific primary antibodies.  
Transient knockdown of target proteins was achieved through consecutive rounds of 
liposome-mediated transfection with the appropriate siRNA oligonucleotides, 48 h apart.  
Liposomal transfection reagent (301702, HiPerFect), non-targeting control 
oligonucleotides (1027281, AllStars Negative Control) and P-Rex1 specific 
oligonucleotides (SI00692405, Hs_PREX1_3; SI03144449, Hs_PREX1_5; SI03246383, 
Hs_PREX1_6) were obtained from Qiagen Ltd. 
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2.14  Invasion Assays 
Performed by Dr Andrew Campbell. Inverted matrigel invasion assays were performed as 
previously described (Hennigan et al, 1994). Matrigel protein matrix (BD bioscience) was 
allowed to polymerise in Transwell permeable inserts (Corning Ltd) over a period of 60 
min at 37°C.  Inserts were inverted, and cells seeded directly onto the filter surface in 
complete growth medium. Cells were then allowed to adhere over a period of 3h at 37°C, 
after which both non-adherent cells and residual growth medium were removed with 3x 
washes in appropriate serum-free medium.  Finally, inserts were placed in serum-free 
tissue culture medium (containing 10% foetal calf serum) above the Matrigel matrix to act 
as a chemoattractant.  In the case of siRNA-mediated transient knockdown experiments, 
invasion assays were prepared 24 h after the second round of lipofection.  At 72h post-
seeding, invasive cells which had entered Matrigel were stained with the fluorescent live-
cell dye Calcein-AM, and visualised through confocal microscopy of optical sections 
obtained in the Z-plane at 15 μm intervals. Quantification was with the Area Calculator 
plugin for ImageJ.  
2.15  RT-PCR 
Performed by Dr Richard Mort. For embryo skin, E14.5 (Tyr::CreB/R26YFPR) skin was 
dissected in PBS on ice. Subsequently skin was digested over night in 0.05% collagenase 
and then dissociated mechanically using a pipette. Cells were sorted by FACS into sterile 
PBS and RNA prepared using the Qiagen RNAeasy plus kit. cDNA was prepared using the 
Roche first strand cDNA synthesis kit. Primer sequences were as follows: Prex1, 
Ex22_23_F, FGCACGGTGTGGTTTACGAAT; Prex1, Ex22_23_R, TCTCCAGCTTGGTGTCACAG; 
Prex1, Ex_37_38_F, TCTACCGCCTCATGAAGACC; Prex1, Ex_37_38_R, 
ATGACACACTTGGGCAACAG; Prex1, Ex1_3_F, GCCTCCGTCTGTGCGTACT; Prex1, Ex1_3_R, 
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CAGGATGTCCTCAATGTTGG; Dct, F, TGTGCAAGATTGCCTGTCTC; Dct, R, 
GTTGCTCTGCGGTTAGGAAG; Tyr, F, ATGCACCTATCGGCCATAAC; Tyr, R, 
ATAACAGCTCCCACCAGTGC; GAPDH_F AAGGTCATCCATGACAACTTTGG; GAPDH, R, 
AAGAGTGGGAGTTGCTGTTGAAG. 
2.16  Microarray 
Microarray analyses were performed using the Agilent microarray platform, chip ref 
G4112F. Raw data, including nude mouse work, were provided by Larue laboratory 
(Institut Curie, Paris), then analysed by myself. 
2.17  Human Tissues  
Human tissue was analysed from archival paraffin patient samples from St. Vincent’s 
University Hospital, Dublin, Ireland. Quadruplicate cores from 141 consecutive melanoma 
patients (1994-2007) were used to construct a tissue microarray with insufficient survival 
data. Further samples were received from Radboud University Medical Center, Nijmegen, 
Netherlands. All patient specimens were used in accordance with institutional and 
national policies at the respective locations. All samples were formalin fixed and paraffin 
embedded. TMA samples were analysed independently by 2 people. Analysis in Beatson 
by Dr William Faller. 
2.18  BRaf and NRas Mutation Status of Cell Lines 
The following tables offer details of mutation status of melanoma cell lines used in 
chapter 3 and 5. Further data on the growth phase of the originating tumour are also 
described where possible. RGP = radial growth phase; Met = metastatic. 
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Cell Line Braf status Nras status Growth phase 
NHM WT WT N/A 
SK-Mel 23 WT WT Met 
SK-Mel 187 WT WT VGP 
CHL1 WT WT Met 
Mel505 WT WT VGP 
SK-Mel 2 WT Q61R Met 
SK-Mel 119 WT Q61R Met 
SK-Mel 147 WT Q61R Met 
SBCL2 WT Q61R RGP 
Mel224 WT Q61R Met 
A375 V600E WT VGP 
Colo 829 V600E WT Met 
SK-Mel 5 V600E WT Met 
WM35 V600I WT RGP 
WM266.4 V600D WT VGP 
WM278 V600E WT VGP 
WM793 V600E WT VGP 
WM902b V600E WT VGP 
WM1552c V600E WT RGP 
WM1789 K601E WT RGP 
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Cell Line Braf status Nras status 
WM852 WT Q61R 
LU1205 V600E WT 
MeWo WT WT 
A375M V600E WT 
WM793 V600E WT 
WM983A V600E WT 
WM983B V600E WT 
WM1366 WT Q61L 
SK28 V600E WT 
SK29 V600E WT 
Rosi WT WT 
Daju V600E WT 
Dauv-1 V600E WT 
Mull V600E WT 
Lyse WT Q61K 
Gerlach WT Q61K 
501Mel V600E WT 
G1 WT WT 
T1 WT WT 
888mel V600E WT 
Quar V600E WT 
MNT-1 WT WT 
SKMEL3 V600E WT 
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P-Rex1 has not previously been characterised in genetically modified animal models of 
cancer that can recapitulate the genetics and pathology of the human disease. As detailed 
at the end of the introduction (Section 1.5.1.3), several factors led to our hypothesis that 
P-Rex1 could contribute to invasive and metastatic melanoma: reported direct and 
indirect interactions with PI(3)K and MAPK pathways, amplification of its chromosome 
site 20q13, and the role of Rac and other Rac-GEFs already described in the disease. This 
chapter reports the role of endogenous and ectopic P-Rex1 in a Tyr::NrasQ61K/°; INK4a-/- 
mouse model of melanoma, dissecting some of the results with further experimental 
analysis in allografts, xenografts and invasion studies of human melanoma cell lines. 
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3.1 P-Rex1 deficiency does not alter primary melanoma in a 
Tyr::NrasQ61K/°; INK4a-/- melanoma mouse model 
We first assessed the role of P-Rex1 in primary melanoma development by crossing P-
Rex1-/- mice to a genetically modified model of metastatic malignant melanoma, 
Tyr::NrasQ61K/°; INK4a-/- mice (Ackermann et al, 2005, Welch et al, 2005).  
Tyr::NrasQ61K/°; INK4a-/-; P-Rex1+/+ mice developed primary melanoma with a similar 
penetrance and latency to that previously described (Figure 3.1a, Table 3.1). IHC was 
carried out on primary melanomas taken from P-Rex1+/+ and P-Rex1-/- mice to confirm P-
Rex1 expression in tumours (Figures 3.1b,c). 7/10 primary melanomas from P-Rex1+/+ 
mice showed staining for P-Rex1, compared to 0/9 samples from P-Rex1-/- mice. Although 
Rac function has been shown to be required for primary squamous cell skin and lung 
tumour development (Kissil et al, 2007, Malliri et al, 2002), we observed no difference in 
incidence, latency, or tumour burden of primary melanomas between Tyr::NrasQ61K/°; 
INK4a-/-; P-Rex1+/+ mice and Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- mice (Table 3.1, Figures 
3.1d,e).  
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Figure 3.1 P-Rex1 disruption does not significantly alter primary melanomagenesis in a 
Tyr::Nras
Q61K/°
; INK4a
-/-
 transgenic murine melanoma model 
(a) Example of primary melanoma arising in Tyr::Nras
Q61K/°
; INK4a
-/- 
transgenic mice. White 
arrowhead: pigmented primary skin melanoma. Accompanying photomicrograph (H&E) indicates 
pigmented dermal melanocytosis characteristic of these lesions (white arrow) (Scale bar=100µm). 
(b) MelanA (a common melanocyte marker; black arrows, pink staining) and P-Rex1 (white arrows, 
pink staining) IHC expression in two separate primary melanomas of P-Rex1
+/+
 mice. Varying 
levels of P-Rex1 expression can be seen in mouse melanomas (n=10). Brown staining represents 
melanin pigment. (c) MelanA (black arrows, pink staining) and lack of P-Rex1 IHC expression (no 
pink staining) in two separate primary melanomas of P-Rex1
-/-
 mice. No P-Rex1 expression was 
observed in melanomas from these mice (n=9). Brown staining represents melanoma pigment. (d) 
Comparison of primary tumour burden between Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
+/+
 (blue bar, ‘WT’) 
and Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/-
 (red bar, ‘HOM’) mice (p=0.43, Mann-Whitney, n=29; small 
asterisks represent outlying data) (Box and whiskers plot: box represent 25
th
-75
th
 percentile of 
given value, line represents median value). (e) Kaplan-Meier analysis of primary melanoma latency 
between Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
+/+
 (black line, n=27) and Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/-
 
(red line, n=18) cohorts (p=0.156, log-rank test). Figures (b) and (c) kindly contributed by Dr 
William Faller. 
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Genotypes 
Mice with 
Primary 
Melanoma 
Average 
Age 
(days) 
Mice with 
Melanoma 
Metastases 
Mice with 
Melanoma 
Metastases, 
Excluding Brain 
Lesions 
Tyr::NrasQ61K/°; INK4a-/-;  
P-Rex1+/+ 
30/41 184 13/30 6/30 
Tyr::NrasQ61K/°; INK4a-/-;  
P-Rex1-/- 
30/42 211 1/30 1/30 
                  p=0.001        p=0.044 
 
Table 3.1 P-Rex1 disruption dramatically reduces incidence of metastasis in an 
Tyr::Nras
Q61K/°
; INK4a
-/-
 transgenic murine melanoma model 
Table detailing numbers of mice within both Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
+/+
 and Tyr::Nras
Q61K/°
; 
INK4a
-/-
; P-Rex1
-/-
 cohorts suffering from primary and metastatic melanoma (chi-square test). 
Metastatic sites other than brain for Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
+/+
 cohort were lungs (4 mice), 
liver (3 mice), peritoneum (1 mouse); Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/-
 metastasis was in lungs. 
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3.2 P-Rex1 deficiency impairs metastasis in a Tyr::NrasQ61K/°; 
INK4a-/- melanoma mouse model 
Tyr::NrasQ61K/°; INK4a-/-; P-Rex1+/+ mice also developed melanoma metastasis with a 
similar penetrance and latency to that previously described (Figure 3.2a). All metastases 
from P-Rex1+/+ mice displayed immunoreactivity for P-Rex1 similar to that of MelanA, a 
common melanocyte marker (11 samples; lung, liver, brain) (Figure 3.2b).  A significant 
reduction in melanoma metastasis was observed in the Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- 
cohort (1/30 mice), with the number of metastases in control Tyr::NrasQ61K/°; INK4a-/-; P-
Rex1+/+ mice the same as previously reported (13/30 mice; p=0.001; chi-square) (Table 
3.1).  Tyr::NrasQ61K/o; INK4a-/-; P-Rex1-/- mice also had an improved overall survival (Figure 
3.2c). The one metastasis observed in the experimental Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- 
metastasis was to the lungs. These data suggest that P-Rex1 is a central component of 
metastasis development in this context.  
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Figure 3.2 P-Rex1 disruption dramatically reduces incidence of metastasis in an 
Tyr::Nras
Q61K/°
; INK4a
-/-
 transgenic murine melanoma model 
(a) Examples of metastatic melanomas arising in Tyr::Nras
Q61K/°
; INK4a
-/- 
transgenic mice. White 
arrowheads: multiple pigmented lung metastases; Red arrow: pigmented liver metastasis; White 
arrow: large pigmented brain lesion. Nras
Q61K
 expression was not confirmed in these lesions. (b)  
MelanA (common marker of cells from the melanocyte lineage) and P-Rex1 immunohistochemical 
expression in melanoma metastases from P-Rex1
+/+
 control mice. Left four panels show expression 
in brain lesions, while right four panels show expression in lung metastases (pink staining). n=11. 
Brown staining represents melanoma pigment. (c) Kaplan-Meier curves detailing significant 
improvement in survival of Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/-
 cohort (red line) compared to 
Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
+/+
 cohort (black line) (*p=0.017, log-rank test, n=30 for each 
cohort). Figure (b) kindly contributed by Dr William Faller. 
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Although we were unable to exclude categorically the possibility that our melanoma brain 
lesions are not primary melanocytic neoplasms of the central nervous system (CNS), a 
significant reduction in metastases was still seen when these lesions were excluded from 
our analysis (Table 3.1). Consistent with findings in another genetically modified mouse 
model, these brain lesions extended into the cortex and exhibited locally aggressive 
behaviour, thus either invading the brain parenchyma from a blood-borne metastasis or 
the lepto-meningeal site of origin in primary CNS melanoma (Fig. 3.2b) (Goel et al, 2009). 
However, melanomatous brain lesions are generally infrequent in other genetically 
modified mouse models (see Table 1.3). Regardless of their point of origin, ablation of P-
Rex1 in these lesions either suppresses local invasion or metastasic spread. In support of 
them being genuine metastases, no NrasQ61K mutations were observed in a previous study 
of human primary CNS melanoma (Küsters-Vandevelde et al, 2010).  
3.2.1 P-Rex1 deficiency impairs frequency, growth, and organ spread 
of metastases  
We next explored the pro-metastatic role of endogenous P-Rex1 in melanoma by deriving 
melanocyte cell lines from the early pup skin of Tyr::NrasQ61K/°; INK4a-/-; P-Rex+/+  and 
Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- mice. When injected via TV into C57BL6 mice, 2/4 mice 
treated with Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- melanocytes were found to have 
metastases, compared with 5/5 mice who were treated with Tyr::NrasQ61K/°; INK4a-/-; P-
Rex+/+ cells (Figures 3.3a-f, Table 3.2). A significant reduction in metastatic frequency was 
observed on histological analyses of the cohort injected with Tyr::NrasQ61K/°; INK4a-/-; P-
Rex1-/- melanocytes, with a reduction in metastatic tumour burden also seen but not 
significant (Figures 3.3g,h; methods detailed in section 2.3). Moreover, we observed a 
propensity of the Tyr::NrasQ61K/°; INK4a-/-; P-Rex+/+  cells to metastasise to distant viscera 
(kidney, liver, heart, spleen), metastases that were not seen in the mice TV-treated with 
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Tyr::NrasQ61K/°; INK4a-/-; P-Rex1-/- cells (Figures 3.3b-f, Table 3.2). Collectively, these results 
suggested endogenous P-Rex1 can facilitate frequency and organ spread of metastases in 
melanoma from the intravasation stage of the metastatic cascade (detailed in Section 1.2 
and Figure 1.3), with a strong suggestion that P-Rex1 might also support their secondary 
growth. 
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Figure 3.3 Endogenous P-Rex1 facilitates metastatic frequency and organ spread following 
the intravasation step  
(a) Schematic diagram detailing cell type, cell numbers, injection type, and mouse background 
used in experiment (b) – (f) Metastatic melanomas affecting kidney (b, white arrow), lungs (c, black 
arrows), liver (d, white interrupted line), heart (e, interrupted line), and melanin in spleen (f, black 
arrows) of C57BL6 mice TV-treated with Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex
+/+
 
 
cells; accompanying 
photomicrographs (H&E, scale=500µm for all except 30µm for splenic photomicrograph). (g) 
Quantification of metastases observed in C57BL6 mice TV-treated with melanocytes derived from 
early pup skin of either Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/- 
mice (red bar) or Tyr::Nras
Q61K/°
; INK4a
-/-
; 
P-Rex
+/+
 
 
mice (grey bar) (*p=0.02, Mann-Whitney test; n=5) (Box and whiskers plots: boxes 
represent 25
th
-75
th
 percentiles of given value, lines represent median values). (h) Quantification of 
metastatic tumour burden (method described in Section 2.3) observed in the same C57BL6 TV-
treated mice as described in (g) (p=0.087, Mann-Whitney test; n=5) (Box and whiskers plots: boxes 
represent 25
th
-75
th
 percentiles of given value, lines represent median values).  
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Table 3.2 Endogenous P-Rex1 facilitates metastases to distant sites following the 
intravasation step  
Table indicating number of mice with metastases as well as range of metastatic sites between 
C57BL6 mice TV-treated with either Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex
+/+
 
 
murine melanocytes or 
Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/- 
murine melanocytes. 
 
 Number of Metastatic 
Mice 
Sites of Metastases 
Tyr::NrasQ61K/°; INK4a-/-;             
P-Rex1-/- 
2/4 Skin (1), LN (1), Lung (1) 
Tyr::NrasQ61K/°; INK4a-/-; P-Rex+/+   5/5 Liver (5), kidney (5), lung 
(4), LN (3),  Spleen (3), 
Peritoneal (2), Skin (2), 
Heart (1)  
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3.3 High P-Rex1 is sensitive for the development of metastases 
in immuno-deficient mice 
The above data in genetically modified models of cancer were also supported by analyses 
of immuno-deficient mice which were injected subcutaneously (SC) with a number of 
different melanoma cell lines, derived from human melanomas driven mostly by 
oncogenic Braf or Nras (section 2.8 for cell line details) (Figure 3.4). In total, 18/24 cell 
lines developed tumours following injection, with 4/24 also forming metastases. 
Microarray analysis revealed that, of the cell lines with P-Rex1 intensity above the median 
(‘high’ P-Rex1), all went on to develop tumours in immuno-deficient mice (Figs. 3.4b). This 
included all mice that developed metastases, and notably, the two NrasQ61K and BrafV600E 
cell lines with the highest P-Rex1 intensity both developed metastases. Statistical 
evaluation of these results confirmed high P-Rex1 was 100% statistically sensitive for 
detecting those cell lines that developed metastases in nude mice (Table 3.3) (p=0.005). 
We also found that P-Rex1 intensity below the median in cell lines (‘low’ P-Rex1) was 
100% statistically specific for excluding melanoma development in immuno-deficient mice 
(Table 3.4) (p=0.028). Using qRT-PCR, this data was supported by our finding that P-Rex1 
levels were highest in cell lines that form metastases - after averaging P-Rex1 levels in cell 
lines that formed no tumours, tumours, or metastases (Fig. 3.4c). Furthermore, the 
lowest expression occurred in those cell lines that do not form tumours in immuno-
deficient mice (Fig. 3.4c). Unfortunately we do not have access to raw data to statistically 
confirm our results in Figure 3.4c. 
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Figure 3.4 High P-Rex1 is sensitive for the development of metastases in immuno-deficient 
mice  
(a) Schematic diagram describing experimental details. 24 melanoma cell lines were assessed by 
microarray for presence of key genes (including P-Rex1). They were also SC-injected into immuno-
deficient mice to assess propensity to develop primary and metastatic melanomas. (b) Individual 
value plot derived from cell line microarray showing P-Rex1 intensity in melanoma-derived cell 
lines correlates with propensity to develop metastases in immuno-deficient mice. Interrupted line 
represents median P-Rex1 value. AU = arbitrary units. NHEM = normal human melanocytes. (c) 
qRT-PCR analysis showing average P-Rex1 RQ value of cell lines from each tumour group. Error 
bars represent the standard deviation of the triplicate measurement. RQ = relative quantity. No raw 
data or statistical information available for this figure which was kindly provided by Larue 
laboratory, Institute Curie, Paris. 
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 Melanoma Mets No Melanoma Mets 
High P-Rex1  4 8 
Low P-Rex1  0 12 
                              100% sensitive (p=0.005)           60% specific 
Table 3.3 High P-Rex1 in cell lines is sensitive for detecting metastatic melanoma 
development in immuno-deficient mice  
P-Rex1 intensity levels my microarray divided into those above and below median value (‘high’ vs 
‘low’; chi-square test). Statistical sensitivity is defined as the probability that the test says a person 
has a disease when they do have the disease. Statistical specificity is defined as the probability 
that the test says a person does not have a disease when they are disease free. 
 
 
 Primary Melanoma  No Primary 
Melanoma  
High P-Rex1  12 0 
Low P-Rex1  6 6 
 66.7% sensitive         100% specific (p=0.028) 
Table 3.4 Low P-Rex1 in cell lines is specific for excluding melanoma development in 
immuno-deficient mice  
P-Rex1 intensity levels by microarray divided into those above and below median value (‘high’ vs 
‘low’; chi-square test). Statistical sensitivity is defined as the probability that the test says a person 
has a disease when they do have the disease. Statistical specificity is defined as the probability 
that the test says a person does not have a disease when they are disease free. 
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3.4 P-Rex1 in human melanoma  
3.4.1 P-Rex1 is upregulated in human melanoma 
To test the relevance of our data to human melanomagenesis, we first examined the 
protein expression of P-Rex1 in established human melanoma cell lines derived from 
primary or metastatic disease. Compared to normal human melanocytes (NHM), there 
was marked P-Rex1 overexpression in nearly all of the cell lines (Figure 3.5a). Moreover, 
the 3 cell lines with clearly the highest P-Rex1 expression (CHL1, SK-Mel119, Mel224) 
were all derived from a metastatic source (see Section 2.17), supporting our above 
analysis that showed high P-Rex1 intensity by microarray was sensitive for the 
development of metastases in immuno-deficient mice (Figure 3.4).   
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Figure 3.5 P-Rex1 upregulation is associated with progressive disease in human melanoma  
(a) Western blots illustrating endogenous expression of P-Rex1 in a panel of human melanoma 
derived cell lines. Cell lines with driver mutations in NRAS are represented (‘NRAS’ bracket), along 
with cell lines that are wild-type for NRAS (‘WT’ bracket).  NHM = normal human melanocytes. (b) 
P-Rex1 expression increases with more aggressive disease. Photomicrographs of human tissue 
specimens of normal skin, primary and metastatic melanoma, immunohistochemically labelled 
against P-Rex1 or the melanocyte marker melanA. LN = lymph node. Scale bars = 90µm. (c) P-
Rex1 is not detectable in normal melanocytes by immunohistochemistry. Photomicrographs of 
human melanocytes (black arrows) of normal skin (serial sections from 2 separate patients) 
immunohistochemically labelled against P-Rex1 or the melanocyte marker melanA. Similar staining 
of normal skin from a third patient is seen as part of Figure 3.5b (Scale bars = 90µm). Figure (a) 
kindly contributed by Dr Andrew Campbell, figures (b) and (c) kindly contributed by Dr William 
Faller. 
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3.4.2 P-Rex1 is associated with progression in human melanoma 
We next assessed whether increased P-Rex1 activity in humans is also related to 
melanoma progression: this possibility was raised by both the sensitivity of high P-Rex1 
for nude mouse metastasis development and the increased expression of P-Rex1 
observed in melanoma-derived cell lines compared to normal melanocytes (Figures 3.4 
and 3.5a). IHC for P-Rex1 was performed on human tissue specimens from skin and 
melanoma: although P-Rex1 expression was not detectable in melanocytes in normal skin 
(3 out of 3 specimens), we consistently detected it in biopsies of primary melanomas (112 
out of 141 specimens) and melanoma lymph node metastases (8 out of 9 specimens) 
(Figures 3.5b,c). These data provided further evidence of a role for P-Rex1 in human 
melanoma progression, and were consistent with our prior findings in mice.  
3.4.3 Endogenous and ectopic P-Rex1 drives invasion through its GEF 
activity 
One potential way P-Rex1 could drive progression and metastatic spread is through an 
increased invasive capacity conferred by its DH-domain-mediated GEF activity. To 
examine this, we knocked down endogenous P-Rex1 in the CHL1 human melanoma cell 
line where P-Rex1 was upregulated in Figure 3.5a. Consistently we observed that 3D 
matrigel invasion was diminished following knockdown of endogenous P-Rex1 (Figures 
3.6a-c).  
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Figure 3.6 Endogenous P-Rex1 drives invasion in human melanoma cell lines  
(a) Silencing P-Rex1 by siRNA as shown by western blot analysis. A mock transfection and 
scramble siRNA were used as controls. (b) Comparison of representative matrigel invasion assays 
of CHL1 human melanoma cell lines treated with control or P-Rex1 specific siRNA 
oligonucleotides. (c) Quantification of cells invading beyond 45µm in matrigel invasion assays of 
CHL1 human melanoma cell lines treated with control (‘siControl’) vs P-Rex1 (‘siP-Rex1’) specific 
siRNA oligonucleotides. (*p=0.005, Mann-Whitney test; n=3; error bars = +/- standard error of 
mean (SEM). Figure kindly contributed by Dr Andrew Campbell. 
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As P-Rex1 is overexpressed in the majority of human melanoma cell lines, we used the 
previously described melanocyte cell line derived from early pup skin of Tyr::NrasQ61K/°; 
INK4a-/-; P-Rex1-/- mice (see section 3.2.1) to examine invasion in a cell line where P-Rex1 
is not endogenously expressed. These P-Rex1-/- cell lines, which were genetically 
manipulated to over-express empty vector (‘P-Rex1-/-’), failed to invade in 3D matrigel and 
organotypic assays unless they were re-constituted to express ectopic levels of P-Rex1 (‘P-
Rex1’) (Figures 3.7a-d). Expression of ectopic levels of GEF-dead P-Rex1 (‘GD P-Rex1’) 
failed to phenocopy the invasive phenotype of cells with re-constituted wild-type P-Rex1, 
confirming the GEF activity of P-Rex1 as central to its invasive phenotype (Figures 3.7a-d). 
Ectopic expression of another RacGEF described in melanoma, TIAM1, also failed to 
phenocopy the invasion seen with P-Rex1 expression (Figures 3.7a-d) (Uhlenbrock et al, 
2004). These results showed the GEF activity of P-Rex1 may have a unique role amongst 
RacGEFs: it functions as a vital component of invasion for cells of the melanocyte lineage, 
a mechanism by which it can drive melanoma progression and metastases. 
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Figure 3.7 Exogenous P-Rex1 drives invasion through its GEF activity  
(a) Schematic picture detailing domain structure of GEF-dead P-Rex1 mutant. 2 point mutations 
(E56A, N238A) are introduced to the DH domain, abolishing its GEF activity. (b) Westen blot 
confirming relative expression of ‘P-Rex1’, ‘P-Rex1 GD’, and ‘Tiam1’ cells is well matched. (c) 
Representative matrigel invasion assays comparing melanocytes derived from early pup skin of 
Tyr::Nras
Q61K/°
; INK4a
-/-
; P-Rex1
-/- 
mice and genetically modified to over-express P-Rex1 (‘P-Rex1’), 
empty vector (‘P-Rex1
-/-
’), GEF-dead P-Rex1 (‘GD P-Rex1’), or Tiam1 (‘Tiam1’). (d) Left panel: 
quantification of cells invading beyond 45µm in matrigel invasion assays of P-Rex1
-/-
 vs P-Rex1 vs  
GD P-Rex1 cells (*p=<0.0001 for both comparisons, Mann-Whitney test; n=18 quantifications from 
6 samples). Right panel: quantification of cells invading beyond 45µm in matrigel invasion assays 
of P-Rex1
-/-
  vs P-Rex1 vs  Tiam1 cells (*p=<0.0001 for both comparisons, Mann-Whitney test; 
n=18 quantifications from 6 samples; error bars for both panels = +/- standard error of mean 
(SEM). Figures (b) – (d) kindly contributed by Dr Andrew Campbell. 
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3.5 What is the most effective molecular strategy for targeting P-
Rex1? 
Mutational studies have identified the DH domain of P-Rex1 as key to its GEF enzymatic 
activity (Hill et al, 2005). In this chapter, we have also revealed its importance to invasion 
of melanoma cell-lines (Figure 3.7). We next explored the importance of GEF-dead P-Rex1 
in vivo by using the same melanocyte cell lines derived from early pup skin that were 
described in Section 3.4.3: ‘P-Rex1-/-‘, ‘ectopic P-Rex1’, or ‘GD P-Rex1’. Cells were injected 
into immuno-compromised mice via subcutaneous injection (Figure 3.8a).  
All injected mice developed melanoma at their site of injection with 100% consistency 
(Figure 3.8b). It became quickly apparent in tumour growth analysis that control ‘P-Rex1-/-
‘ tumours were growing at a significantly different rate compared to ‘ectopic P-Rex1’ and 
‘GD P-Rex1’ tumours: ‘ectopic P-Rex1’ tumours grew significantly more quickly than ‘P-
Rex1-/-‘ tumours, while ‘GD P-Rex1’ tumours grew significantly more slowly than ‘P-Rex1-/-
‘ tumours (Figure 3.8c). Prior to metastatic development, all mice were euthanised due to 
fatigue and large primary tumour burden. No difference in tumour burden was observed 
between melanomas of the three genotypes (Figure 3.8d). Survival analysis from time of 
injection till death were consistent with the differences seen in tumour growth: mice 
which developed ‘ectopic P-Rex1’ tumours required euthanisation most quickly, while 
mice which developed ‘GD P-Rex1’ tumours had the most prolonged lifespan (Figure 
3.8e). These results therefore show an anti-tumour effect of GEF-dead P-Rex1, validating 
the DH domain of P-Rex1 as the primary molecular focus of its tumourigenic activity, and 
confirming that any potential small molecule inhibitor of P-Rex1 should specifically target 
this domain. 
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Figure 3.8 Ectopic GEF-dead P-Rex1 inhibits tumour growth and promotes mouse survival  
(a) Schematic diagram detailing cell type, cell numbers, injection type, and mice used in 
experiment (SC = subcutaneous). Also a reminder of domain structure of GEF-dead P-Rex1 
mutant (detailed in figure 3.7a). (b) Example of primary melanoma arising following SC injection of 
nude mice. White interrupted line: pigmented primary skin melanoma. Accompanying 
photomicrograph (H&E) indicates pigmented melanocytosis characteristic of these lesions (white 
arrowheads) (c) Quantification and comparison of primary melanoma growth between ‘P-Rex1
-/- 
‘
(red bars), ‘GD P-Rex1’ (blue bars), and ‘ectopic P-Rex1’ (green bars) treated mice (Week 1: n=9 
(P-Rex1
-/-
) vs n=5 (GD P-Rex1) vs n=6 (ectopic P-Rex1); Mann-Whitney; p = 0.289 (P-Rex1
-/-
, 
ectopic P-Rex1); *p = 0.023 (GD P-Rex1, ectopic P-Rex1); *p = 0.033 (P-Rex1
-/-
, GD P-Rex1)) 
(Week 2: n=9 (P-Rex1
-/-
) vs n=5 (GD P-Rex1) vs n=3 (ectopic P-Rex1); Mann-Whitney; *p = 0.042 
(P-Rex1
-/-
, ectopic P-Rex1); *p = 0.037 (GD P-Rex1, ectopic P-Rex1); *p = 0.008 (P-Rex1
-/-
, GD P-
Rex1)) (Week 3: n=9 (P-Rex1
-/-
) vs n=5 (GD P-Rex1) vs n=1 (ectopic P-Rex1); Mann-Whitney; *p = 
0.011 (P-Rex1
-/-
, GD P-Rex1); stats not possible for P-Rex1
-/-
 vs ectopic P-Rex1 and GD P-Rex1 
vs ectopic P-Rex1). (d) Comparison of primary melanoma tumour burden between mice treated 
with ‘P-Rex1
-/- ‘
(red bars, n=9), ‘GD P-Rex1’ (blue bars, n=6), and ‘ectopic P-Rex1’
 
cells (green 
bars, n=10) (P-Rex1
-/- 
,ectopic P-Rex1: p=0.191; P-Rex1
-/- 
,GD P-Rex1: p=0.377; GD P-Rex1
 
, 
ectopic P-Rex1: p=0.871; Mann-Whitney). (e) Kaplan-Meier curves detailing survival of nude mice 
SC-injected with the same cells: ‘Ectopic P-Rex1’, (n=10); P-Rex1
-/- 
(‘P-Rex1
-/- ‘
; n=9); or GEF-dead 
P-Rex1 (‘GD P-Rex1’, n=8) (log-rank; P-Rex1
-/- 
vs GD P-Rex1: p=*0.003;  ectopic P-Rex1
 
vs GD P-
Rex1: p=*0.0001; P-Rex1
-/- 
vs ectopic P-Rex1: p=*0.0001). 
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3.6 Summary 
In this chapter we have evaluated the role of the Rac-specific GEF, P-Rex1, for the first 
time in a genetically modified animal model of cancer. In particular we examined its role 
in melanoma progression, invasion and metastasis. Our results are more fully discussed 
with suggestions for further study in Sections 7.1.1 and 7.1.4. This summary offers a 
synopsis of our findings so far. 
Progression. First we showed P-Rex1 has a role in progression through its upregulation in 
tumour compared to normal human melanocytes (Figures 3.4 and 3.5). IHC showed 
increased expression of P-Rex1 with the transformations from benign melanocyte to 
primary melanoma, and also primary melanoma to LN metastasis (Figures 3.5b,c). Despite 
our discovery of a role for P-Rex1 following the intravasation stage of metastasis, the 
increase in P-Rex1 levels observed in primary human melanoma would also suggest an 
early role for P-Rex1 in the metastatic phenotype; this hypothesis could perhaps be 
examined further with orthotopic murine injection of luciferase-labelled melanoma cell 
lines treated with P-Rex1 siRNA. Western blots and our microarray analysis supported 
these findings, with the highest P-Rex1 levels seen in cell lines with a metastatic 
propensity (Figures 3.4 and 3.5a). 
Invasion. Matrigel invasion assays confirmed P-Rex1 is a key component of invasion in 
both humans and mice, channeled through its GEF activity (Figures 3.6 and 3.7). 
Endogenous and exogenous expression of P-Rex1 impacted on the invasive capacity of 
our cell lines. Ectopic expression of TIAM1 failed to phenocopy the invasion seen with P-
Rex1 expression, suggesting P-Rex1 may be a unique mediator of invasion for melanoma 
cells. 
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Metastasis. Finally and most importantly, we have determined that genetic ablation of 
PREX1 impairs melanoma metastases in Tyr::NrasQ61K INK4a-/- mice (Figure 3.2). We 
extended this analysis using mouse allografts to show that endogenous P-Rex1 can 
facilitate metastatic frequency and organ spread following the intravasation stage of the 
metastatic cascade (Figure 3.3). An increase in metastatic growth, although it did not 
reach statistical significance, could suggest a potential proliferative role for P-Rex1 on top 
of its expected pro-invasive function, although further experiments such as 
immunohistochemistry staining for proliferative markers were not performed to confirm 
this possibility (Figure 3.3h). 
Taken together, these results confirm that P-Rex1 upregulation is an important 
component of melanoma progression, invasion and metastatic signaling, supporting the 
value of pharmacological inhibition of P-Rex1 activation of Rac for treatment of 
metastatic or high risk primary melanomas. To finish the chapter, we confirmed that the 
DH domain of P-Rex1 is the most important molecular target for therapeutic intervention 
to curtail its tumourigenic signalling (Figure 3.8).  
  
 
    Chapter 4  
The role of P-Rex1 in embryonic models of the 
melanocyte lineage 
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The imprint of past migratory behaviour of MBs has been suggested to confer a 
propensity of primary melanomas to establish distant metastases (Gupta et al, 2005, 
Uong et al, 2010, Strizzi et al, 2011). This chapter employs two embryonic models with 
which we investigate the effect of endogenous P-Rex1: Dct-lacZ and Tyr::Cre Z/EG mice. 
With these mice, we further delineate the mechanisms by which loss of P-Rex1 function 
might affect metastases and invasion in melanoma, and in turn, offer detail of how an 
anti P-Rex1 drug might work. There is little doubt from chapter 3 that invasion, as well as 
metastases, is important to the P-Rex1 effect in NrasQ61K-driven melanoma, suggesting a 
putative inhibitor would have utility as an anti-invasive and anti-metastatic measure 
(Figures 3.6 and 3.7). Our main aims in this chapter were to validate this hypothesis, but 
also to investigate whether P-Rex1 may also have a proliferative or survival effect that 
could contribute to its metastatic role, a finding which would uncover potential cytotoxic 
or cytostatic effects for a putative P-Rex1 inhibitor.  
We finish the chapter by combining Rac1-depleted mice with the same embryonic models 
to clarify whether the downstream effects of P-Rex1 are uniquely driven through Rac. We 
speculate that a P-Rex1 role outside of its pro-migratory/invasive function (eg survival or 
proliferation) might employ an alternative RhoGTPase to Rac. This in turn would suggest 
that Rac levels would not suffice as a downstream readout for the efficacy of a P-Rex1 
inhibitor, whilst also suggesting that inhibition of Rac may not be an appropriate 
therapeutic alternative to targeting P-Rex1.  
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4.1 P-Rex1-deficient mice have a white belly phenotype 
Prior to characterising the cancer phenotypes described in chapter 3, we had already 
identified an in vivo relevance for P-Rex1 by back-crossing the P-Rex1-/- mouse to mice of 
a pure C57BL6 background (Welch et al, 2005). We identified a ‘white belly’ phenotype 
with 100% penetrance in P-Rex1-/- mice when on a pure C57BL6 background (Figure 4.1a). 
Belly spots or spotting phenotypes in mice have been identified before with deregulation 
of other genes (‘Color Genes’, www.espcr.org/micemut). Given the importance of 
oncogenic Nras in human melanoma (see Section 1.1.4.1) and the known activation of P-
Rex1 by the PI(3)K pathway downstream of Nras (see Section 1.5.1.1), we also crossed P-
Rex1-/- mice to the Tyr::NrasQ61K/° mice (Tyr::NrasQ61K/°; P-Rex1-/-) described in chapter 3 
(Ackermann et al, 2005). A white belly phenotype was also evident in these mice (Figure 
4.1a), a finding which directly led to the money and time invested to assess the 
metastatic effects of P-Rex1 knockout in the Tyr::NrasQ61K/° cancer model (Chapter 3). 
Depigmentation affecting the feet was also observed in Tyr::NrasQ61K/°; P-Rex1-/- mice 
(Figure 4.1a). Tissue sections of bellies from P-Rex1-/- and Tyr::NrasQ61K/°; P-Rex1-/- mice 
suggested no melanocytes were present throughout the skin in the white belly area 
(Figure 4.1b). Thus expression of NrasQ61K was not able to overcome the ‘white belly’ 
induced by ablation of PREX1. 
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Figure 4.1 P-Rex1 deficient mice have a ‘white belly’ phenotype  
(a) Belly and feet of P-Rex1
+/+
 and P-Rex1
-/-
 mice in combination with both Nras
+/+
 and Nras
Q61K/°
 
transgenic modification. (b) Photomicrographs (H&E) of belly skin from the four genotypes 
represented in (a). Normal melanocyte situation in a C57BL6 mouse is in the bulge of the hair 
follicles (black arrows show melanin pigment deposition). Melanocytes and deposition of melanin in 
the dermis (red arrow) and adipose tissue (red arrowheads) are seen in Nras
Q61K/°
 mice. No 
melanocytes or pigment deposition were observed in belly skin of P-Rex1
-/-
 mice. Scale bars = 
100µm. 
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4.2 P-Rex1 deficiency impairs normal melanoblast migration 
The belly, feet, and tail are the furthermost points of mouse melanoblast migration from 
the neural crest during embryogenesis. In line with this and the pro-metastatic role of P-
Rex1 described in chapter 3, we hypothesised that the areas of depigmentation in P-Rex1-
/- mice predominantly represented a defect of melanoblast migration during 
embryogenesis, rather than an impaired proliferative capacity or indeed an inability to 
produce melanin pigment in adult melanocytes. Examining each of these possibilities 
would offer further insight into the tumourigenic mechanisms used by P-Rex1 in its pro-
metastatic role. Before testing our hypothesis, we first ensured the presence of PREX1 in 
melanoblasts (Figure 4.2a). The confirmed presence of P-Rex1 in motile melanoblasts 
compared to the lack of P-Rex1 expression previously described in non-motile adult 
melanocytes was consistent with its Rac-specific role and influence on the actin 
cytoskeleton in migratory cells such as melanoblasts or melanoma (Figure 3.5, Figure 
4.2a). However, the mechanism by which P-Rex1 may be switched ‘off’ or ‘on’ at different 
stages of the melanocyte lineage is as yet unknown.  
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Figure 4.2 P-Rex1
 
is present in mouse melanoblasts  
(a) RT-PCR of P-Rex1 mRNA in E14.5 embryo skin following FACS selection of cells enriched for 
melanoblasts (YFP+) compared to the rest of the embryo skin (YFP-). Mice expressing YFP were 
inter-crossed with mice expressing the melanocyte-specific Tyr::Cre, then skin cells isolated from 
their progeny and FACS-sorted. Tyrosinase and Dct controls confirm melanoblast enrichment of 
YFP+ cells. DCT = dopachrome tautomerase, a common marker of cells of the melanocyte lineage 
along with tyrosinase. (b) Schematic diagram detailing breedings of DCT::β-galactosidase 
melanoblast reporter mice to P-Rex1 and Nras
Q61K
 mice. To label melanoblasts with β-
galactosidase, P-Rex1
-/-
 and Nras
Q61K
 mice mice were inter-crossed with reporter DCT::β-
galactosidase mice that express β-galactosidase in a melanocyte-specific fashion (see Section 
2.7.4). Progeny were then analysed using techniques described in Section 2.1.  (c) Representative 
photos of melanoblast distribution observed in wild-type and P-Rex1
-/-
 embryos at E15.5. White 
arrow indicates melanoblast sparing of belly, white interrupted lines represent most distal point of 
melanoblast migration along forepaw. Figure (a) kindly contributed by Dr Richard Mort, MRC 
Human Genetics Unit, Edinburgh. 
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To address whether melanoblast number, pigmentation, or migratory behaviour was 
altered, we next analysed P-Rex1-/- mice and Tyr::NrasQ61K/°; P-Rex1-/- mice which had 
been intercrossed to mice carrying the DCT::β-galactosidase transgene (hereon referred 
to as DCT-lacZ), a melanoblast reporter line (Figure 4.2b) (Mackenzie et al, 1997).  
Melanoblast sparing of the feet and belly was apparent in both DCT-lacZ P-Rex1-/- and 
DCT-lacZ Tyr::NrasQ61K/°; P-Rex1-/- mice at E15.5, excluding a defect in melanin production 
as a cause for their depigmentation (Figure 4.2c, Figure 4.3).  
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Figure 4.3 P-Rex1
-/-
 mice have a defect in melanoblast migration 
To label melanoblasts with β-galactosidase, P-Rex1
-/-
 and Nras
Q61K
 mice mice were inter-crossed 
with reporter DCT::β-galactosidase mice that express β-galactosidase in a melanocyte-specific 
fashion (see Section 2.7.4). Progeny were then analysed using techniques described in Section 
2.1. (a) E15.5 representative pictures comparing melanoblast migration to the belly in X-gal stained 
embryos. Scale bars = 500µm. (b) Comparison of melanoblast migration along forepaw in X-gal 
stained embryos at E15.5. A migratory deficit is evident in both P-Rex1
-/-
 (with either Nras
+/+
 or 
Nras
Q61K/°
) embryos. Scale bars = 500µm. 
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Using the melanoblast migration assays detailed before (Figure 2.1a,b), analysis of E13.5 
and E15.5 embryos showed a statistical difference in melanoblast migration between 
DCT-lacZ P-Rex1-/- and DCT-lacZ P-Rex1+/+ mice (Figures 4.4a-f). This was not overcome by 
NrasQ61K/° expression (Figures 4.4c,f). These results were recapitulated using an 
alternative migration assay at E15.5 (detailed in figure 2.1c), applied to preclude any 
biasing effects of cell-cell contact inhibition should cell numbers be different between 
genotypes (Figures 4.4g,h). Consistent with a migratory defect, melanoblasts on the flank 
of the DCT-lacZ P-Rex1-/- mice had fewer protrusions than DCT-lacZ P-Rex1+/+ controls 
(Figures 4.5a,b). More recently, we were able to confirm a migratory deficit in E15.5 skin 
using live ex vivo timelapse (technique detailed in Figure 2.3), which revealed a statistical 
reduction in both speed and Euclidean distance travelled by GFP-expressing melanoblasts 
with ablated PREX1 (Figures 4.5c,d). 
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Figure 4.4 P-Rex1
-/-
 mice have a defect in melanoblast migration at E13.5 and E15.5  
(a) Schematic picture showing method of quantification of melanoblast migration used for (b) and 
(c) (b,c) Comparison of melanoblast migration between P-Rex1
+/+
 (‘WT’, blue bars) and P-Rex1
-/-
 
(‘HOM’, red bars) mice. Upper panel (b) represents Nras
+/+
 embryos (*p=0.01/0.02, Levels 2/3; 
Mann-Whitney test, n=5), lower panel (c) represents Nras
Q61K/°
 embryos (*p=0.02/0.02/0.01, Levels 
1/2/3; Mann-Whitney test, n=5) (All box and whiskers plots: boxes represent 25
th
-75
th
 percentiles of 
given value, lines represent median values). (d) Schematic picture showing method of 
quantification of melanoblast cell migration used for (e) and (f)  (e,f) Comparison of melanoblast 
migration between P-Rex1
+/+
 (‘WT’, blue bars) and P-Rex1
-/-
 (‘HOM’, red bars) mice along torso in 
X-gal stained embryos at E13.5. Left panel (e) represents Nras
+/+
 embryos (*p=0.016/0.021 at 
levels 2/3, Mann-Whitney test; n=5), right panel (f) represents Nras
Q61K/°
 embryos 
(*p=0.021/0.021/0.012 at levels 1/2/3, Mann-Whitney test; n=5) (g) Schematic picture detailing 
alternative method for quantification of melanoblast migration used in (h) (h) Quantification and 
comparison of migration as described in (g): P-Rex1
+/+
 (‘N WT’, blue bars) and P-Rex1
-/-
 mice (‘N 
HOM’, red bars) (left hand panel; *p=0.012, Mann-Whitney; n=5); Tyr::Nras
Q61K/°
; P-Rex1
+/+
 (‘Y WT’, 
blue bars) and Tyr::Nras
Q61K/°
; P-Rex1
-/-
 (‘Y HOM’, red bars) mice (right hand panel; *p=0.012; 
Mann-Whitney, n=5). All migration assay detail found in chapter 2.  
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Figure 4.5 P-Rex1
-/-
 mice have reduced protrusions at E15.5  
(a) Representative pictures at E15.5 of melanoblast morphology and protrusions (red arrows) on 
the flank of X-gal stained embryos. Scale bars = 100µm. (b) Quantification and comparison of 
percentage of cells with 1+ protrusions: P-Rex1
+/+
 (‘N WT’, blue bars) and P-Rex1
-/-
 mice (‘N HOM’, 
red bars) (left hand panel; *p=0.05, Mann-Whitney; n=4); Tyr::Nras
Q61K/°
; P-Rex1
+/+
 (‘Y WT’, blue 
bars) and Tyr::Nras
Q61K/°
; P-Rex1
-/-
 (‘Y HOM’, red bars) mice (right hand panel; *p=0.03; Mann-
Whitney, n=4). (c) Quantification and comparison of individual melanoblast speed at E15.5 under 
live confocal timelapse: P-Rex1
+/+
 (‘WT’, blue bars) and P-Rex1
-/-
 (‘HOM’, red bars) compared 
(*p=0.00001; Mann-Whitney, n=60). (d) Quantification and comparison of Euclidean distance 
travelled by individual melanoblasts at E15.5 under live confocal timelapse: P-Rex1
+/+
 (‘WT’, blue 
bars) and P-Rex1
-/-
 (‘HOM’, red bars) compared (*p=0.00001; Mann-Whitney, n=60). 
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4.3 P-Rex1 deficiency causes a reduction in melanoblast 
proliferation 
Recent reports have implied a role for P-Rex1 in proliferation as well as migration (Qin et 
al, 2009, Montero et al, 2010). A clue to the effect of P-Rex1 on proliferation was also 
offered by its possible effect on metastatic tumour burden in chapter 3 (Figure 3.3h). We 
therefore investigated this possibility more closely using our two melanoblast model 
systems as potential surrogates for the metastatic effect seen in chapter 3. A proliferative 
role for P-Rex1 could have important implications for its potential as a novel anticancer 
target. 
A melanoblast cell number assay at E13.5 (detailed in Figure 2.2b) showed no difference 
in cell numbers between DCT-lacZ P-Rex1-/- mice and DCT-lacZ P-Rex1+/+ mice unless DCT-
lacZ P-Rex1-/- was inter-crossed with Tyr::NrasQ61K/° (Figures 4.6a,b). There was however a 
small but significant reduction of E15.5 cell numbers (assay detailed in Figure 2.2a) in 
DCT-lacZ P-Rex1-/- mice compared to DCT-lacZ P-Rex1+/+, and DCT-lacZ Tyr::NrasQ61K/°; P-
Rex1-/- mice compared to DCT-lacZ Tyr::NrasQ61K/°; P-Rex1+/+ mice (Figures 4.6c,d). This 
difference is likely to represent a proliferative deficit in P-Rex1-/- melanoblasts: cell death 
was not observed in E15.5 whole skin from P-Rex1+/+ or P-Rex1-/- mouse embryos using 
live ex vivo imaging described in Section 2.2 (Figure 4.7a). Moreover, it is well 
characterised that cells of the melanocyte lineage are noteworthy by their resistance to 
apoptosis, owing to a lifetime of UV damage occurring in the skin (Terzian et al, 2010). A 
significant reduction in E15.5 cell numbers was again seen in P-Rex1-/- embryos compared 
to P-Rex1+/+ controls using this technique (Figure 4.7b). Collectively, these results would 
be consistent with previous reports of a role for Rac in cell cycle control, as well as the 
proliferative defect observed when P-Rex1 was knocked down in breast cancer cell lines 
(Moore et al, 1997, Michaelson et al, 2008, Qin et al, 2009, Montero et al, 2011). They 
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suggest that a small proliferative defect is accompanied by a marked migration defect in 
P-Rex1-/- mice. 
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Figure 4.6 P-Rex1
-/-
 mice have a reduction in melanoblast cell numbers using DCT-lacZ 
reporter mice  
(a) Schematic pictures detailing method for quantification of melanoblast numbers used in (b) (b) 
Comparison of E13.5 melanoblast numbers between P-Rex1
+/+
 (N WT, blue bars) and P-Rex1
-/-
 (N 
HOM, red bars) mice (left hand panel), and also between Tyr::Nras
Q61K/°
; P-Rex1
+/+
 (Y WT, blue 
bars) and Tyr::Nras
Q61K/°
; P-Rex1
-/-
 (Y HOM, red bars) mice (right hand panel) (*p =0.02, Mann-
Whitney test; n=5) (c) Schematic picture detailing method for quantification of melanoblast cell 
numbers used in (d) (d) Comparison of E15.5 melanoblast numbers between P-Rex1
+/+
 (‘N WT’, 
blue bars) and P-Rex1
-/-
 (‘N HOM’, red bars) mice (left hand panel), and also between 
Tyr::Nras
Q61K/°
; P-Rex1
+/+
 (‘Y WT’, blue bars) and Tyr::Nras
Q61K/°
; P-Rex1
-/-
 (‘Y HOM’, red bars) mice 
(right hand panel). (left panel: *p =0.01; right panel: *p =0.01; Mann-Whitney test, n=5). (Box and 
whiskers plots: boxes represent 25
th
-75
th
 percentiles of given value, lines represent median 
values). All cell number assay details found in chapter 2. 
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Figure 4.7 P-Rex1
-/-
 embryos have a reduction in melanoblast proliferation using live ex vivo 
timelapse 
To label melanoblasts with GFP, P-Rex1
-/-
 mice were inter-crossed with reporter Tyr::Cre Z\EG 
mice which express GFP in a melanocyte-specific fashion (see Section 2.7.4). Progeny were then 
analysed using technique described in Section 2.2. (a) E15.5 representative pictures comparing ex 
vivo numbers of melanoblasts expressing green fluorescent protein in the skin. Last panel, used as 
a positive control, shows apoptotic blebbing (white arrows) induced following treatment with 100µM 
LY294002, an inhibitor of the pro-survival PI(3)K pathway. This is not observed in P-Rex1
-/-
 skin 
despite reduction in cell numbers. (b) Ex vivo quantification and comparison of numbers of 
melanoblasts expressing green fluorescent protein in the skin: P-Rex1
+/+
 (‘WT’, blue bars) and P-
Rex1
-/-
 (‘HOM’, red bars) compared (*p=0.0216; Mann-Whitney, n=5). 
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4.4 Are the downstream effects of P-Rex1 uniquely driven 
through Rac? 
Another important question with P-Rex1 signalling was to establish whether its 
downstream effects were mediated specifically by Rac alone. As mice with melanocyte-
specific RAC1 abrogation require early adult euthanisation due to neurological problems 
(Li et al, 2011), our embryonic reporter models offered the most appropriate way to 
assess this question in vivo. 
4.4.1 P-Rex1 and Rac are fundamental components of mouse coat 
colour phenotype 
Earlier in the chapter we described the ‘white belly’ phenotype of mice with P-Rex1 
deletion (Figure 4.8a). Considering the Rho-GTPase signalling mechanisms that might be 
responsible for melanoblast migration to the perimeter of the P-Rex1-null white belly, it 
seemed likely that other Rac-GEFs might activate Rac and potentially other Rho-GTPases 
too (Figure 4.8a). Constitutive deletion of RAC1 is embryonically lethal, but a coat colour 
defect of mice with melanocyte-specific RAC1 abrogation (Tyr::Cre Racfl/fl) has recently 
been described: these mice have an even larger belly spot on their ventral side, 
suggesting that other GEFs (and potentially P-Rex1) can stimulate alternative Rho-
GTPases to enable melanoblast migration to the perimeter of the Tyr::Cre Racfl/fl white 
belly (Figure 4.8b) (Li et al, 2011, Sugihara et al, 1998).  
To confirm whether P-Rex1 was Rac-specific, we hypothesised that the offspring of a 
mating between P-Rex1-/- mice and Tyr::Cre Racfl/fl mice (Tyr::Cre Racfl/fl; P-Rex1-/-) would 
exhibit the same coat colour phenotype as Tyr::Cre Racfl/fl mice alone. However, we 
discovered that P-Rex1 has a major additional function to that which it confers through 
Rac:  Tyr::Cre Racfl/fl; P-Rex1-/- mice display a dramatic alteration in coat colour phenotype 
from Tyr::Cre Racfl/fl mice (Figure 4.8c) (n=7). In detail, the ventral and dorsal coats of 
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these mice are almost entirely white, with hypopigmented limbs and tail also. Greying 
pigmented areas were only observed in the head coat, as if melanoblasts could not 
escape beyond this point in the early stages of development. We conclude from this 
experiment that P-Rex1 and Rac together constitute fundamental signalling components 
of the mouse coat colour phenotype, with minimal rescue of melanoblast development 
conferred by other GEFs or Rho-GTPases (Figure 4.8c). It is also clear that P-Rex1 must be 
able to exert phenotypic effects through Rho-GTPases other than Rac.  
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Figure 4.8 P-Rex1 and Rac are fundamental components of mouse coat colour phenotype  
(a) Schema detailing potential signalling mechanisms which could influence migration of 
melanoblasts to the level of the ‘white belly’ in the absence of P-Rex1. (b) Schema detailing 
potential P-Rex1 and Rho-GTPase signalling mechanisms which could influence migration of 
melanoblasts to the level of the ‘white belly’ in the absence of Rac1. (c) Representative pictures 
showing coat colour phenotype of Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
 mice. Schema shows potential 
‘escape’ signalling mechanisms by which melanoblasts may migrate and contribute to the minimal 
pigmentation observed in these mice.  Picture in (b) kindly contributed by Dr Ang Li and Professor 
Laura Machesky, Beatson Institute. 
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4.4.2 P-Rex1 promotes cell numbers using a Rac1-independent 
mechanism 
To explore the Rac-independent effects of P-Rex1 further, we crossed Tyr::Cre Racfl/fl; P-
Rex1-/- mice to mice carrying the reporter DCT-lacZ transgene. Relative to Tyr::Cre 
Racfl/flmice or P-Rex1-/- embryos alone, Tyr::Cre Racfl/fl; P-Rex1-/- embryos at E15.5 
displayed a substantial reduction in melanoblast numbers across their entire body 
(Figures 4.9a,b). Closer microscopic examination of cell morphology revealed amoeboid 
cell-rounding, consistent with what has been described in Tyr::Cre Racfl/flmice or P-Rex1-/- 
melanoblasts alone (Fig. 4.9c). Unfortunately, quantification and comparison of 
melanoblasts with this technique was impossible as the Machesky laboratory, who kindly 
gifted the Tyr::Cre Racfl/fl photomicrographs, had destroyed their embryos. In any case, 
application of the previously described DCT-lacZ assays to differentiate between cell 
numbers and migration would not have been accurate with so few melanoblasts present 
in Tyr::Cre Racfl/fl; P-Rex1-/- mice. It was therefore necessary to use live imaging to 
delineate whether the coat colour phenotype of Tyr::Cre Racfl/fl; P-Rex1-/- mice occurs as a 
result of migratory failure, proliferative failure, or even cell death. 
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Figure 4.9 P-Rex1 and Rac1 are fundamental components of mouse coat colour phenotype  
(a) Bellies of Tyr::Cre Rac1
fl/fl
 and P-Rex1
-/-
 mice in isolation and combination. (b) Representative 
photos of DCT-lacZ melanoblast distribution observed in wild-type, P-Rex1
-/-
, Tyr::Cre Rac1
fl/fl
 and 
Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
 embryos at E15.5 (scale bars=1mm; n=3). Melanoblast sparing is 
evident in Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
 embryos in particular. (c) Representative pictures at E15.5 of 
wild-type, P-Rex1
-/-
, Tyr::Cre Rac1
fl/fl
 and Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/- 
melanoblast sparing on the 
flank of X-gal stained embryos. (Scale bars = 200µm; n=3). Tyr::Cre Rac1
fl/fl
  pictures kindly 
contributed by Dr Ang Li and Professor Laura Machesky, Beatson Institute. 
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Mice with the Z/EG double reporter transgene were crossed to Tyr::Cre Racfl/fl; P-Rex1-/- 
mice, driving GFP expression in the melanoblast lineage. First observations again 
suggested a marked reduction in melanoblast numbers in the flank skin of Tyr::Cre Racfl/fl; 
P-Rex1-/- E15.5 embryos compared to Tyr::Cre Racfl/fl or P-Rex1-/- embryos alone (Figure 
4.10a). Cell quantification suggested a small but significant reduction in Tyr::Cre Racfl/fl; P-
Rex1-/- melanoblast speed of migration compared to Tyr::Cre Racfl/fl or P-Rex1-/- embryos 
alone (Figure 4.10b). However, this speed reduction was not matched by any difference in 
Euclidean distance travelled by melanoblasts of the same three genotypes (Figure 4.10c). 
As expected, wild-type melanoblasts had a significant increase in speed, numbers and 
Euclidean distance travelled relative to all other genotypes (Figures 4.10b-d). Finally, 
there was a dramatic reduction in melanoblast numbers between Tyr::Cre Racfl/fl; P-Rex1-/- 
embryos and all other genotypes, with no difference in numbers observed between 
Tyr::Cre Racfl/fl and P-Rex1-/- embryos (Figure 4.10d). As no cell death was seen in all 
timelapse movies of any genotype, our suspicion is that P-Rex1 contributes to coat colour 
phenotype by promoting cell proliferation using a Rac1-independent mechanism. 
However, we cannot completely exclude the possibility that P-Rex1 might contribute to 
this phenotype by promoting melanoblast survival (discussed further in section 7.3.4). 
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Figure 4.10 P-Rex1 promotes an increase in cell number using a Rac1-independent 
mechanism  
(a)  Representative pictures comparing ex vivo numbers of melanoblasts expressing green 
fluorescent protein in the skin of wild-type, P-Rex1
-/-
,  Tyr::Cre Rac1
fl/fl
 and Tyr::Cre Rac1
fl/fl
;
 
P-
Rex1
-/-
 embryos at E15.5 (n=3). (b) Quantification and comparison of individual melanoblast speed 
at E15.5 under live confocal timelapse: wild-type (‘wt’, n=60 cells), P-Rex1
-/-
(‘prex’, n=56 cells),  
Tyr::Cre Rac1
fl/fl
(‘rac’, n=60 cells) and Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
(‘racprex’, n=45 cells)
-
 cells 
compared (‘wt’ vs ‘prex’: *p=0.00001; ‘wt’ vs ‘rac’: *p=0.00001; ‘wt’ vs ‘racprex’: *p=0.00001; ‘prex’ 
vs ‘rac’: p=0.1417; ‘prex’ vs ‘racprex’: *p=0.0097; ‘rac’ vs ‘racprex’: *p=0.00001; Mann-Whitney; 3 
timelapses per genotype). (c) Quantification and comparison of euclidean distance travelled by 
individual melanoblasts at E15.5 under live confocal timelapse: wild-type (‘wt’, n=60 cells), P-Rex1
-
/-
(‘prex’, n=56 cells),  Tyr::Cre Rac1
fl/fl
(‘rac’, n=60 cells) and Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
(‘racprex’, 
n=45 cells)
-
 cells compared (‘wt’ vs ‘prex’: *p=0.00001; ‘wt’ vs ‘rac’: *p=0.00001; ‘wt’ vs ‘racprex’: 
*p=0.00001; ‘prex’ vs ‘rac’: p=0.8165; ‘prex’ vs ‘racprex’: p=0.1099; ‘rac’ vs ‘racprex’: p=0.064; 
Mann-Whitney; 3 timelapses per genotype). (d) Ex vivo quantification and comparison of numbers 
of melanoblasts expressing green fluorescent protein in the skin: wild-type (‘wt’, n=60 cells), P-
Rex1
-/-
(‘prex’, n=56 cells),  Tyr::Cre Rac1
fl/fl
(‘rac’, n=60 cells) and Tyr::Cre Rac1
fl/fl
;
 
P-Rex1
-/-
(‘racprex’, n=45 cells)
-
 cells compared (‘wt’ vs ‘prex’: p=0.1; ‘wt’ vs ‘rac’: *p=0.01; ‘wt’ vs ‘racprex’: 
*p=0.002; ‘prex’ vs ‘rac’: p=0.429; ‘prex’ vs ‘racprex’: p=*0.01; ‘rac’ vs ‘racprex’: p=*0.0002; Mann-
Whitney; 3 timelapses per genotype). Tyr::Cre Rac1
fl/fl
 pictures and movies kindly contributed by Dr 
Ang Li and Professor Laura Machesky, Beatson Institute. 
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4.5 Summary 
Mechanistic experiments in this chapter have highlighted the key similarities between the 
molecular machinery involved in the movement of melanoblasts and that of metastatic 
melanoma cells. Our results here are more fully discussed with suggestions for further 
study in Sections 7.1.1, 7.1.3, 7.1.4, and 7.3.4. This summary offers a synopsis of our 
findings in this chapter. 
We have shown in this chapter that genetic ablation of PREX1 impaired migration of 
melanoblasts, evidenced by a ‘white belly’ phenotype that reflected the diminished 
metastases seen in Tyr::NrasQ61K INK4a-/- mice (Figures 3.2, 3.3, 4.1, and 4.4). A potential 
pathophysiological link with the incidence of metastases therefore fits with the 
physiological role of P-Rex1 seen in melanoblast migration. The predominant role of P-
Rex1 in invasion and migration is also suggested by its presence in motile melanoblasts 
and its upregulation in the metastatic melanoma cell lines observed in chapter 3 (Figures 
3.4, 3.5, and 4.2). Consistent with this, an association between P-Rex1 and number of 
melanoblast protrusions was observed (Figure 4.5). Outside of it migratory/invasive role, 
a small proliferative deficit was also observed in P-Rex1-/- embryos, a finding which was 
consistent with the trend towards diminished metastatic tumour burden noted in chapter 
3 (Figures 3.3h, 4.6 and 4.7). Taken together, these results therefore confirm an anti-
metastatic role for a putative P-Rex1 inhibitor, but also raise the possibility that 
therapeutic intervention may confer anti-proliferative cytostatic effects.  
A proliferative effect for P-Rex1 was again suggested when, using the same embryonic 
models, it was shown to promote cell numbers in the absence of Rac1 (Figures 4.8, 4.9, 
and 4.10). There has previously been another suggestion that P-Rex1 can exert 
proliferative effects using a Rac-independent mechanism in cancer (Montero et al, 2010). 
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This finding potentially carries at least two important caveats for development of a 
putative P-Rex1 inhibitor. First, as a downstream readout is crucial to understanding the 
pharmacodynamics of a lead compound in drug development, it is important to be aware 
that a reduction in Rac activity does not fully represent a biological ‘hit’ of P-Rex1: it must 
also signal through an as yet unidentified Rho-GTPase(s). Second, a Rac-independent 
mechanism for P-Rex1 could confer proliferative effects on cancer beyond its pro-
metastatic migratory potential driven through Rac: this has implications for cytostatic or 
cytotoxic effects of P-Rex1 inhibition, on top of an expected anti-metastatic role. Such an 
inhibitor would be much more straightforward to justify in the context of drug 
development (see Section 1.2.2 for more detail). 
  
                            Chapter 5 
Exploring the role of P-Rex1 in Braf
V600E
-driven 
melanoma 
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We have shown in chapters 3 and 4 that P-Rex1 can influence metastases, migration, 
invasion and proliferation in the context of oncogenic Nras. However, human melanoma 
driver mutations in BRAF occur more commonly than those in NRAS, contributing to 50-
60% of all cases (Davies et al, 2002).This chapter therefore describes our investigation of 
P-Rex1 in melanomas driven by oncogenic BrafV600E. A relevance of P-Rex1 to BrafV600E-
driven tumours was a clear possibility given the identification of P-Rex1 as a 
transcriptional target of ERK signalling in melanoma, as well as the common downstream 
MEK-ERK signalling shared by Braf and Nras (Shields et al, 2007). 
There have now been a number of high profile success stories in cancer where targeted 
antibody or small molecule inhibitors are applied to specific genotypic subsets of patients 
with a given cancer (Slamon et al, 2001, Kwak et al, 2010, Flaherty et al, 2010). One report 
has already identified P-Rex1 as having particular relevance to the specific ER+ (+/- ErbB2) 
subset of breast tumours (further detail in section 1.5.1.2) (Sosa et al, 2010). Such a 
finding could improve the efficacy, toxicity, and cost-benefit profile of any putative P-
Rex1 inhibitors, enabling a straightforward genetic selection for patient enrichment in 
early phase clinical trials (see Section 1.4 for further details). 
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5.1 P-Rex1 is upregulated in human melanoma driven by 
BrafV600E 
To test the relevance of our data to human melanomagenesis, we started by assessing 
the expression of P-Rex1 in established human melanoma cell lines derived from primary 
or metastatic BrafV600E-driven melanoma. Compared to normal human melanocytes, 
upregulation of P-Rex1 was observed in nearly all of the cell lines (Figure 5.1). This 
immunoblotting also suggested that this over-expression was less than that observed in 
melanomas driven by NrasQ61K (Figure 3.5a; immunoblot performed at the same time as 
that in Figure 5.1). However, review of our previous microarray data showed no 
difference in P-Rex1 intensity between melanoma cell lines with NrasQ61 mutations 
(WM852, WM1366, Lyse, Gerlach) or BrafV600E (the majority of other cell lines) (Figure 
3.4).  
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Figure 5.1 P-Rex1 is upregulated in human melanoma driven by oncogenic Braf 
Western blot illustrating endogenous expression of P-Rex1 in a panel of human melanoma derived 
cell lines. Cell lines with driver mutations in BRAF are represented.NHM = normal human 
melanocytes. Figure kindly contributed by Dr Andrew Campbell. 
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5.2 BrafV600E drives proliferation of melanoblasts during murine 
development 
In line with the embryonic detail described in chapter 4, we next wanted to delineate the 
developmental effects of PREX1 ablation on the BRAFV600E mutation in melanoblasts. 
However, this experiment was virtually precluded by the reported in utero mortality of 
BrafV600E-expressing embryos following recombination with the constitutively active 
melanocyte-specific Tyr::Cre (Dhomen et al, 2010). We were able to at least characterise 
the phenotype of BrafV600E expression (without P-Rex1 depletion) in melanoblasts using ex 
vivo live timelapse of E15.5 wholemount skin (detailed in Figure 2.3). A large increase in 
melanoblast numbers was noted in Tyr::Cre BrafV600E embryos compared to wild-type 
controls (Figure 5.2a). This result fell short of statistical significance, most likely as a 
consequence of the limited embryo numbers obtained due to the common in utero death 
of Tyr::Cre BrafV600E embryos prior to dissection. Consistent with other reports, it is likely 
that a potential difference in cell number is accounted for by an increase in proliferation, 
given that no cell death was observed in samples from either cohort (Figure 5.2b) 
(Dhomen et al, 2010). No difference in cell speed or Euclidean distance travelled was 
noted between the two cohorts (Figures 5.2c,d).  
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Figure 5.2 Expression of Braf
V600E
 increases melanoblast cell numbers at E15.5  
(a) Ex vivo quantification and comparison of numbers of melanoblasts expressing green 
fluorescent protein in the skin: wild-type (‘WT’, white bars) and Tyr::CreER Braf
V600E
 (‘V600E’, pink 
bars) compared (p=0.081; Mann-Whitney; n=3 embryos, 3 slices counted per embryo). (b) 
Representative pictures comparing ex vivo numbers of WT and Tyr::CreER Braf
V600E
 melanoblasts 
expressing green fluorescent protein in the skin. No cell death was seen in any sample. (c) 
Quantification and comparison of individual melanoblast speed at E15.5 under live confocal 
timelapse: : wild-type (‘WT’, white bars) and Tyr::CreER Braf
V600E
 (‘V600E’, pink bars) compared 
(p=0.099; Mann-Whitney; n=60 cells, 20 per timelapse). (d) Quantification and comparison of 
Euclidean distance travelled by individual melanoblasts at E15.5 under live confocal timelapse: 
wild-type (‘WT’, white bars) and Tyr::CreER Braf
V600E
 (‘V600E’, pink bars) compared (*p=0.054; 
Mann-Whitney; n=60, 20 per timelapse). (Box and whiskers plots: boxes represent 25
th
-75
th
 
percentiles of given value, lines represent median values). 
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5.3 Ablation of PTEN does not rescue the P-Rex1-/- migration 
phenotype 
Metastases were rare and required a prolonged latency period when conditional 
expression of BrafV600E was induced in a melanoma mouse model (Dhomen et al, 2009). 
However, the inducible melanocyte-specific combination of PTEN ablation and expression 
of BrafV600E has been reported to confer metastatic melanoma with 100% penetrance and 
short latency in mice (Dankort et al, 2009).  This second model therefore seemed more 
appropriate for assessing a potential anti-metastatic effect of P-Rex1 deletion in 
melanomas driven by oncogenic Braf. 
As P-Rex1 is known to be directly stimulated by PI(3)K-stimulated phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) production, we first ensured ablation of PTEN did not rescue 
the P-Rex1-/- migratory phenotype (detailed in Figure 4.4) by upregulating the PI(3)K 
pathway (Welch et al, 2002). It was necessary to assess this embryologically as 
melanocyte-specific PTEN ablation using the constitutively active Tyr::Cre is lethal in the 
late stages of development or shortly after birth (Lionel Larue, personal communication; 
Delmas et al, 2003).  This lethality is consistent with the early neurological defects and 
death seen when PTEN was conditionally depleted by Cre recombinase under the control 
of an alternative melanocyte-specific promoter, Dct (Inoue-Narita, 2008). P-Rex1-/- and 
Tyr::Cre Ptenlox/lox mice were inter-crossed to mice carrying the reporter DCT-lacZ 
transgene (Figure 5.3a). Initial inspection suggested that P-Rex1 depletion still inhibited 
melanoblast migration when either one or two copies of PTEN were concomitantly 
ablated (Figure 5.3b). This finding was quantitatively confirmed using an E15.5 migration 
assay (described in Figure 2.1) (Figures 5.4a-c). Notably, homozygous deletion of PTEN 
also increased melanoblast numbers compared to Tyr::Cre Ptenlox/+ mice (regardless of P-
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Rex1 genotype): this was consistent with the increase of melanoblast numbers seen when 
PTEN was deleted under the control of the Dct promoter (Inoue-Narita, 2008). 
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Figure 5.3 PTEN ablation does not rescue the P-Rex1 migration phenotype  
(a) Schematic diagram detailing breedings of DCT-lacZ melanoblast reporter mice to PREX1 and 
PTEN gene modifications. (b) Comparison of melanoblast migration along forepaw in X-gal stained 
embryos at E15.5. A migratory deficit is evident in both P-Rex1
-/-
 (with either PTEN
lox/+
 or 
PTEN
lox/lox
) embryos. Scale bars = 500µm. 
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Figure 5.4 PTEN ablation does not rescue the P-Rex1-null migration phenotype  
(a) Schematic picture showing method of quantification of melanoblast migration used for (b) and 
(c) (b,c) Comparison of melanoblast migration between P-Rex1
+/+
 (‘WT’, blue bars) and P-Rex1
-/-
 
(‘HOM’, red bars) mice. Upper panel (b) represents PTEN
lox/+ 
embryos (*p=0.03, Levels 1/2/3; 
Mann-Whitney test, n=4), lower panel (c) represents PTEN
lox/lox 
embryos (*p=0.012, Levels 1/2/3/4; 
Mann-Whitney test, n=5) (All box and whiskers plots: boxes represent 25
th
-75
th
 percentiles of given 
value, lines represent median values). 
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5.4 Ptenlox/+ combination with BrafV600E is an appropriate model 
for studying P-Rex1 activity 
We next assessed whether heterozygous or homozygous melanocyte-specific disruption 
of PTEN (in combination with BrafV600E expression) is a more appropriate model for 
characterising any putative anti-metastatic effects of P-Rex1 depletion.  To avoid 
problems with embryonic lethality, Ptenlox/lox, BrafV600E/+, and P-Rex1-/- mice were inter-
crossed to mice carrying a melanocyte-specific inducible Tyr::CreER promoter (Figure 5.5) 
(Yajima et al, 2006). Using this model, no PTEN deletion or expression of BrafV600E would 
occur until mice were shaved and induced using skin painting with topical tamoxifen 
(Dhomen et al, 2009).  
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Figure 5.5 Schematic diagram detailing breeding of inducible Braf
V600E
 melanoma model to 
P-Rex1 and PTEN mice  
Offspring are shaved and painted with topical tamoxifen to induce recombination in melanocytes 
(detailed in section 2.3.2). 
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Comparison of survival between the first 6 painted Tyr::CreER BrafV600E/+; Ptenlox/lox mice 
and Tyr::CreER BrafV600E/+; Ptenlox/+ mice revealed a considerably shortened overall survival 
for Tyr::CreER BrafV600E/+; Ptenlox/lox mice, with nearly all requiring euthanisation due to 
overgrowth or ulceration of primary melanoma (Figures 5.6a,b). We therefore concluded 
that Tyr::CreER BrafV600E/+; Ptenlox/+ mice would be a more appropriate model for 
investigation of P-Rex1: the longer survival of these mice would allow more time for 
metastases to develop, without their survival extending for a period that was too 
prolonged.  Both epithelioid and spindle cells were observed in the dermis of induced 
Tyr::CreER BrafV600E/+; Ptenlox/+ mice, with a predominance of melanomas macroscopically 
non-pigmented (Figures 5.6b,c). As is characteristic of many genetically modified 
melanoma mouse models, the presence of both of these cell types is consistent with the 
nodular histological subtype of primary melanoma (detailed further in section 1.3.1.2). P-
Rex1 expression was consistently observed in all melanomas, whether characterised by 
spindle or epithelioid cell morphology (Figures 5.6c). 
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Figure 5.6 PTEN
lox/+
 combination with the Braf
V600E
 melanoma model is appropriate for 
studying P-Rex1 activity  
(a) Kaplan-Meier curves detailing significant survival improvement of first 6 mice from TyrER::Cre 
Braf
V600E/+
; PTEN
lox/+
 cohort (black line) compared to first 6 from TyrER::Cre Braf
V600E/+
; PTEN
lox/lox
 
cohort (red line) (*p=0.001, log-rank test, n=6). (b) Example of primary melanomas arising in 
TyrER::Cre Braf
V600E/+
; PTEN
lox/+
 transgenic mice. Red arrows: non-pigmented primary skin 
melanomas. (c) Representative H&Es and melanA/P-Rex1 immunohistochemistry showing 
consistent expression of P-Rex1 in two melanomas characterised by different cell populations. Pink 
staining represents expression of melanA (black arrows) or P-Rex1 (white arrows), black/brown 
areas are melanin pigment. 057238/051103 =mouse identification numbers. 051103 melanoma 
predominantly composed of epithelioid cells, 057238 predominantly composed of spindle cells with 
hyperchromatic nuclei compared to 051103 (n=3) (Scale bars = 100µm, 30µm for inserts). 
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5.5 PREX1 disruption does not alter primary melanoma 
parameters in Tyr::CreER BrafV600E/+; PTENlox/+ mice 
Consistent with our analysis of Tyr::NrasQ61K/°; INK4a-/- mice in Chapter 3, we could not 
confirm an alteration of primary melanoma characteristics when P-Rex1 was reduced in 
Tyr::CreER BrafV600E/+; PTENlox/+ mice. 100% of mice in both cohorts developed primary 
melanoma after induction with tamoxifen (Table 5.1). No difference in rate of growth was 
observed between Tyr::CreER BrafV600E/+; PTENlox/+; P-Rex1-/- mice and control Tyr::CreER 
BrafV600E/+; PTENlox/+; P-Rex1+/+ mice (Figure 5.7a). In the experimental Tyr::CreER 
BrafV600E/+; PTENlox/+; P-Rex1-/- cohort, there was a trend towards diminished tumour 
burden as a consequence of  fewer primary melanomas developed per mouse following 
tamoxifen induction, but no statistically significant change seen (Figures 5.7b,c). There 
was no difference in ulceration incidence or median size at which ulceration occurred 
(Table 5.2). Finally, primary melanoma latency following tamoxifen induction was not 
altered (Figure 5.7d). 
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Figure 5.7 P-Rex1 depletion does not alter primary melanoma growth parameters in 
TyrER::Cre Braf
V600E/+
; PTEN
lox/+
 mice  
(a) Quantification and comparison of first 6 weeks primary melanoma growth between TyrER::Cre 
Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+
 mice (‘WT’, blue bars) compared to first 6 weeks from TyrER::Cre 
Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/-
 mice (‘HOM’, red bars) (Week 1: n=16 vs n=7, Mann-Whitney, 
p=0.229; Week 2: n=16 vs n=7, Mann-Whitney, p=0.3; Week 3: n=16 vs n=6, Mann-Whitney, 
p=0.285; Week 4: n=13 vs n=4, Mann-Whitney, p=0.734; Week 5: n=3 vs n=4, Mann-Whitney, 
p=0.596; Week 6: n=1 vs n=2, statistical assessment not possible). (b) Comparison of primary 
melanoma tumour burden between TyrER::Cre Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+
 mice (‘WT’, blue 
bars, n=23) and TyrER::Cre Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/-
 mice (‘HOM’, red bars, n=7) (p=0.155, 
Mann-Whitney) (c) Quantification and comparison of primary melanoma frequency observed 
between TyrER::Cre Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+
 mice (‘WT’, blue bars, n=23) and TyrER::Cre 
Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/-
 mice (‘HOM’, red bars, n=7) (p=0.162, Mann-Whitney)  (Box and 
whiskers plots: boxes represent 25
th
-75
th
 percentiles of given value, lines represent median 
values).  (d) Kaplan-Meier analysis of primary melanoma latency between TyrER::Cre Braf
V600E/+
; 
PTEN
lox/+
; P-Rex1
+/+
 (black line, n=19) and TyrER::Cre Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/-
 (red line, 
n=7) cohorts (p=0.286, log-rank test). 
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Genotype 
Mice with 
Primary 
Melanoma 
Mice with 
Melanoma 
Metastases 
TyrER::Cre BrafV600E/+; PTENlox/+; P-Rex1+/+ 25/25 3/10 
TyrER::Cre BrafV600E/+; PTENlox/+; P-Rex1-/- 7/7 2/7 
 
Table 5.1 P-Rex1 depletion does not reduce incidence of metastasis in a Tyr::CreER 
Braf
V600E/+
; PTEN
lox/+
  murine melanoma model  
Table detailing numbers of mice within both Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+ 
and 
Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/- 
cohorts suffering from primary and metastatic 
melanoma. Metastatic sites were all observed in the lung, except for 1 liver lesion in the Tyr::CreER 
Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/- 
cohort. 
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Genotype 
Number of 
mice assessed 
for ulceration 
Number of 
mice with 
ulceration 
Median diameter 
of melanoma at 
ulceration (mm) 
TyrER::Cre BrafV600E/+; PTENlox/+; P-Rex1+/+ 23/25 19/23 7 
TyrER::Cre BrafV600E/+; PTENlox/+; P-Rex1-/- 7/7 7/7 7.5 
 
Table 5.2 There is no difference in primary melanoma ulceration when P-Rex1 is depleted in 
Tyr::CreER Braf
V600E/+
; PTEN
lox/+
 mice  
Table detailing incidence of ulceration and size of tumour at which ulceration occurs. 
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5.6 PREX1 disruption does not alter metastases or survival in 
Tyr::CreER BrafV600E/+; PTENlox/+ mice 
Contrary to what we observed in chapter 3 when P-Rex1 was ablated in Tyr::NrasQ61K/°; 
INK4a-/- mice, no difference in metastatic incidence was observed between age-matched 
Tyr::CreER BrafV600E/+; PTENlox/+; P-Rex1-/- mice and control Tyr::CreER BrafV600E/+; PTENlox/+; 
P-Rex1+/+ mice  (Table 5.1).   However, only 7 mice were assessable in the Tyr::CreER 
BrafV600E/+; PTENlox/+; P-Rex1-/- cohort. Across both cohorts, one liver and four lung 
metastases were seen, with mild staining intensity of the melanocyte marker, S100, 
observed in these lesions (Figure 5.8a; Table 5.1). There was no difference in survival 
between the two cohorts, measured from induction or time of primary melanoma 
development (Figures 5.8b,c). 
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Figure 5.8 P-Rex1 disruption does not alter metastases or survival in Tyr::CreER Braf
V600E/+
; 
PTEN
lox/+
 mice  
(a) Representative photomicrographs of IHC showing lung and liver metastasis with rare 
expression of the melanocyte marker S100 (white arrow) (n=5 across both cohorts; Scale bars = 
30µm) (b) Kaplan-Meier analysis of time till death after melanoma onset: comparison between 
Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+
 (black line, n=19) and Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; 
P-Rex1
-/-
 (red line, n=7) cohorts (p=0.311, log-rank test). (c) Kaplan-Meier analysis of time till death 
from tamoxifen induction: comparison between Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; P-Rex1
+/+
 (black 
line, n=19) and Tyr::CreER Braf
V600E/+
; PTEN
lox/+
; P-Rex1
-/-
 (red line, n=7) cohorts (p=0.303, log-
rank test). 
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5.7 Summary 
This chapter describes several important features of P-Rex1 function which expand our 
knowledge of the potential use of a P-Rex1 inhibitor in the clinic. We have analysed and 
discussed these in more detail in sections 7.1.2 and 7.3.1. This summary offers a synopsis 
of our findings in chapter 5. 
Importantly, we have not been able to prove an effect of P-Rex1 depletion on BrafV600E-
driven melanomas that matches its anti-metastatic effects in NrasQ61K-driven tumours. 
There was no reduction in metastases or survival observed in P-Rex1-null BrafV600E-driven 
melanomas (Table 5.1, Figure 5.8). Moreover, extensive analyses of BrafV600E primary 
tumours did not suggest any difference in tumour growth, burden, frequency, timing of 
onset, or ulceration without endogenous P-Rex1 (Table 5.2, Figure 5.7). It should be noted 
that metastases observed using the BrafV600E-driven model were limited, perhaps 
reflecting the rarity of metastatic success described by Fidler in 1970 (Fidler, 1970) 
(detailed in section 1.2). Other possible reasons for the small number of BrafV600E-driven 
metastases, and the apparent metastatic discrepancy with P-Rex1 depletion between 
BrafV600E-driven and NrasQ61K-driven models, are discussed in detail in section 7.1.2. 
For the first time in this thesis, this chapter uncouples our P-Rex1 embryonic phenotype 
from the phenotype which we might have expected in our cancer model. The persisting 
migrational deficit observed when PTEN was ablated in P-Rex1-depleted embryos 
suggested we would again see a metastasis reduction with P-Rex1 manipulation in the 
TyrER::Cre BrafV600E/+; PTENlox/+ cancer model (Figures 5.3, 5.4). As already mentioned, this 
was not the case and there was no change in metastases with P-Rex1 depletion (Table 
5.1, Figure 5.8). Sections 7.1.2 and 7.3.1 detail why the TyrER::Cre BrafV600E/+; PTENlox/+ 
cancer model may not be optimal for study of metastases, a potential reason why there 
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was no fit between the cancer and embryonic phenotypes on this occasion. The 
possibility that we may have missed a P-Rex1 effect due to use of a sub-optimal model is 
supported by the clear upregulation of P-Rex1 observed in human melanoma cell lines 
driven by BrafV600E (Figure 5.1). However, as mentioned in section 1.1.5, it is possible that 
a ‘developmental’ hypothesis for cancer using embryonic models may prove to be too 
simplistic in this case, unable to offer an insight of the complicated mutational and 
biological processes involved in BrafV600E-driven metastases. 
Finally, in this chapter we have established important practical considerations for the 
future utility of murine TyrER::Cre BrafV600E/+cancer models. Their optimal use in our 
hands was in combination with heterozygous PTENlox/+ mice, rather than the PTENlox/lox 
mice previously reported (Figure 5.6) (Dankort et al, 2009). It is also clear that their 
greatest current advantage is for the study of primary melanomas rather than 
metastases, at least until a facility and protocol for primary tumour removal can be 
efficiently set up (see sections 1.3.1.2, 7.1.2 and 7.3.1). 
 
 
  
Chapter 6  
Exploring the tumourigenic role of FAK in the 
melanocyte lineage 
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In chapters 3-5, we have established a melanomagenic role for P-Rex1 using a number of 
different cancer and embryonic genetically modified mouse models. This chapter focuses 
on validating the diversity of these models by assessing an alternative molecule described 
in tumourigenesis, FAK. FAK has been described as a key player in cancer for several 
years, and has been characterised as pro-migratory using a Xiphophorus model of 
melanoma (see section 1.5.2, Meierjohann et al, 2006). It represents an altogether 
different type of anticancer target to P-Rex1 for the following reasons: 
1. Expression. Unlike P-Rex1, FAK is widely expressed in human cells, suggesting that 
finding a therapeutic window for its inhibition in tumourigenesis may be less 
straightforward (Schaller et al, 1992, Hanks et al, 1992). Other than in large bowel 
cancers (5 mutations in 47 cancers analysed), there is little evidence from the cancer 
genome project that FAK can contribute to cancer secondary to its mutation rather 
than changes in expression levels (total of 14 mutations in 1503 cancer samples), so 
targeting a mutant form of FAK would not be an appropriate strategy for narrowing 
the therapeutic window (http://cancer.sanger.ac.uk/cosmic/gene/analysis 
?ln=PTK2#histo). Despite this, several small molecule inhibitors of FAK have been 
developed and are now in advanced clinical assessment (Sui et al, 2008). 
2. Cancer biology. Through its complex involvement in various downstream signalling 
networks such as MAPK, PI(3)K, Src, and EGFR, FAK has confirmed roles in cancer-
related processes such as angiogenesis, surv`ival and migration (Weiner et al, 1993, 
Owens et al, 1995, Schaller et al, 2001, Ilic et al, 2003). This contrasts with the solitary 
Rac-specific downstream role reported for P-Rex1 in cancer invasion, but also 
suggests that optimising the benefits of FAK inhibition could be a complicated 
Chapter 6: Results  182 
 
process. It is also unclear how the many roles of FAK relate to its kinase activity 
compared to its intra- and inter-molecular protein-protein interactions.  
3. Possible role in tumour inhibition. A pro-tumourigenic role for P-Rex1 through its 
capacity to induce migration is intuitive and has been straightforwardly described in 
the previous chapters, as well as other reports (Qin et al, 2009). Despite a majority of 
literature asserting that the same is the case for FAK, there are conflicting data that 
suggest FAK upregulation can be beneficial in certain tumour contexts (Gabriel et al, 
2006, Giaginis et al, 2009, Zhao et al, 2009). This might support the cell biological 
hypothesis that downregulation of FAK might permit primary melanoma cells to 
become more migratory by reducing their focal adhesions to the extra-cellular matrix 
(Schultze et al, 2010). 
Currently melanoma is a cancer where there is a relative deficit of translational research 
involving FAK. Given the cancer-specific roles described above, we deemed it would be 
important to analyse FAK in more detail using our mouse models. 
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6.1 FAK deletion reduces melanoblast numbers during 
embryogenesis 
As highlighted throughout this thesis, mechanistic and observational studies have 
revealed key similarities between the molecular machinery involved in signalling of 
melanoblasts and that of melanoma cells (detailed in section 1.1.5) (Gupta et al, 2005, 
Uong et al, 2010, Strizzi et al, 2011). In line with the role of FAK in development of other 
cell lineages, we first explored its role in development of melanocyte precursors, looking 
for parallels that could offer insight into a potential cancer phenotype (Fonar et al, 2011, 
Zhao et al, 2010).  
Embryonic lethality at E8.5 occurs when FAK is ablated in mice (Ilic et al, 1995, Furuta et 
al, 1995). To address whether melanoblast behaviour is altered by FAK abrogation, we 
therefore inter-crossed mice with a melanocyte-specific FAK deletion, Tyr::Cre FAKfl/fl, to 
mice carrying the DCT-lacZ transgene, the melanoblast reporter line described in chapter 
4 (McLean et al, 2004, Mackenzie et al, 1997). Consistent with the reported role of FAK in 
proliferation and anoikis, there was a statistically significant reduction of E15.5 
melanoblast numbers in DCT-lacZ; Tyr::Cre FAKfl/fl mice compared to DCT-lacZ; Tyr::Cre 
FAK+/+ mice (Figures 6.1a,b). 
Given the importance of oncogenic Nras in human melanoma (see Section 1.1.4.1) and 
the known interaction of FAK with a number of cancer-associated pathways (see Section 
1.5.2.3), we also crossed Tyr::Cre FAKfl/fl mice to the Tyr::NrasQ61K/° mice (Tyr::NrasQ61K/°; P-
Rex1-/-) described in chapter 3 (Ackermann et al, 2005). The FAKfl/fl cell number phenotype 
shown in Figure 6.1b was overcome by expression of Tyr::NrasQ61K/° (Figures 6.1a,c). 
Examination of melanoblast morphology revealed possible apoptotic bodies present in 
both DCT-lacZ; Tyr::Cre FAKfl/fl mice and DCT-lacZ; Tyr::NrasQ61K/°; Tyr::Cre FAKfl/fl mice, 
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which were not present in their relative wild-type FAK controls (Figure 6.2). An alternative 
hypothesis was that these areas represent an increased dermal localisation of 
melanoblasts when FAK is conditionally deleted (Figure 6.2, arrows). Comparison of E15.5 
cell numbers when Tyr::NrasQ61K/° was expressed with or without FAK disruption did not 
show a change in melanoblast cell numbers (Figures 6.3a,b).  
Collectively, these findings do no yet convey a clear physiological picture of the role of 
FAK in melanocyte embryology: there is an undoubted cell number deficit induced by its 
deletion and overcome by expression of Tyr::NrasQ61K/°, but further delineation of the 
relative contributions of proliferation, apoptosis, and dermal mislocalisation to this 
phenotype is required. This will start with clarification of what these potential dermal or 
apoptotic bodies are, followed by their quantification. 
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Tyr::NrasQ61K/°
FAK+/+
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*
 
Figure 6.1 Tyr::Cre FAK
fl/fl 
mice have a deficit of melanoblasts at E15.5  
(a) Representative pictures at E15.5 comparing cell numbers on the flank of X-gal stained embryos 
in wild-type, Tyr::Cre FAK
fl/fl
, Tyr::Nras
Q61K/°
; FAK
+/+
 and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 mice. Scale 
bars = 1mm (b)(c) Comparison of E15.5 melanoblast numbers between wild-type (‘FAK WT’, white 
bars) and Tyr::Cre FAK
fl/fl 
(‘FAK fl/fl’, red bars) mice (b), and also between Tyr::Nras
Q61K/°
; FAK
+/+
 
(‘NrasQ61K; FAK WT’, white bars) and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 (NrasQ61K; FAK fl/fl’, red 
bars) mice (c). (b: *p =0.012; c: p =0.06; Mann-Whitney test, n=5) (Box and whiskers plots: boxes 
represent 25
th
-75
th
 percentiles of given value, lines represent median values). 
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Tyr::NrasQ61K/°
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Figure 6.2 There may be fewer epidermal melanoblasts in FAK-deleted embryos at E15.5  
Representative pictures at E15.5 comparing melanoblasts on forearms of X-gal stained embryos of 
wild-type, Tyr::Cre FAK
fl/fl
, Tyr::Nras
Q61K/°
; FAK
+/+
 and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 mice. Scale 
bars = 200µm. White arrows likely show either apoptotic bodies or a dermal localisation of 
melanoblasts (n=4).   
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Figure 6.3 Expression of Nras
Q61K 
does not increase cell numbers at E15.5  
(a)  Comparison of E15.5 melanoblast numbers between wild-type (‘Nras WT’, white bars) and 
Tyr::Nras
Q61K/°
 (‘NrasQ61K’, grey bars) (p =0.21; Mann-Whitney test; n=5) (Box and whiskers plots: 
boxes represent 25
th
-75
th
 percentiles of given value, lines represent median values). (b) 
Comparison of E15.5 melanoblast numbers between Tyr::Cre FAK
fl/fl 
(‘Nras WT; FAK fl/fl’, white 
bars) mice and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 (NrasQ61K; FAK fl/fl’, grey bars) mice (p =0.403; 
Mann-Whitney test; n=5)  
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6.2 FAK deletion may impair melanoblast migration during 
embryogenesis 
Using the melanoblast migration assay detailed in Figure 2.1c, a statistical reduction in 
melanoblast migration between DCT-lacZ; Tyr::Cre FAKfl/fl and DCT-lacZ; Tyr::Cre FAK+/+ 
mice was observed (Figure 6.4a,b). Again this phenotype was overcome by NrasQ61K/° 
expression (Figure 6.4c). No increase in cell rounding when FAK was deleted (through a 
reduction in focal adhesion) was evident on inspection of melanoblast morphology 
(Figure 6.2). As well as differing with the morphological changes seen with P-Rex1 
ablation in figure 4.5, this result contrasts with a study showing an increase in cells with 
amoeboid morphology when FAK was knocked down using RNA interference in a breast 
cancer cell line (Golubovskaya et al, 2009).  
Collectively, our embryo results show that the developmental phenotype of FAK deletion 
in melanoblasts potentially parallels its reported proliferative and migratory role in 
epithelial cell tumourigenesis.  Although our migratory results parallel those described 
with dominant-negative FAK using a Xiphophorus melanoma model, it should be stressed 
that so far only one assay has been used to quantify migration in Tyr::Cre FAKfl/fl mice: 
their lack of a white belly spot or any cell morphological change (Figure 6.4c) might 
suggest that our result in Figure 6.4a,b could be artefact, resulting from the reduction in 
cell numbers described in Section 6.1 and Figure 6.1 (Meierjohann et al, 2006). This 
possibility is discussed further in Section 7.3.4. 
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Figure 6.4 Tyr::Cre FAK
fl/fl 
mice have a deficit of melanoblast migration at E15.5  
(a) Schematic picture showing method for quantification of melanoblast migration used in (b) and 
(c) (detailed in Figure 2.1c) (b) (c) Comparison of E15.5 melanoblast migration wild-type (‘FAK 
WT’, white bars) and Tyr::Cre FAK
fl/fl 
(‘FAK fl/fl’, red bars) mice (e), and also between 
Tyr::Nras
Q61K/°
; FAK
+/+
 (‘NrasQ61K; FAK WT’, white bars) and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 
(‘NrasQ61K; FAK fl/fl’, red bars) mice (f). (b: *p =0.03; f: c =0.47; Mann-Whitney test, n=4) (Box and 
whiskers plots: boxes represent 25
th
-75
th
 percentiles of given value, lines represent median 
values). 
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6.3 FAK disruption promotes a coat colour phenotype in 
Tyr::NrasQ61K/°  mice 
Many mouse coat colour phenotypes resulting from genetically manipulated oncogenes 
have offered insights into melanomagenesis, notably including Kit 
(www.espcr.org/micemut, Berlin et al, 2012). In line with this, as well as the key role FAK 
has in normal cell physiology, we next investigated the health and phenotype of adult 
mice with melanocyte-specific FAK disruption. 
Mice were interbred as described in the developmental analysis above, but this time 
omitting the DCT-lacZ reporter and allowing the mice to litter and age until ill health 
necessitated euthanisation. No change in coat colour or condition was detected for up to 
12 months in experimental Tyr::Cre FAKfl/fl mice when compared to FAK+/+ controls. 
However, a coat colour phenotype was noted from the age of 3 months when 
melanocyte-specific expression of the Tyr::NrasQ61K/°  transgene was combined with FAK 
deletion (Figure 6.5a). In detail, these Tyr::NrasQ61K/°; Tyr::Cre FAKfl/fl mice consistently 
exhibited glossier coats compared to Tyr::NrasQ61K/°; Tyr::Cre FAKfl/+ mice and 
Tyr::NrasQ61K/°; Tyr::Cre FAK+/+ controls (100% penetrance) (Figure 6.5a). While 
Tyr::NrasQ61K/°; Tyr::Cre FAK+/+  and Tyr::NrasQ61K/°; Tyr::Cre FAKfl/+ mice developed skin 
hypertrophy, blackening of skin, greying of hair, and hair loss from early adulthood, 
Tyr::NrasQ61K/°; Tyr::Cre FAKfl/fl mice persistently maintained a full healthy coat of black 
hair more characteristic of wild-type C57BL6 mice. Histological inspection and 
quantification of skin sections from Tyr::NrasQ61K/°; Tyr::Cre FAKfl/fl mice showed a 
reduction in tissue thickness and melanin deposition compared to Tyr::NrasQ61K/°; Tyr::Cre 
FAKfl/+ mice (Figure 6.5b,c). In summary, endogenous FAK has an important role in 
melanocyte homeostasis when combined with oncogenic NrasQ61K. Thus, divergent effects 
of endogenous FAK signalling in melanocyte homeostasis and development exist: 
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expression of oncogenic NrasQ61K rescues the FAKfl/fl phenotypes of melanoblasts but can 
promote an adult coat colour phenotype not seen in Tyr::Cre FAKfl/fl mice alone. 
 
Chapter 6: Results  192 
 
 
Tyr::N-RasQ61K
Tyr::Cre FAKfl/+
Tyr::N-RasQ61K
Tyr::Cre FAKfl/fl
Tyr::N-RasQ61K
Tyr::Cre FAKfl/+
Tyr::N-RasQ61K
Tyr::Cre FAKfl/fl
a
c
*
b
Tyr::N-RasQ61K
Tyr::Cre FAKfl/+
Tyr::N-RasQ61K
Tyr::Cre FAKfl/fl
 
Figure 6.5 FAK disruption promotes a coat colour phenotype in Tyr::Nras
Q61K/°
  mice  
(a) Coats of Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fll+
 mice and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 mice. Inserts 
show shaved area of back skin. (b) Photomicrographs (H&E) of back skin from the two genotypes 
represented in (a). Melanocytes and deposition of melanin in the dermis (red arrow) and adipose 
tissue (red arrowheads) are indicated (Scale bars=100µm). (c) Quantification of back skin 
thickness from epidermis to adipose tissue compared between Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/+
 
(NrasQ61K; FAK fl/+’, white bars) and Tyr::Nras
Q61K/°
; Tyr::Cre FAK
fl/fl
 (‘NrasQ61K; FAK fl/fl’, red 
bars) mice (*p =0.012; Mann-Whitney test, n=4) (Box and whiskers plots: boxes represent 25
th
-75
th
 
percentiles of given value, lines represent median values). 
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6.4 Primary melanomagenesis is delayed by FAK deletion 
Disruption of endogenous FAK has been shown to retard primary cancer formation and 
progression (McLean et al, 2004, Lahlou et al, 2007, Provenzano et al, 2008). Given our 
previous results combining FAK deletion with expression of oncogenic Nras, we crossed 
Tyr::Cre FAKfl/fl and Tyr::Cre FAKfl/+ mice to the Tyr::NrasQ61K/°; INK4a-/-  genetically 
modified model of metastatic malignant melanoma, assessing whether FAK may also be 
important for primary melanoma development and/or metastasis. 
Having observed similar coat colour phenotypes between mice expressing one or two 
copies of wild-type FAK (described in section 6.3), we first confirmed that control 
Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/+  mice developed primary melanoma with a similar 
incidence and latency  to that previously described with Tyr::NrasQ61K/°; INK4a-/- mice 
(Table 6.1; Figures 6.6a,b; Figure 3.1e and Table 3.1). As this was the case, it allowed us to 
continue our experiments efficiently, using littermate Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre 
FAKfl/+ controls to compare with our experimental  Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/fl 
mice.  
No difference in incidence of primary melanomas between Tyr::NrasQ61K/°; INK4a-/-; 
Tyr::Cre FAKfl/+ mice and Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/fl mice was observed (Table 
6.1). Consistent with prior studies of FAK in genetically modified cancer models of other 
tumour types, we observed significant prolongation of melanoma onset when FAK was 
abrogated (median 167 days vs 113 days; p=0.0001) (Figure 6.6b, Table 6.1). This 
prolongation did not correlate with any difference in primary tumour burden between 
the two cohorts (Figure 6.6c).  
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We next derived cell lines from the primary melanomas of Tyr::NrasQ61K/°; INK4a-/- mice 
with wild-type FAK, FAKfl/+, or FAKfl/fl. Western Blotting performed at 8-10 passages in 
culture revealed FAK expression in Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/fl mice 
comparable to that seen in Tyr::NrasQ61K/°; INK4a-/-; FAK+/+ mice (Figure 6.6d). This 
suggested there was a propensity for melanoma cell populations which have escaped 
conditional FAK deletion, as a result of the inherent inefficiencies of Cre recombinase 
technology in mouse modelling, to outgrow those with FAK deletion (see Sections 2.6.2 
and 2.6.3). Further in vitro characterisation of endogenous FAK depletion in our mice was 
therefore precluded, and we alternatively investigated using IHC.  
First, we confirmed with IHC that there was no in vivo outgrowth of Tyr::NrasQ61K/°; INK4a-
/-; Tyr::Cre FAKfl/fl melanomas by escaping populations of melanoma cells expressing wild-
type FAK: FAK expression could not be visualised in FAKfl/fl melanomas (Figure 6.6e). 
Preliminary IHC assessment showed enhanced proliferation at the invasive edge of FAK-
depleted melanomas, although we were unable to effectively compare or quantify this 
observation with Tyr::NrasQ61K/°; INK4a-/-; FAKfl/+ controls given their saturation with 
melanin pigment (Figure 6.7). Tissue ‘bleaching’ of melanin pigment is a technique that 
can be employed in the future to characterise this result further and ensure an unbiased 
approach. Collectively, our findings suggest that, consistent with our results in 
melanocyte embryogenesis, FAK disruption can affect onset of primary melanoma driven 
by oncogenic Nras. 
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Figure 6.6 Primary melanomagenesis is delayed by FAK deletion  
(a) Primary pigmented melanoma arising in Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fll+
 transgenic 
mice  (white arrows).  Accompanying photomicrograph (H&E) indicates muscle invasion (white 
arrows) as well as vascular involvement (black arrows) (Scale bars=500µm). (b) Kaplan-Meier 
analysis of primary melanoma latency between Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fll+
 (black line, 
n=15) and Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fllfl
 (red line, n=16) cohorts (*p=0.0001, log-rank 
test). (c) Comparison of primary melanoma tumour burden between Tyr::Nras
Q61K/°
; INK4a
-/-
; 
Tyr::Cre FAK
fl/+
 (NrasQ61K; FAK fl/+’, white bars, n=15) and Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre 
FAK
fl/fl
 (‘NrasQ61K; FAK fl/fl’, red bars, n=16) mice (p =0.353; Mann-Whitney test) (Box and 
whiskers plots: boxes represent 25
th
-75
th
 percentiles of given value, lines represent median 
values). (d) Western blots illustrating endogenous expression of FAK in melanoma cell lines 
derived from Tyr::Nras
Q61K/°
; INK4a
-/-
 vs Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/+
 vs Tyr::Nras
Q61K/°
; 
INK4a
-/-
; Tyr::Cre FAK
fl/fl
 mice (e) Photomicrographs of adult mouse melanomas 
immunohistochemically labelled against FAK. Black arrows indicate FAK upregulation (brown 
staining) in control Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/+
 melanomas, not observed in the 
Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/fl
  cohort. Black melanin pigment is clearly distinct from 
brown Fak staining (Scale bars = 100µm; n=4).
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Genotypes 
Number of 
Mice with 
Primary 
Melanoma 
Number of 
Metastatic 
Mice 
Mean time 
till primary 
melanoma 
(days) 
Mean time from 
melanoma to 
death (days) 
Mean 
Survival  
(days) 
Tyr::NrasQ61K/°; INK4a-/-; 
FAKfl/+ 
15/16 8/15 113 76 182 
Tyr::NrasQ61K/°; INK4a-/-; 
FAKfl/fl 
16/19 9/16 167 44 198 
 p=0.0001          p=0.03 p=0.166 
 
Table 6.1 FAK deletion delays melanoma onset but increases disease aggressiveness 
following melanoma onset 
Table comparing numbers and melanoma parameters of mice within Tyr::Nras
Q61K/°
; INK4a
-/-
; 
Tyr::Cre FAK
fl/+
 and Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/fl
 cohorts suffering from primary and 
metastatic melanoma. (Chi-square test used for primary and metastatic melanoma incidence, log-
rank test to compare survival and melanoma onset). 
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Figure 6.7 Enhanced proliferation occurs at the invasive edge of FAK-deleted melanomas 
Photomicrographs of adult mouse melanomas immunohistochemically labelled against the 
melanocyte marker S100 or proliferative marker Ki67. Saturation with melanin pigment precluded 
clear analysis of Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/+
 melanomas, although melanoma cell 
presence was confirmed (brown staining, red arrow). This one Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre 
FAK
fl/fl
 melanoma was less pigmented, showing clear S100 upregulation (brown staining) as well as 
enhanced Ki67 at the invasive edge of tumour (black interrupted line) (Scale bars = 100µm; n=1). 
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6.5 Metastatic and invasive melanoma is promoted by FAK 
deletion 
An ambivalent picture is described in reports characterising the role of FAK in human 
cancer, with both pro-tumourigenic and tumour suppressive roles suggested. Of interest, 
although studies of primary cancers predominantly suggest a pro-tumourigenic role for 
FAK, reduction in FAK expression has been noted in human metastatic tissue compared to 
a matched sample of primary adenocarcinoma (Ayaki et al, 2001). Cell biology studies of 
invasion and survival have also shown an inhibitory effect of FAK in certain contexts 
(Schaller et al, 2004, Zheng et al, 2009, Sandilands et al, 2011).  
In chapter 3, our control Tyr::NrasQ61K/°; INK4a-/- mice developed visceral melanotic lesions 
in line with the initial report describing this model (31% of cases; Figures 6.8a,b), offering 
an opportunity for seamless in vivo analysis of FAK between primary and metastatic 
tumours. We therefore continued our mouse breeding until sufficient data were available 
to assess the effect of FAK ablation on melanoma metastasis.  
In contrast to our primary melanoma results, Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/fl mice 
showed a clear propensity to deteriorate rapidly after they had developed primary 
melanoma (median 44 days vs 76 days; p=0.03) (Figure 6.8c, Table 6.1), despite there 
being no difference in number of mice affected by metastases between the two cohorts 
(Table 6.1). These results are consistent with the findings and paradoxical mechanism 
reported by Zheng and colleagues, whereby loss of FAK promotes tumour cell invasion in 
the context of Ras signalling (Zheng et al, 2009). Moreover, this acceleration of invasion 
and metastases precluded any overall survival benefit offered by prolongation of primary 
tumour onset when FAK is deleted (median 198 days vs 182 days; p=0.166) (Figure 6.8d, 
Table 6.1). IHC performed so far has shown proliferating malignant cells in the brain 
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lesions of both FAK-depleted and FAKfl/+ controls (Figure 6.9a). The limited number of lung 
metastases seen in experimental Tyr::NrasQ61K/°; INK4a-/-; FAKfl/fl mice has so far precluded 
comparison with the proliferation observed in heterozygous controls (Figure 6.9b). Taken 
together, our results confirm a paradoxical and biphasic role for FAK in tumourigenesis: 
pro-oncogenic in the context of primary tumour onset, and tumour suppressive following 
development of primary melanoma. The mechanisms behind this have yet to be fully 
delineated. 
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Figure 6.8 Metastatic and invasive melanoma is promoted by FAK deletion  
(a) Representative picture showing typical metastatic pigmented melanoma (white arrow) arising in 
lungs of Tyr::Nras
Q61K/°
; INK4a
-/-
 transgenic mice with both FAK genotypes. Accompanying  
photomicrograph (H&E)  shows multiple pigmented lung lesions (black arrows) (Scale 
bars=100µm). (b) Representative picture showing typical pigmented brain lesion (black arrow) 
arising in Tyr::Nras
Q61K/°
; INK4a
-/-
 transgenic mice with both FAK genotypes. Accompanying  
photomicrograph (H&E)  shows clear demarcation between normal brain and tumour (white 
interrupted line) (Scale bars=100µm). (c) Kaplan-Meier analysis of time from onset of primary 
melanoma till death from melanoma.  Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fll+
 (black line, n=12) 
and Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fllfl
 (red line, n=12) cohorts were compared (*p=0.03, log-
rank test). (d) Kaplan-Meier analysis of overall survival: time from birth till death from melanoma.  
Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fll+
 (black line, n=12) and Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre 
FAK
fllfl
 (red line, n=12) cohorts were compared (p=0.166, log-rank test). 
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Figure 6.9 Increased invasion occurs in melanomatous brain lesions of FAK wild-type and 
FAK-depleted mice  
Photomicrographs of adult mouse melanoma lesions in brain (a) and lungs (b): H&E, or 
immunohistochemically labelled against the melanocyte marker S100 or the proliferative marker 
Ki67. (a) Ki67 upregulation in Tyr::Nras
Q61K/°
; INK4a
-/-
; Tyr::Cre FAK
fl/+
 and Tyr::Nras
Q61K/°
; INK4a
-/-
; 
Tyr::Cre FAK
fl/fl
 brain lesions (black arrows) (Scale bars = 100µm; n=4) (b) Lung metastases (red 
arrows) seen in control Tyr::Nras
Q61K/°
; INK4a
-/-
; FAK
fl/+ 
mice exhibited proliferation (black arrows) 
concordant with S100 expression (red arrows) (Scale bars = 100µm; n=4). 
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6.6 Summary 
Here we describe a tumour suppressor function of FAK for the first time using genetically 
modified mouse models of cancer. This chapter is analysed and discussed in greater detail 
in Sections 7.2.1 and 7.2.2. 
In summary, we have shown divergent functions for endogenous FAK in both a 
physiological and pathophysiological context. In normal murine physiology, FAK 
disruption compromises melanoblast cell numbers in development, but has no long-term 
effect on melanocyte homeostasis (Figures 6.1 and 6.5). Combined expression of 
oncogenic Nras with FAK deletion apparently reverses these effects, promoting a rescue 
of the embryonic cell number deficit and an adult coat colour phenotype not seen in 
Tyr::Cre FAKfl/fl mice alone (Figures 6.1 and 6.5). Finally and most importantly, FAK 
signalling promotes primary tumour formation but slows development of invasion and 
metastases in a Tyr::NrasQ61K/°; INK4a-/- murine model of melanoma (Figures 6.6 and 6.8). 
These final cancer results support the cell biology hypothesis that downregulation of FAK 
initially diminishes its pro-survival function to delay primary melanoma onset, but 
eventually primary melanoma cells will form and become more migratory as a 
consequence of their reduced focal adhesions to the extra-cellular matrix (Schultze et al, 
2010). This is discussed further in Section 7.2.1. 
Mechanistic experiments in our study have again contended the orthodoxy that key 
similarities often exist between the molecular machinery involved in melanoblast and 
melanoma signalling (see section 1.1.5 for more detail). Genetic ablation of FAK impaired 
melanoblast cell numbers, reflecting the delayed onset of primary melanomas seen in 
Tyr::NrasQ61K/°; INK4a-/-; Tyr::Cre FAKfl/fl mice (Figures 6.1 and 6.6). However, a divergent 
role for FAK in motility was revealed by the contrasting effect of inhibition of melanoma 
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invasion and metastasis compared to its limited effect on melanoblast migration 
observed in DCT-lacZ mice expressing Tyr::NrasQ61K/° (Figures 6.4 and 6.8).  
Another noteable result from these experiments was that E15.5 expression of oncogenic 
Nras did not significantly increase melanoblast cell numbers relative to wild-type 
embryos, suggesting that any hyper-proliferative effect induced by NrasQ61K occurs 
following birth: this contrasts with the non-significant increase in melanocyte numbers 
observed in BrafV600E-expressing embryos (Figure 5.2a and 6.3). Given  the coat colour 
phenotype we have described in adult Tyr::NrasQ61K/°; Tyr::Cre FAKfl/fl mice, it is tempting 
to speculate that FAK ablation induces its phenotype in mice only once melanocyte 
numbers have increased to an undefined post-natal threshold in response to  NrasQ61K 
expression.  
In conclusion, this chapter contends a context-dependent role for FAK as both a tumour 
promoter and tumour suppressor in cancer. Our experiments provide stringent preclinical 
validation of a role for FAK in melanoma using informative genetically defined mouse 
models that recapitulate common human mutations. The biological and structural 
complexity of FAK likely confers the variable functions described in this study (see 
sections 1.5.2 and 7.2.1). We suggest considerable thought must be given to the 
appropriate clinical application of FAK inhibitors in the medium to long-term (discussed in 
detail in section 7.2.2).  
  
 
Chapter 7 
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The end of each results chapter offers a synopsis of results accumulated for each topic. 
Rather than re-iterate these, this discussion aims to dissect some key questions that have 
arisen from the data in each chapter, with reference to what further investigations could 
be applied in the future. 
7.1 P-REX1 
7.1.1 Study relevance 
Possibly the most surprising aspect of endogenous P-Rex1 loss in our analysis is its 
capacity to induce such profound phenotypes. P-Rex1 is only one of approximately 70 
Dbl-GEFs which can activate a host of Rho-GTPases, yet there is no question of any 
functional redundancy in the case of melanoma (Rossmann et al, 2005). In fact, it has 
been identified on at least two occasions for its striking functional contribution in other 
contexts, both physiological and cancer-specific (Welch et al, 2002, Sosa et al, 2010). In 
this study, metastases within the context of NrasQ61K-driven melanoma are largely reliant 
on P-Rex1, despite the mutational drift and diversity of signalling you might expect at this 
stage. Other signalling molecules that can induce such striking phenotypes include Atf2 
and Ikkb, deletion of which nearly abrogated melanoma using similar in vivo models (Shah 
et al, 2010, Yang et al, 2010).  
In explanation of this biological impact, it seems likely that P-Rex1 can contribute to the 
metastatic phenotype outside of its activation of Rac-mediated invasion; there have been 
suggestions of alternative cancer-specific functions for P-Rex1 in this thesis as well as 
another report, but nothing that has fully been characterised as yet (Montero et al, 2010). 
For instance, a role for P-Rex1 in proliferation has been implicated on a number of 
occasions here: melanoblast cell number differences, secondary growth following TV-
injection, and the Tyr::Cre Racfl/fl; P-Rex1-/- double knockout phenotype (Figure 3.3h, 
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Figure 4.6, Figure 4.10). Although our results in Tyr::Cre Racfl/fl; P-Rex1-/- embryos might 
suggest that endogenous P-Rex1 can only exert significant proliferative effects when Rac1 
is disrupted, the non-significant trend towards secondary growth observed after TV-
injection of P-Rex1+/+ melanocytes raises the prospect that this process might become 
Rac-independent in cancer (Figure 3.3h). This possibility is supported by one of the P-Rex1 
breast cancer studies, which showed a decrease in Rac-GTP that was far less pronounced 
than the deficit of proliferation induced by P-Rex1 siRNA interference; consistent with our 
study, no increase in apoptosis was seen in breast cancer cells when P-Rex1 was 
abrogated (Montero et al, 2010).   
The P-Rex1 cancer phenotype is also significant when one considers the biological 
complexity of metastasis, which requires the co-ordinated spatiotemporal activation of a 
multitude of signalling pathways for its different steps: local invasion, intravasation, 
vascular migration, extravasation, and colonisation (detailed in Figure 1.3). P-Rex1 might 
have been expected to be an insignificant part of this process, but our results suggest that 
its abrogation can exploit the fragility and inefficiency of the metastatic process (Fidler, 
1970).  
7.1.2 BrafV600E and P-Rex1 
A significant finding in this thesis was that the pro-metastatic effect of endogenous P-
Rex1 in NrasQ61K-driven mouse melanoma was not matched by any cancer phenotype in 
BrafV600E-driven models. This is despite a common upregulation of MAPK signalling by 
both models (Dhomen et al, 2009, Dankort et al, 2009). This result could be explained by 
biological nuances of P-Rex1 signalling, or deficiencies of the BrafV600E model used for this 
study. Biological explanations include: 
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1. P-Rex1 expression. As shown by comparison of Figure 3.5a with Figure 5.1 
(immunoblots from both figures were performed together), P-Rex1 upregulation in 
human BRAF mutant melanoma cell lines is not as marked as in cell lines expressing 
mutant NRAS or with neither mutation. Review of our microarray data did not support 
this finding, suggesting there was no difference in P-Rex1 intensity levels between 
melanoma cell lines with NrasQ61 (WM852, WM1366, Lyse, Gerlach) or BrafV600E (the 
majority of other cell lines) (Figure 3.4). However, there remains a possibility that the 
lack of a phenotype in the BrafV600E-driven model could therefore represent a 
threshold effect, whereby P-Rex1 can only exert its pro-tumourigenic effects at a 
certain level of upregulation. The first step in delineating this further will be more 
detailed analyses of P-Rex1 protein and RNA levels in cell lines expressing mutant Braf 
or Nras. 
2. Alternative Rac-GEFs. Other Rac-GEFs have been implicated in melanomagenesis and 
cancer (Uhlenbrock et al, 2004, Sanz-Moreno et al, 2008, Minard et al, 2004, 
Fernandez-Zapico et al, 2005, Patel et al, 2007). It is therefore likely that more 
RacGEFs will feature in melanoma than are presently reported, perhaps suggesting 
that alternative RacGEFs could compensate for P-Rex1 depletion in BrafV600E-driven 
cancer. Neutrophil studies have already suggested a relative reciprocity and functional 
redundancy of P-Rex1 function with another Rac-GEF, Vav (Mayeenuddin et al, 2006). 
3. Endogenous BrafV600E. The potential effect of P-Rex1 levels mentioned above may be 
modulated by the relative expression of Tyr::NrasQ61K/° and Tyr::CreER BrafV600E in the 
two mouse models. Transgenic expression of NrasQ61K in the first model will likely 
simulate its ectopic expression in melanoma, whereas expression of BrafV600E in the 
second model was designed to reflect its endogenous expression. Direct activation of 
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P-Rex1 by PI(3)K signalling (downstream of NrasQ61K) was described on its discovery, 
and it has also been highlighted as a downstream target for ERK signalling (Welch et 
al, 2002, Shields et al, 2007). However the relative quantities and patterns of 
differential inputs required to induce a functional effect of P-Rex1 is less clear. 
4. Synergistic activation of P-Rex1. The direct synergistic activation of P-Rex1 by both 
PIP3 and Gßγ was described in its initial characterisation (Welch et al, 2002). At 
present, we are unaware of the biochemical nature of the interaction between MAPK 
signalling and P-Rex1 (Shields et al, 2007). It may also be the case that synergy of 
inputs from MAPK and PI(3)K effectors are what is necessary to induce a 
phenotypically meaningful effect of endogenous P-Rex1 in melanoma: this is more 
likely to be provided by the Tyr::NrasQ61K/° model, as opposed to the Tyr::CreER 
BrafV600E which retains PTEN heterozygosity. 
5. Alternative BrafV600E mouse. This BrafV600E-driven mouse used in this study was not the 
same as that in which metastases were reported with PTEN ablation: the relative 
expression of BrafV600E in these mice is unreported (Dhomen et al, 2009, Dankort et al, 
2009).  
 
Despite the plausibility of these factors above, it also should be acknowledged that study 
of P-Rex1 is not optimal in the Tyr::CreER BrafV600E model for the following reasons: 
1. Primary tumour removal. Under UK home office guidelines, many mice required 
euthanisation for overgrowth or ulceration of their primary melanomas prior to 
looking unwell. In this context, metastases may not have had sufficient time to occur. 
The issue of primary tumour removal is detailed in the introduction (Section 1.3.1.2) 
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and may become necessary for further in vivo studies of P-Rex1-facilitated 
metastases: the short-term difficulty of optimising such a technique would likely be 
outweighed by the benefit of having a model that can directly reflect the clinical 
course of melanoma in humans (Francia et al, 2011). 
2. Limited metastatic detail. In line with the previous description of what is required 
from an optimal melanoma mouse model (Section 1.3.1.2), a criticism of the 
Tyr::CreER BrafV600E/+; Ptenlox/lox model described by Dankort and colleagues is the 
limited metastatic detail offered (Dankort et al, 2009). 100% LN metastases are 
reported, along with an unspecified number of lung metastases. However, normal 
populations of melanocytes have frequently been described in mice and human 
lymph nodes, a possibility which would confound this analysis (Otsuka et al, 1998, 
Gupta et al, 2005). In contrast to the Tyr::NrasQ61K/° mouse report, no qualification for 
this possibility was mentioned. For this reason, LNs were excluded from our 
metastatic analysis of both NrasQ61K- and  BrafV600E-driven models, and our results may 
have been more striking if we had not done this.  
3. Limited mouse numbers. Breeding of this cohort was particularly difficult given the 
limited life expectancy of Tyr::CreER BrafV600E/+; PTENlox/lox; P-Rex1-/- mice useful for 
deriving a population of heterozygous PTENlox/+progeny (Figure 5.6a). Our analysis was 
therefore limited to only 7 mice in the experimental Tyr::CreER BrafV600E/+; PTENlox/+; P-
Rex1-/-  cohort. 
The potential lack of relevance for P-Rex1 in BrafV600E-driven melanoma has important 
translational implications: therapeutic inhibition of P-Rex1 may not have an effect in this 
context. In this era of personalised medicine, such a finding can improve the efficiency of 
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early phase clinical trial design, whilst potentially improving the clinical outcomes and 
toxicity profiles of its participants (de Bono et al, 2010). 
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7.1.3 Tyr::Cre Racfl/fl; P-Rex1-/- mice 
Although the proliferative defect contributing to the Tyr::Cre Racfl/fl; P-Rex1-/- coat colour 
phenotype is mentioned above (section 7.1.1), we have not yet speculated which Rho-
GTPase might be employed to stimulate this phenotype in the absence of Rac1. Two 
other isoforms of Rac (Rac2 and Rac3) can be stimulated by P-Rex1 in other cell types, 
including neutrophils and neurones (Welch et al, 2005, Yoshizawa et al, 2005). However, 
the dominant Rac isoform in cells of the melanocyte lineage is Rac1, suggesting that an 
alternative Rho-GTPase may be responsible for this effect (Uhlenbrock et al, Sci 2004, 
Sanz-Moreno et al, 2008, Laura Machesky, personal communication).  
RhoG is possibly the most likely candidate for P-Rex1 interaction. This Rho-GTPase is the 
most structurally similar to Rac, and has been shown to co-operate with Rac for induction 
of cell transformation (Roux et al, 1997). Moreover, there are distinct regulatory and 
functional similarities between P-Rex1 and Vav proteins, which have been characterised 
as the predominant GEFs required for RhoG activation (Samson et al, 2010, Lawson et al, 
2011). One of our main future aims in the laboratory will therefore be to assess the 
possibility of a novel RhoG activation by P-Rex1. Tyr::CreER Racfl/fl melanocytes have been 
derived from our mice models and can readily be assessed for RhoG and its interaction. 
The functional consequences of P-Rex1 interference in the presence or absence of Rac 
can also be further dissected in vitro. 
 
Chapter 7: Discussion  212 
 
7.1.4 Translation 
The vast majority of small molecule inhibitors in existing preclinical and clinical 
development target the tyrosine kinase activity of a given protein, but this strategy is 
clearly inappropriate in the case of P-Rex1. Targeting a new class of compound can be 
unappealing to large pharmaceutical companies, who usually have a massive library of 
potential inhibitors of a given target available to perform high-throughput screens. 
However, this approach often ends in failure, and more adventurous pharmaceutical-
academic collaborations are vital to improve the current low success rate in translational 
drug development.  
P-Rex1 and other GEFs represent a novel challenge in drug development, but one that has 
already been shown not to be insurmountable (Vigil et al, 2010, Mardilovich et al, 2012). 
Development of small molecules targeted against P-Rex1 has recently begun (Heidi 
Welch, personal communication). The great hope is that GEF targeting in different cancer 
contexts could be applicable to all tumours driven by Ras. This thesis and other studies 
have demonstrated several features of P-Rex1 signalling which should be considered in 
the development of any putative P-Rex1 inhibitors (Figure 7.1): 
1. Cytostatic potential. The introduction to this thesis highlights the clinical difficulties 
involved in confirming efficacy of an inhibitor considered to be an ‘anti-metastatic’ 
(Section 1.2.2). In short, we do not currently have a clinical trial framework in the UK 
that can optimise the potential of such agents. Thus the additional cytostatic potential 
of a P-Rex1 inhibitor, most strikingly demonstrated by the Rac-independent 
proliferative deficit observed in Tyr::Cre Racfl/fl; P-Rex1-/- embryos, creates a more 
appealing therapeutic prospect. 
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2. Patient selection. Strategies for inhibiting Ras have been a perennial therapeutic 
challenge (Flaherty et al, 2006). Our findings suggest that targeting P-Rex1 signalling 
might have great relevance to melanomas driven or co-driven by oncogenic Nras: a 
significant subset who have very limited treatment options (Heidorn et al, 2010). In 
breast cancer, Sosa and collegues have clearly shown a specificity of P-Rex1 in ER (+/-
HER2) positive disease (Sosa et al, 2010). Finally, prostate cancer studies of P-Rex1 
have suggested it is derepressed by HDAC inhibition, and thus might be a negative 
predictor of efficacy in this treatment context: the upregulation of P-Rex1 here 
appears to confound the hypothesis that HDAC inhibitors would confer efficacy 
through derepression of TSGs alone (Wong et al, 2011). 
3. Therapeutic window. The lack of P-Rex1 expression in most other normal human cell 
types offers a clear therapeutic window and basis for selective inhibition (Welch et al, 
2002, de Bono et al, 2010). In combination with the possibilities of patient selection 
described above, this treatment window offers potential to improve patient outcomes 
and toxicity, as well as expedite the clinical trial process. 
4. Targeting the DH domain. Figure 3.8 provides preliminary evidence that targeting the 
catalytic DH domain of P-Rex1 may be the most effective strategy for therapeutic 
intervention. In fact the dominant negative effect observed suggests it may have a 
more beneficial effect than ablating P-Rex1 altogether.  This result dovetails nicely 
with our invasion assays in Figure 3.7, which show that ectopic expression of the GEF-
dead P-Rex1 mutant did not match the invasion observed with ectopic P-Rex1. An 
important future aim will be to ascertain the mechanism(s) responsible for the 
dominant-negative effect of the P-Rex1 GEF-dead mutant.  
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5. Pharmacodynamics. A downstream readout of biological P-Rex1 suppression is 
necessary for putative inhibitors, acting as a surrogate or intermediate endpoint by 
which early clinical trials may be expedited. Rac is the predominant biomarker which 
might fulfil this role, although one wonders if RhoG or another Rho-GTPase may add 
value given the Rac-independent role of P-Rex1 discussed in sections 7.1.1 and 7.1.3. 
6. Rac targeting. A cursory assessment of P-Rex1 might incorrectly suggest that its 
effects can be straightforwardly diminished by Rac inhibitors, which are already in 
clinical development. There are a number of reasons why this is not the case. First, we 
have shown and discussed that P-Rex1 has significant Rac-independent effects that 
will likely contribute to a cancer phenotype. Second, Rac is ubiquitously expressed in 
human cells, and thus its inhibition could induce significant toxicity whilst assessing 
for a narrow therapeutic window. Finally, Rac can also regulate the actin cytoskeleton 
in a manner that minimises invasion of melanoma cells, thus suggesting it can act as 
an anti-metastatic which should not be inhibited in some contexts (Uhlenbrock et al, 
2004). Taken together, the invasive character of Rac is GEF-dependent and does not 
mimic all the phenotypic features of P-Rex1: upstream control by an inhibitor of P-
Rex1 with a large therapeutic window seems a more desirable option.  
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Figure 7.1 The drug discovery cascade and P-Rex1 
(a) Reminder of drug development cascade described in Figure 1.4 (b) Common traffic lights 
system applied for consideration of potential novel drug targets. Red, amber or green dots are 
estimated by myself, and suggest suitability of a given target for each respective category. 
Validation (‘V’) suggests how well characterised P-Rex1 has been as an anticancer target. Assay 
(‘A’) describes feasibility of developing an in vitro assay for large scale assessment of P-Rex1. 
Druggability (‘D’) conveys whether the target class of P-Rex1 (ie GEFs) is known and whether 
there are inhibitors developed against that class. Toxicity (‘T’) shows potential for selective 
inhibition of P-Rex1, thereby reducing side-effects. Structure-based drug design suitability (‘S’) 
describes the limited structural knowledge we currently have of P-Rex1. 
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Finally, it is also worth noting that Figure 3.4 and Tables 3.3/3.4 in chapter 3 also reveal 
detail of the potential of P-Rex1 as a prognostic biomarker in melanoma. For instance, 
microarray revealed that P-Rex1 levels above the median (‘high’ P-Rex1) were 100% 
statistically sensitive for the detection of metastatic melanoma. It is tempting to 
speculate that ‘low’ P-Rex1 detected in the biopsy of a patient with newly-diagnosed 
primary melanoma could therefore exclude the possibility of metastases and guide 
treatment accordingly. Similarly, we also showed that ‘low’ P-Rex1 was 100% statistically 
specific for excluding primary melanoma: this could be of clinical use for excluding 
melanoma in a suspected skin lesion. Even in the absence of a P-Rex1 inhibitor, this sort 
of biomarker assessment could straightforwardly be incorporated in any melanoma 
clinical trial.  
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7.2 FAK 
7.2.1 Study relevance 
One of the key advances in our FAK study has been consolidation and tempero-spatial 
clarification of the disparate reports describing the role of FAK in tumourigenesis, 
something that would likely not have been elucidated without the use of genetically 
modified mouse models (Fujii et al, 2004, Lark et al, 2005, Giaginis et al, 2009, Gabriel et 
al, 2009, Tavernier-Tardy et al, 2009, Schmitz et al, 2005, Theocharis et al, 2003, 
Furuyama et al, World J Surg 2006, Gabriel et al, 2006). Our results also support the cell 
biology hypothesis that downregulation of FAK might permit primary melanoma cells to 
become more migratory by reducing their focal adhesions to the extra-cellular matrix 
(Schultze et al, 2010). 
The structural and biological complexities of FAK help explain its myriad roles within 
normal cell physiology as well as tumourigenesis (detailed in Section 1.5.2). Multiple FAK 
tyrosine phosphorylation residues have been identified and implicated in regulation of its 
kinase activity, with a number of serine phosphorylation residues also implicated in its 
function (Zheng et al, 2009). In addition to its physiological responses to integrin 
signalling, FAK mediates downstream signalling of common cancer-associated receptors 
such as the platelet-derived growth factor receptor (PDGFR), epidermal growth factor 
receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) (Garces et al, 
2006, Sieg et al, 2000).The four-point-one, ezrin, radixin, moesin (FERM) domain of FAK is 
pivotal to this control of downstream signalling and its upstream biological responses. It 
has key roles in regulation of FAK kinase activity, FAK auto-inhibition, and sub-cellular 
localisation of FAK mediated by scaffolding interactions (Frame et al, 2010). The variable 
nature of FAK function described in this study would likely be clarified further by systemic 
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investigation of the differential roles FAK plays in response to a number of factors 
including: upstream receptor signalling, phosphorylation status, kinase/scaffold activity, 
and sub-cellular localisation. 
Future studies will focus on confirming a mechanism for the tumour suppressive capacity 
of FAK in melanoma, as well as establishing a definitive human relevance to the mouse 
data compiled so far. The divergent role of FAK in NrasQ61K- driven melanoma could be 
explained by a cell line study which revealed a mechanism for a paradoxical pro-migratory 
role of FAK depletion in the context of Ras signalling:  one initial step in our project will 
therefore be to confirm whether this mechanism also applies to our animal model results 
(Zheng et al, 2009).  
 
7.2.2 Translation 
In contrast to our analysis of P-Rex1, the analysis of FAK here is an example of the 
benefits of re-iterative research promoted in the introductory chapter (Section 1.4.1). The 
heterogeneous nature of FAK signalling suggests there is a need for considerable detailed 
thought to be given to the application of clinical FAK inhibition. Presently there are a 
number of ATP-competitive FAK small molecule inhibitors being tested in early phase 
clinical trials, with no clear clinical activity identified in initial results from four years ago 
(Siu et al, 2008). It is prescient that a final report of these data are still awaited at a time 
when an edition of the British Medical Journal scrutinised the pharmaceutical industry’s 
compliance with the mandatory reporting of clinical trial results (Prayle et al, 2012). 
Our results suggest a clinical investigator should always consider common upstream 
receptor signalling mechanisms of a patient’s cancer before intervening with FAK 
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inhibition. For instance, our study shows that abrogation of FAK would be inappropriate 
and could accelerate metastases in patients with melanoma driven by NrasQ61K, a finding 
that might extend to all patients with cancer driven by Ras signalling (Zheng et al, 2009, 
Lu et al, 2001). On a preclinical level, more investigation is required to delineate how 
scaffold vs kinase FAK activity can modulate its role in survival, proliferation, and 
migration; targeting the kinase activity of FAK may not always be an appropriate strategy, 
and characterisation of the tumourigenic relevance of FAK biochemistry will assist in the 
generation of a new generation of ‘smarter’ FAK small molecule inhibitors (Siesser et al, 
2006). 
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7.3 Working towards improved mouse models 
This section uses our experience of the various mouse models described in this thesis to 
document the practical advantages and limitations of each technique. I hope that this 
might serve as a useful reference for other researchers to plan their potential 
experiments.   
7.3.1 NrasQ61K versus BrafV600E mouse models 
Despite their mutual signalling through the MAPK pathway, these are two markedly 
different mouse models which carry relative advantages and disadvantages. Table 7.1 
details the merits and limitations of each model, but two general rules are worth 
considering before a choice is made: 
1. Primary versus metastatic melanomagenesis. In our hands, Tyr::NrasQ61K/°;  INK4a-/- 
mice have been a useful metastatic model with limited value for primary melanoma 
study, whereas the Tyr::CreER BrafV600E/+; PTENlox/+ mice offer an excellent platform for 
primary melanoma analyses but rarely succumb to metastases. 
2. Additional allograft/xenograft studies. These are likely necessary to complement and 
detail a metastatic result uncovered using the Tyr::NrasQ61K/°;  INK4a-/- model: for 
instance, to detail whether a deficit of metastases may have occurred after the 
intravasation stage or before. In contrast, primary melanomagenesis assessed using 
the Tyr::CreER BrafV600E/+; PTENlox/+ does not necessarily require a further cell line 
injection study. 
Varying levels of pigmentation between the two models can also cause practical 
difficulties, although nothing that is insurmountable (Table 7.1). 
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Mouse Model 
System 
Advantages Disadvantages 
Tyr::NrasQ61K/°; 
INK4a-/- 
 Good metastatic model with 
appropriate organ spread. 
 Characteristic human 
mutations. 
 Pigmented, mets easily 
assessed on dissection. 
 Rare euthanisation for 
primary tumour outgrowth: 
allows mets to develop. 
 Cell lines easily derived. 
 Limited value as primary 
tumour model: multiple tiny 
tumours grow, rather than 
single discrete lesions. 
 Pigmentation precludes 
immunofluorescence, IHC 
achieved with difficulty. 
 INK4a-/- prompts lymphoma in 
some mice, require exclusion 
from cohort and increased 
mouse numbers. 
Tyr::CreER 
BrafV600E/+; 
PTENlox/+ 
 Inducible, temperospatial 
control. 
 Excellent primary tumour 
model: initiation, growth and 
ulceration easily assessed. 
 Characteristic human 
mutations. 
 Little pigmentation: 
straightforward IHC and 
immunofluorescence 
possible.  
 Healthy mice, no other 
illnesses. 
 
 Rare metastases, primary 
tumour resection likely 
required: frequent 
euthanisation for primary 
tumour outgrowth precludes 
metastases. 
 Little pigmentation: mets not 
easily assessed on dissection. 
 Cell lines not derived easily  
 
Table 7.1 Relative merits and limitations of the two main genetically modified mouse models 
of melanoma analysed in this thesis. 
 
7.3.2 Allografts/xenografts  
A key advance in this thesis is the characterisation of P-Rex1 in animal models of cancer 
which recapitulate the common human genetics of the disease. Prior P-Rex1 cancer 
studies have shown an effect on both primary tumour growth and LN metastases using 
xenotransplantation of human cancer cell lines into immunodeficient mice (Qin et al, 
2009, Sosa et al, 2010, Montero et al, 2010). However this technique often fails to 
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recapitulate the characteristics of the original tumour they are meant to represent, and 
their use for informative studies of novel cancer target validation has become increasingly 
contentious (see Section 1.3.1.4) (Becher et al, 2006, Sausville et al, 2006).  
Despite this criticism, this thesis argues there is still a role for allograft and xenograft 
study, particularly in the context of metastasic melanoma where we still do not have a 
genetically modified mouse model that can recapitulate its different stages fully. It has 
recently been recommended that metastatic melanoma research should involve two 
animal models, with genetically modified models complementing traditional xenograft 
analyses: our experience here suggests that this is broadly correct, except we believe 
xenografts (or allografts) must be utilised for validation and delineation after initial 
characterisation using a genetically valid model (Sethi et al, 2011). For instance, our P-
Rex1 results in Tyr::NrasQ61K/°; INK4a-/- mice was validated using TV allograft injections to 
further define the nature of the P-Rex1 effect on metastases (Figure 3.3); this allowed us 
to bypass the potential time-limitation and technical difficulty involved in primary tumour 
removal. A xenograft study would likely have complemented our results this way too.  
7.3.3 Improved assessment of melanoma parameters 
The importance of conscientious and efficient documentation of melanoma parameters is 
highlighted in the introduction to this thesis (Section 1.3.1.2). Measurement of 
metastases and propensity for metastases should routinely occur in a manner that can 
accurately reflect what might occur in a human clinical trial. Our experience in this thesis 
has evolved to include increasing amounts of melanoma detail in chapters 5 and 6: 
 Primary melanoma. Standard practice should record time of induction (if applicable), 
time of onset, anatomical site, rate of growth, ulceration, and size at which ulceration 
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occurs. Survival measures may not be of particular use if otherwise healthy mice only 
require euthanisation because of their primary tumour burden. The dermal 
localisation of most mouse melanoma precludes assessment of Breslow thickness for 
metastatic propensity, although a practiced pathologist could alternatively offer 
information about mitotic rate. 
 Metastic Melanoma. Standard practice should record anatomical sites on dissection, 
and survival measures from birth, induction (if applicable), and tumour onset. Our FAK 
analysis demonstrated the benefits of these different survival analyses, offering 
biologically relevant results with the measurement of survival from tumour onset that 
would not have been elicited had survival been measured from birth alone. CT or CT-
PET offer the best means of recording metastatic site, number, and size, although 
thorough assessment of these measures with dissection and histological analysis can 
provide a less costly alternative. As discussed earlier, potential LN lesions should be 
interpreted with caution, and excluded if there is any doubt between malignancy and 
benign overgrowth. 
7.3.4 Embryonic models 
With our analyses of P-Rex1 and FAK, this thesis both reaffirms and challenges the 
conventional wisdom that embryonic phenotypes can simulate cancer-specific events: 
whereas a reduction in metastasis with P-Rex1 ablation is mirrored by a deficit of MB 
migration, the increased invasion observed with FAK depletion was not apparent on 
embryonic assessment. It is easy to speculate that the likely reality is somewhere in 
between: embryonic migratory detail offers excellent information about potential 
mechanisms of melanoma metastases, but by itself is not sufficient as a tool for cancer 
assessment. 
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We have utilised two reporter models for embryonic assessment of P-Rex1 and FAK, DCT-
lacZ mice and mice carrying the Z/EG double reporter transgene (Mackenzie et al, 1997, 
Novak et al, 2000, Mort et al, 2010). Again, the use of both can validate and further 
delineate initial results, and in this case we would suggest that the relative values of each 
model make them inter-changeable for embryonic assessment (Table 7.2).  
In our analysis, a lack of cell death observed using a 6 hour timelapse of GFP-expressing 
melanoblasts often is assumed to indicate that a cell number difference (perhaps elicited 
using the DCT-lacZ model) might be accounted for by a proliferative impairment or 
enhancement. The limitations of cell death assessment over such a small timeframe are 
obvious, although the characteristic resistance to cell death in cells of the MC lineage 
supports this method (Gray-Schopfer et al, 2007). In addition, we would concede that our 
methods in our embryonic assessment of the Tyr::Cre Racfl/fl; P-Rex1-/- coat cannot 
exclude the possibility of a large amount of early MB death. 
For assessment of melanoblast migration, our techniques and analyses have evolved over 
the past three years. The live imaging offered by use of the Z/EG double reporter remains 
a near gold standard for migratory assessment, albeit over a potentially limited 
timeframe. However, these GFP-expressing mice are often beset by delays such as 
breeding difficulty, poor litter sizes, and limited microscope availability: DCT-lacZ mice can 
therefore offer a worthy and straightforward alternative. Our migration assays in DCT-
lacZ mice have measured both cell numbers at the distal point of MB migration (Figures 
2.1a,b), and distances from the end of the forepaw to the 5th last melanoblast (Figure 
2.1c).  It might be reasoned that the former migratory analysis is limited by concerns 
regarding cell-cell interactions if a phenotype also reveals an alteration of cell numbers. 
With P-Rex1-null mice, we reasoned that the cell number method could straightforwardly 
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be justified by the clear belly spot and forepaw melanoblast migration difference 
represented in Figure 4.1 and Figure 4.3. Moreover, we were latterly able to confirm this 
migratory difference using the Z/EG reporter mice (Figure 4.5c,d). However, FAK mice 
have no belly phenotype and we have not yet been able to assess its phenotype in GFP-
expressing melanoblasts: we therefore concluded that it was more appropriate to use the 
DCT-lacZ analysis of distance (Figure 2.1c), in an effort to exclude potential confounding 
cell-cell interactions conferred by the cell number deficit elicited (Figure 6.4). 
Finally, it should be noted that the processes of cell division and cell migration cannot be 
completely uncoupled using the migration and cell number assays covered in this thesis. 
For this reason, the precise temperospatial functions of around 80 genes implicated in 
melanocyte development remain largely uncharacterised (Lamoreux et al, 2010). Recent 
efforts to mathematically model murine melanoblast distribution have shown that their 
rate of proliferation in the dermis is similar to their rate of migration from the dermis to 
epidermis (Luciani et al, 2011). To minimise this potential limitation in this thesis, our aim 
was to assess each given phenotype using all the assays and reporter models described in 
Sections 2.1 and 2.2, thereby consolidating any initial findings with an alternative assay. 
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Embryo Model 
System 
Advantages Disadvantages 
DCT-lacZ  Good litter sizes, breed well 
 Straightforward staining 
method 
 Visualisation of whole 
anatomy 
 Single cell detail possible 
 Migration and cell numbers 
assessable 
 Simple microscopy 
 Limited tempero-spatial detail, 
‘snapshots’ of each timepoint 
used to make deductions. 
 
Z/EG  Excellent tempero-spatial 
information allows assay of 
distance, speed, and cell 
numbers. 
 Information on cell death 
available. 
 Confocal microscopy reveals 
excellent single cell 
morphological detail. 
 
 Breed poorly, small litters 
 Precarious and expensive 
technique, improves with 
experience. 
 Limited anatomy visualised 
 Confocal microscope 
availability can be difficult, low 
throughput. 
Table 7.2 Relative merits and limitations of the two melanoblast reporter mice analysed 
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